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Aneurysmal disease of the aorta is a degenerative condition characterised by 
inflammation and extracellular protein loss, in particular, loss of cross-linked 
elastin. 18F-FDG is currently the most widely available tracer used in assessing 
the metabolic activity of tissues and is known to be taken up in aneurysmal 
wall, but its biological correlates, other than metabolism, have yet to be 
evaluated. Other novel tracers for more specific functional imaging of proteins 
such as elastin in the aneurysm wall have also yet to be evaluated in the 
context of aneurysmal disease.  
 
18F-FDG uptake in aneurysms was characterised using a combination of laser 
scintigraphic 3D aortic masks generated from PET-CT that allowed precise 
aortic biopsy of areas of high and low tracer uptake. Positive correlations were 
obtained between 18F-FDG uptake and total leukocyte, B-cell, T-cell and NK-cell 
content in human aneurysmal wall, while elastin and collagen content was 
reduced at sites of inflammatory cell infiltrate. B and T-cells had significant 
modulatory affects on vascular smooth muscle cell (VSMC) proliferation, 
survival and protein synthesis in-vitro. 
 
18F-FDG uptake and its inflammatory correlates were similarly characterised in 
ApoE-/--ATII model. There was a temporal, heterogeneous 18F-FDG uptake in 
the aneurysms associated with increased immune cell content, but no 
correlation was found between uptake and aortic expansion or diameter.  
 
Elastin-specific MR contrast agent (ESMA) uptake was characterised in the 
ApoE-/--ATII model and found to correlate with elastin, tropoelastin, immune 
cell content and extracellular matrix organisation, as well as aortic expansion. 
Treatment with elastin modulating antagomirs decreased aneurysm expansion 
and rupture. This was through modulated down-stream gene and protein 
expression of proteins and enzymes involved in elastin and collagen 
homeostasis namely TGFβ, LOX and MMP’s. 
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It appears therefore that 18F-FDG uptake correlates with specific immune cell 
infiltrates, in particular that of B- and T-cells that can modulate VSMC function. 
There are distinct cellular populations that are responsible for a pro-
aneurysmal phenotype and B-T-regulatory cell populations that lead to aortic 
remodeling response. ESMA uptake was related to elastin remodelling and 
may provide a novel predictor of aneurysm behavior. Antagomir mediated 
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Chapter 1: General Introduction 
 
1.1 Historical perspective 
Arterial dilations were described as far back as ancient Egyptian times during 
2000BC in the Ebers Papyrus medical scrolls. The first accurate descriptions 
were by Greek physicians such as Galen (A.D.126-c216)1. These were based on 
observations in the 2nd century A.D., of gladiators who were injured in battle 
and developed false aneurysms. Antyllus also described traumatic aneurysms 
and was the first person to attempt surgical correction with proximal and distal 
ligation, opening the aneurysm sac and evacuating the contents. The 1500’s 
saw the description of syphilitic aneurysms by Pare (1510-1590)1. John Hunter 
made real surgical progress in 1800s when he popularised arterial ligation2. It 
was not till early twentieth century that Alexis Carrel and Charles Guthrie made 
advances using anastomotic techniques and the use of homografts as 
replacement conduits. Carrel won a Nobel Prize for his work and provided the 
basis for modern anastomotic techniques3. Innovative treatment options 
included aneurysm thrombosis by application of electric current (Fig 1.0) to 
wrapping aneurysms with cellophane. It was in 1944 that Ochsner performed 
the first open repair of a saccular aneurysm of the descending aorta with 
Denton Cooley (as an intern) performing an open repair of an ascending aortic 
false aneurysm a year later. In 1948 Rudolph Nissen operated on Albert 
Einstein at the Jewish Hospital in Brooklyn, New York by cellophane wrapping 
his aortic aneurysm. Due to this timely intervention the renowned physicist 
survived over 5-years before succumbing to aneurysm rupture. It was not till 
1952 when Dubost repaired the first abdominal aortic aneurysm with an aortic 
homograft. 
 
The balloon expandable stent was invented by Julio Palmaz and patented in 
1985, but it was not until 1986 that the Ukrainian surgeon Nicholas Volodos 
performed the first endovascular repair of a traumatic thoracic aortic 
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aneurysm4. Parodi carried out the first infra-renal abdominal aortic aneurysm 
repair using an endograft in 1990. With the application of aortic screening 
programs and increasingly powerful imaging modalities available for aneurysm 
diagnosis, treatment and follow-up the outcomes for patients with this lethal 
condition should continue to improve. 
 
The great physician Sir William Osler observed, “there is no condition more 
conductive to clinical humility than aneurysm of the aorta.” Although progress 
has been made since then, Osler’s observation regarding the challenge posed 
by aortic disease remains true to this day. 
 
 
Fig 1.0 The historical treatment of aortic aneurysms 
Electroshock therapy being used in Osler’s time to stop aortic aneurysm progression and 







1.2 Aortic aneurysms 
The aorta is anatomically described according to its location and relationships 
as it originates from the heart and ends by bifurcating into the iliac vessels (Fig 
1.1). An aneurysm is an abnormal dilation of an artery to twice its normal 
diameter. In the case of adults, an abdominal aortic aneurysm (AAA) means an 
aortic diameter greater than 3cm and for the thoracic aortic aneurysm (TAA) 
greater than 4.5cm (Figs 1.2 and 1.3). Aneurysms are the 13th leading cause of 
death in the UK6. The incidence of TAA is around 5.9-10.4 per 100000 person 
years and this seems to be increasing with screening and better imaging 
techniques7,8. AAA affects 5.5% of men over the age of 65 and about 2.2% of 
women. It is estimated that around 8000 people die because of ruptured aortic 












Fig 1.2 A thoracic aortic aneurysm in Marfans patient opened 
The patient underwent replacement of the aortic root and ascending aorta with a Dacron 





Fig 1.3 Degenerative abdominal aortic aneurysms  
Open repair of a juxtarenal aortic aneurysm. A branch fenestrated endograft used for a 





1.3 Natural history of aortic aneurysms  
Successful surgical treatment relies on understanding the risks of surgery 
balanced against the natural history of the disease. These data come from 
those aneurysm patients who did not have operative treatment. For thoracic 
aortic aneurysms overall 74% of patients rupture and of these 94% of patients 
will die from this11. For abdominal aortic aneurysms the average risk of rupture 
in men with 5-5.9cm aneurysms is 1% per year and in women with same sized 
aneurysms its around 3.9% per year12-14. Complications such as aortic rupture 
and dissection are determined by aortic diameter and underlying aortic 
pathology. 
 
The diameter of the aneurysm increases the wall tension increases (T=PR, 
Laplace’s law); where tension is proportional to pressure x radius. Increased 
systemic blood pressure and increased aneurysm diameter, therefore, 
markedly increase the risk of rupture. Logistic regression analysis has 
demonstrated over 4 fold increased rupture or dissection risk when aneurysm 
is 6.0-6.9cm in diameter compared with a 4.0-4.9cm13,14. Aneurysm size and 
growth rate are important clinical predictors for treatment decisions as they 
are know to determine aortic outcome. A 5cm thoracic aneurysm expands at 
an average rate of 0.08-0.12cm/year; whereas larger aneurysms grow at a 
greater rate: 8cm aneurysms grow at around 0.19-0.22cm/ year14.  The growth 
rate varies depending on the site of aortic aneurysm independent of size. 
Ascending aortic aneurysms grow at 0.1cm annually compared to 0.29 for 
descending thoracic aneurysms. The mean growth is approximately 0.42cm per 
year14. This rate is accelerated in patients who smoke. Although hypertension 
is a risk factor for aneurysm development, none of the measures of 
hypertension are associated with abdominal aortic aneurysm expansion15. 
Similar data has been reported for thoracic aortic disease16. There are, 
however, indications that there is an association between diastolic blood 
pressure and the rate of aortic expansion17.  
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Mechanical forces also contribute to aortic remodelling with three distinct 
influences on the aortic wall: i) pressure created by the hydrostatic forces ii) 
circumferential stretch exerting longitudinal forces and iii) shear stress caused 
by the blood flow18. The net resultant force comprises therefore of the 
pressure along the aortic wall, shear stress and the difference in the maximal 
pressure differences i.e. pulse pressure. Perturbation in the flow conditions 
leads to flow turbulence, contributing to aneurysm growth. Areas of oscillator 
and extremes in shear stress (high and low) correlate to sites of development 
of aneurysms18,19. Clinical studies have shown conflicting data where flow in 
aortic aneurysms can be smooth and laminar or irregular and turbulent with 
little information on the effects of wall shear stress in aneurysms18-20. The 
accelerated rate of aneurysm growth and lower mean death from rupture in 
patients with monogenetic causes of aneurysmal disease have provided the 
impetus for earlier aneurysm repair to be undertaken in these patients21.  
 
When lifetime risks of rupture and dissection are analysed there is a concept of 
aortic “hinge points”, when there is a sharp increase in risk of complications 
due to an aneurysms size (Fig 1.4). These hinge points occur at 6cm in the 
ascending aorta, 7cm in the descending aorta and 6cm in the abdominal aorta, 
in those without connective tissue disease14,22,23. It is also widely recognized 
that symptomatic aneurysms should be treated regardless of size as this 
heralds aortic rupture or dissection24. However 5% of patients are 
symptomatic before an acute aortic event. The first presenting symptom in 
95% of cases is death. The overall 5-year survival for thoracic aortic aneurysms 
is 60-64%14,22,25. Survival is lower in descending aortic aneurysms (39% at 5 





Fig 1.4 Risk of complications along the natural history of aortic aneurysms23 
This depiction of ‘hinge points’ for lifetime natural history complications at various sizes of the 
aorta. The y-axis shows the likelihood of aortic dissection, rupture or death. The x-axis shows 
the aneurysm size.  (A) Ascending aorta (B) Descending aorta23. 
 
Natural history data such as these have guided clinical trails that indicate that 
surveillance is a safe and effective tool in management of small AAAs15,26-30. 
Continued data collection on aortic aneurysms and multi-institutional pooling 
of outcomes data will enable analyses to improve our understanding and 
clinical decision making for managing aortic aneurysms. A better 
understanding of the pathophysiology of aneurysmal disease is, however, 
needed to facilitate the development of medical interventions that inhibit 
expansion. 
 
1.3.1 Aetiology and pathophysiology 
The risk factors for aneurysm development are male sex, hypertension, 
hypercholesterolemia, smoking and genetic predisposition. There are certain 
monogenetic conditions such as Marfan’s, Ehlers-Danlos, Loeys-Dietz and 
other metabolic syndromes that predispose to early aneurysms31. There are 
certain familial polygenetic conditions that account for up to 10-15% of 
aneurysms with the remainder being classed as ‘degenerative’ occurring 
typically in those aged over 65yrs21,32. Recent genome wide association studies 
have shown that mutations in LDL receptor33,34 and MMP335,36 might have a 
role in these ‘degenerate aneurysm patients. The aortic wall expands and 
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contracts with the cardiac cycle. This is required to generate forward flow of 
pulsatile blood in the aorta. Aortic strength and elasticity is derived from the 
medial layer composed of collagen, elastin, vascular smooth muscle cells 
(VSMCs) and extracellular matrix (ECM) (Fig 1.5). As the aortic wall weakens 
and there is loss of elasticity, dilatation occurs and in some subjects there is 
elongation of the aorta. According to the law of Laplace, the dilatation leads to 
increased wall tension relative to intra-aortic pressure. This causes further 
progressive dilatation that is exacerbated by hypertension ultimately leading 
to dissection and or rupture.  
 
 
Fig 1.5 Aortic wall histology 
The typical architecture of the aorta, composed of adventitia (Ad), tunica media (Tm) 
containing up to 60 elastic lamellae concentrated into bands (concentrated into internal and 
external elastic lamina) and intima (I) composed of endothelial cells. H&E attained human 
aorta demonstrating the aortic histology. 
 
The aortic structure changes from ascending aorta (high in elastin) to 
descending thoracic and abdominal aorta (lower elastin content) where the 
media becomes thinner. The aortic wall is biologically active with VSMCs 
proliferating and producing elastin, collagen and proteoglycans. During 
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aneurysmal disease there is breakdown of the elastin and collagen with 
alterations in VSMC function and VSMC death37-39. Mucoid degeneration is a 
pathology of the thoracic aorta that is accelerated by smoking through 
increased levels of proteolytic enzymes40. Activation of the AMP-activated 
protein kinase ά2 by nicotine has is thought to be responsible for abdominal 
aortic aneurysm formation in mice41. 
Atherosclerosis is more commonly seen in the descending and abdominal 
aorta, rather than in the ascending aorta. It was thought atherosclerosis leads 
to damage of the elastic fibers and VSMCs leading to a weakened dilated 
aorta42,43. The causative role of atherosclerosis in aortic aneurysm has 
centered on aortic remodelling. There is some evidence to suggest that arterial 
stenosis leads to compensatory changes in the tunica media in response to the 
shear stress43. The extracellular matrix (ECM) remodelling promotes arterial 
expansion to normalise the aortic diameter and wall shear stress. This 
excessive aortic remodelling might lead to development of aortic aneurysms. 
Elastin breakdown in the tunica media caused by medial proteolysis through 
the action of matrix metalloproteinases44-47 and other proteolytic enzymes 
such as cathepsins48-50, and increased levels of pro-inflammatory cytokines 
could provide the stimulation for a chronic inflammatory response in the aortic 
wall43. This hypothesis has been scrutinised more carefully and it is now 
proposed that atherosclerosis is a concomitant process that infiltrates the 
diseased media51-53. It is postulated that chronic adventitial inflammation is the 
main contributor to aneurysm progression54,55. It is therefore shared 
environmental and genetic risk factors that promote the concurrent presence 
of atherosclerosis and aneurysms (Table 1.0). The mechanisms involved are, 
however, distinct. Another possibility is that that either atherosclerosis or 
aneurysms develop initially and both can then go on to stimulate the 





Table 1.0 Similarities and differences in between the pathogenesis of atherosclerosis and 
aortic aneurysms. 
 
Characteristic Similarity Difference 









Genetic Chromosome 9p21 Numerous genes only 
associated with 
aneurysms (e.g. FBN, 
TGFBR2, ACTA2) 
Histology Atheroma and thrombus 
in abdominal aneurysm 
Elastin degradation and 
chronic inflammation 
Animal models ApoE-/- 
ApoE−/− × eNOS−/− 
LOX deficiency 
















1.4 Genetic disorders 
There are a variety of genetic disorders associated with aneurysmal disease. 
These range from autosomal dominant single gene defects, to multiple 
complex genetic polymorphisms that attribute a small cumulative risk to 
developing aortic aneurysms. 
 
1.4.1 Marfan syndrome 
Marfan syndrome is an autosomal dominant connective tissue disorder that 
manifests with a skeletal, ocular and life-threatening cardiovascular 
phenotype. It affects 0.2% of the overall population and, in a fifth of cases, 
occurs as a result of a new mutation. The cardiovascular complications include 
aortic dilatation, dissection (accounting for 5% of dissection patients) and 
rupture. The condition occurs as a result of defects in the fibrillin-1 (FBN1) 
gene that localises to chromosome 15q21.156. FBN1 encodes a 250kD cysteine-
rich glycoprotein, which is an important component of the 10nm microfibrils 
that constitute elastic fibres57,58. Fibrillin-1 interacts with numerous 
components of the extracellular matrix, including fibrins, integrins, 
fibronectins, TGF binding proteins, insoluble elastin and collagens. In the 
aortic wall fibrillin provides a scaffold for the deposition of elastin and anchors 
smooth muscle cells by fibronectin59. Dilatation of the aorta is therefore, 
thought to be related to degradation of the insoluble extracellular matrix 
proteins within the arterial wall, in particular elastin and collagens. This results 
in mucoid degeneration (formerly misnamed cystic medial necrosis) which is 
characterised by the presence of alcianophilic glycosaminoglycans, vacuoles 
secondary to local loss of VSMCs, disorganised fibronectin and fibrillin and 
ruptured insoluble elastin and collagen.  
 
A secondary locus for Marfans, MFS2, maps to chromosome 3p25-24.2. This 
accounts for heterogeneous mutations in the TGF- receptor encoding 
sequence60. These include missense mutations and splicing errors in the serine-
threonine kinase domain. TGF- is a growth factor that plays an important part 
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in the control of anti-protease and matrix secretion. It is stored in an inactive 
form when associated with latent TGF- binding protein and interacts with 
fibrillin, fibulins, fibronectin and extracellular matrix proteins. TGF- is released 
in response to tissue injury and binds to receptors within the extracellular 
matrix where it has an important role in tissue repair. There is a relationship 
between TGF- activity and the clinical features of Marfan syndrome60. High 
levels of TGF- signaling has been reported in aneurysm samples and, although 
little is known about the precise pathogenesis of TGF- mediated aneurysm 
formation, these data have lead to two multi-centre randomised control trials 
evaluating the role of angiotensin II receptor (AT1R) antagonists (such as 
Losartan) which can antagonise TFG- activity to treat aneurysms61,62 (Fig 1.6). 
Similarly there are ongoing trials looking at the role of angiotensin converting 
enzyme inhibitors in medically managing small infra-renal aortic 
aneurysms63,64. Recent evidence has also implicated intracellular cytokine 
signaling with P-Smad-2 in smooth muscle cells within the aortic wall, aortic 
and mitral valves, as well as with Smad independent pathways (Ras, Rhoa, TGF-
 activated kinase 1)57 (Fig 1.6). Although it is still unclear how these interact 
with TGF-, they may also be putative pharmacological targets for the 




Fig 1.6 Angiotensin II mediated vascular inflammation65 
Schematic diagrams depicting the cellular events implicated in angiotensin II mediated vascular 
inflammation. The vascular remodelling response is directly due to down stream signaling 
interactions between VSMCs and immune cells (lymphocytes, NK cells, mast-cells)65. 
 
1.4.2 Loeys-Dietz syndrome (LDS) 
This is an autosomal dominant syndrome that has features that are similar to 
Marfan syndrome. It is characterised by mutations in genes encoding the TGF-
 receptor 1 (TGFR1) or 2 (TGFR2)66. Characteristically, patients with type 1 
LDS present with early, aggressive vascular disease, arterial tortuosity, 
aneurysms, hypertelorism, bifid uvula and craniosynostosis. Type 2 LDS 
patients have abnormalities of the skin, joint laxity, ectopia lentis and present 
with rupture of visceral organs as well as cardiovascular manifestations 67. 
Aortic rupture and dissection occur at smaller aortic diameters in LDS patients, 
generally at an earlier age compared with patients with Marfan syndrome 68. 
The aortic dilatation is maximal at the sinuses of Valsalva but is also observed 
throughout the arterial tree. The mean age of death in these patients is 26 
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years. Valve-sparing root replacement by graft implantation is the treatment of 
choice69. Open repair of thoracic and thoracoabdominal aneurysms is the 
treatment of choice70.   
 
1.4.3 Ehlers-Danlos syndrome 
Ehlers-Danlos syndrome comprises a group of autosomal dominant conditions 
that arise as a result of mutations in the gene encoding collagen type III alpha 1 
(COL3A1) and various enzymes that regulate collagen and elastin homeostasis 
(ADAMTs2, PLOD1, B4GALR7)71. Type IV Ehlers-Danlos syndrome can manifest 
with life-threatening cardiovascular complications, including spontaneous 
rupture of mesenteric vessels, development of thoracic and abdominal 
aneurysms and dissections.   
 
1.4.4 Other genetic syndromes  
Turner’s syndrome is a condition that affects phenotypic females who lack all 
or part of the X-chromosome. Thoracic aortic aneurysm affects between 36-
618/100,000 women with Turners syndrome per year72,73. The majority of 
these patients go onto develop type A aortic dissection (68%)74. The aneurysms 
occur at a younger age and are highest risk in those aged 30-39 years72,73,75,76. 
Numerous other conditions are associated with aneurysms, such as polycyctic 
kidney disease, scleroderma and osteogenesis imperfecta.  
 
1.4.5 Familial aneurysms 
Familial aggregation studies suggest that 11-19% of patients with thoracic 
aneurysms have a first degree relative with thoracic aortic disease. These 
patients with a family history of thoracic aortic disease present at a mean age 
of 56 years; this is significantly younger compared with non-familial, sporadic 
thoracic aneurysm cases that present at a mean age of 64 years77. In cases 
where multiple family members are affected, the disease behaves in an 
autosomal dominant inherited pattern with variable expression and 
penetration. The most frequently implicated genetic locus is TAAD1 at 
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chromosome 5q13-1431. Other putative loci are FAA1, mapped to 11q23-24, 
mutated NK (locus 5q13-14 – TAAD1), TGFBR2 (locus 3p24-25 - TAAD2), NK 
(locus 15q24-26 – TADD3), ACTA2 (locus 10q23-24 – TAAD4), and MYH11 
(locus 16p12-13). Increased low-density lipoprotein receptor-related protein 1 
(LRP-1) expression towards rs1466535 or the 12q13.3 locus significantly 
increased the risk of developing infra-renal abdominal aortic aneurysms33.  
Despite the identification of several genetic loci related to aneurysm formation 
there are multiple familial cases that have not been attributed to these, 
indicating the presence of additional and as yet unidentified gene mutations. 
The mode of the genetic inheritance of aneurysms is difficult to identify 
because of the considerable variation in clinical heterogeneity, variable 
penetration, age of onset and numerous associated features. It is 
recommended that all individuals in a ‘at risk’ family have aortic imaging 
throughout their lifetime.  
 
It is also increasingly apparent that there are genetic mutations that increase 
the susceptibility of individuals to develop aortic aneurysms. These are 
phenotypically expressed with particular environmental insults such as 
smoking, aging and development of atherosclerosis78-80. It is also likely that 
individuals will acquire a set of mutations that are expressed in an increased 
number of cells and multiple mutations represent an increased disease burden 
to the acquisition and development of aneurysms. 
 
1.4.6 Aneurysms associated with bicuspid aortic valves 
Bicuspid aortic valves (BAV) are the commonest congenital cardiac defect with 
a prevalence estimated between 0.5 and 2%83-85. BAV is part of a large 
spectrum of structural developmental abnormalities involving the great 
vessels. The aortic valve and ascending aorta share the same embryonic origin 
from neural crest cells. BAV is associated with medial degeneration, increased 
MMP activity and decreased fibrillin-1 in the aorta. BAV is autosomal dominant 
with incomplete penetrance. The male-to-female ratio ≥3:1. BAV with Turner 
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syndrome suggests an X-linked aetiology. Heritability studies have found no X-
linkage but linkage to chromosomal regions 5q, 13q, and 18q, including 
mutations in the NOTCH1 gene (chromosome 9q) that lead to signaling 
abnormalities that may be responsible not only for development of a bileaflet 
aortic valve but also accelerated valvular calcium deposition81,82.  ACTA2 gene 
(chromosome 10q), which encodes VSMC α-actin are associated with familial 
thoracic aortic aneurysms and BAV. Deletions of chromosome 22q11.2 
resulting in DiGeorge syndrome and velocardiofacial syndrome have 
demonstrated concomitant BAV, implying ubiquitin fusion degradation 1-like 
(UFD1L) gene downregulation. BAV thus encompasses a diverse large spectrum 
of conditions associated with aortic aneurysms that are discussed in following 
reviews83-86. 
 
1.4.7 Degenerate aneurysms 
Fragmentation of elastin fibres is reported to have an immunological, 
infectious, inflammatory and/or idiopathic aetiology. Historically termed 
medial degeneration, it is characterised by the disruption and loss of elastin 
fibres and increased deposition of proteoglycans. VSMC in the media are also 
markedly reduced in aortic pathology associated with myosin heavy chain11, 
smooth muscle (MYH11) and actin, alpha2, smooth muscle aorta (ACTA2) 
defects87. Degenerated aneurysms are also associated with increased 
expression of matrix metalloproteinase’s (MMPs) in the aortic media, in 
particular MMP2, 3, 9 and 13. The vasculitidies, including giant-cell arteritis 
and Takayasu’s arteritis, are typified by T-cell clonal expansion, suggesting an 
antigenic trigger. Marked adventitial inflammatory cytokine and MMP 
production leads to granuloma formation and vascular destruction by fibrosis. 
Takayasu’s arteritis results in obstructive arterial lesions with a dilatation in up 





1.5 The role of inflammation in aneurysm development 
Fragmentation of elastin fibres is reported to have an immunological, 
infectious, inflammatory and/or idiopathic aetiology (Fig 1.7). Aortic 
aneurysms are characterised by the presence of a pro-inflammatory cellular 
infiltrate. Historically termed medial degeneration, this is characterised by the 
disruption and loss of elastin fibres, increased collagen that is haphazardly 
arranged and increased deposition of proteoglycans. VSMC numbers in the 
media are also markedly reduced in aneurysms. There are numerous 
associated genetic mutations as discussed above (MYH11, ACATA2)83, 
upregulation of MMPs that are produced by immune cells41,47,89-93. Marked 
adventitial inflammatory cytokine and MMP production leads to granuloma 
formation and vascular destruction by fibrosis. There is periadventitial 
inflammation with a host of immune cells infiltrating the aortic media. This 
involves lymphocytes, NK cells, monocyte recruitment and differention to 
macrophages all leading to an increased ECM turnover, increased vascularity 







Fig 1.7 Schematic illustration of the mechanisms involved in aortic aneurysm 
development94 
The most important processes involved are vascular inflammation and extracellular matrix 
breakdown94. 
 
1.5.1 Inflammatory mediators 
The aneurysm wall produces cytokines, TNF, interleukin (IL-1), interferon 
(INF) and interleukin-6 (IL6)94,95. IL6 activates B and T lymphocytes, while INF 
stimulates B, T lymphocytes, macrophages, fibroblasts and endothelial cells to 
produce a pro-inflammatory response. These inflammatory cascades that are 
seen in in-vitro might have a role in the development of aortic wall dilatation, 
medial degeneration, VSMC apoptosis and loss of ECM96-99. Soluble mediators 
such as monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) are 
expressed in human aortic aneurysms and might be responsible for stimulation 
of early inflammatory responses97,98. There is a corresponding 40-fold more 
prostaglandin E2 (PGE2, produced by the infiltrating inflammatory cells) in 
aneurysmal wall compared with normal aortic wall98. PGE2 suppresses VSMC 
proliferation and causes cell apoptosis. PGE2 inhibition reduces expression of 
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pro-inflammatory IL1 and IL6 in the aneurysm wall and this might provide a 
potential therapeutic targets98-102.  
 
1.5.2 Modulation of inflammatory cell activity 
The immune system is divided into the innate and the adaptive immune 
systems. There is strong evidence to suggest that numerous inflammatory cells 
have a key role in the pathogenesis of aneurysms. Unlike atherosclerosis, 
where monocytes/ macrophage cells predominate, aneurysmal disease is 
characterised by lymphocytes, dendritic cells, mast-cells102-105. These 
inflammatory cell subtypes infiltrate the tunica adventitia and the outer layer 
of the tunica media through the network of vasa vasora that are found in these 
regions106-111. Little is known regarding the immunogenic triggers for these 
cells, or what initiates and propagates these inflammatory responses. The key 





Fig 1.8  Haematopoietic cell lineage 
The haemtopoietic stem cells give rise to two major progenitor cell lineages, namely myeloid 









T-cells account for over 50% of the CD45+leucocytes present in aneurysmal 
tissue37,101,111-113. Most T-cell subtypes are present, including CD8+ cytotoxic T-
cells (Th1), helper CD4+ (Th2), natural killer cells (NKT) and gamma delta T-
cells97,107,110,111. The ratio of CD8+:CD4+ cells is increased in aneurysms 
compared with normal aorta suggesting increased antigen presentation, T-cell 
activation and interaction with B-cells101, 102. This would inturn promote a pro-
inflammatory cascade with ECM degradation. The activation marker CD69 is 
present in all aneurysm related T-cells along with HLA-DR expression. T 
lymphocytes found in the aortic wall were CD11a+, CD11b−, CD31+/−, CD54+, 
CD29+ (clone 4B4), CD29act+/−, CD49a−, CD49d+, CD49e+, CD44+, and CD103−97. 
This suggests expression of adhesion molecules such as 1, 2 integrins, 
selectins and the Ig-superfamily members in the aortic wall102. These 
molecules are responsible for cell-cell interaction of activated lymphocytes 
that are reacting to antigenic triggers in the aortic wall and likely to derive 
aortic ECM breakdown. This also suggests interaction with VSMCs with 
alteration of cell adhesion, proliferation and viability114-116. 
 
There are four subtypes of the T helper cell family (Th1, Th2, Th17 and iTreg 
cells) Fig1.9. Th1 and Th2 depending on the cytokine production117. Th1 cells 
produce INF that activates macrophages and dendritic cells, whereas Th2 
produce IL-4, IL-5 and IL-13. The main effectors for these cytokines are 
eosinophils, basophils and mast cells along with IgE B-cells. Activation of Th2 
responses therefore leads to release of histamine, serotonin and leukotrienes 
and typically mediates autoimmune phenomena such as allergic rhinitis, atopic 
dermatitis and asthma. This subset can also convert B-cells to become plasma 
cells and produce antibodies or form memory cells113. The presence of local 
pro-inflammatory cytokines such IL6 and IL21 can skew the differentiation of T-
cells into a Th1 phenotype113-115. TGF, a cytokine associated with tissue repair 
114-116 drives differentiation of native T helper cells into Th17 cells118-121. Th17 
cells are responsible for host immunity against extracellular agents122. Once 
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triggered by IL-6 and TGF, their main effector cytokines are IL-6, IL-1 and 
TNF. These cells inturn activate neutrophils, B-cells (IgM/ IgA producing) and 
other IL17 producing CD4+ T-cells119,121-124. They derive the complement system 
of proteins and are implicated in autoimmune conditions such as rheumatoid 
arthritis125.  
 
Activation of the Foxhead box transcription factor, FoxP3, by TGF production 
and Th17 cells enhances the formation of Treg cells124. IL23 is required for the 
formation of Th17 cells, which are responsible for production of various 
chemokines (IL17A, IL17F, IL21, IL22 and IL17) that mediated recruitment of 
leucocytes and the interaction of T-cells with B and NK cells124-125. There is little 
literature published on the role that Th17 and Treg cells might have in the 
pathogenesis of aneurysmal disease, but the available data suggests that they 
might have a role in modulating the inflammatory response. Induced T 
regulatory cells (iTregs) are those expressing CD3+CD4+CD25+FoxP3+ and are 
involved in self-tolerance. These cells have been shown to suppress Th1/ Th2 
cells. These cells are derived from mature CD4+ cells outside the thymus and 
are different from the natural Tregs. Although they function in a similar 












Fig 1.9 T-cell subtypes 
After stimulation by antigen presenting cells (APCs) the T helper cells differentiate into variety 
of subsets, each defined by the cytokines that they secrete. TGF is a critical factor in 
differentiation of the two lineages with completely different attributes. Th1/Th2 are the 
inflammatory subset whereas the Th17/ Tregs are the anti-inflammatory cells. T-bet, T-box 











1.5.2.2 B-cells  
B-cells account for up to 40% of the mononuclear cell infiltrate in the 
aneurysm wall. B-lymphocytes express the surface markers, CD19+, CD20+ and 
CD40+, but also other markers suggestive of activation (Fig 1.10)101. B-cells 
might take part in formation of germinative centres of inflammation as 
histologically plasma cells have been demonstrated in the wall of aneurysms 
127-129. B-cell subpopulations produce immunoglobulins, but the significance of 
this within the aneurysm wall remains unknown. The activated B-cells and 
plasma cells in the aortic aneurysm wall express activation markers CD69+ and 
CD80+ 102, 129. There is increased production of IgA+ and IgG+ B-cells in the aortic 
wall compared to the blood of patients with abdominal aortic aneurysms102, 128. 
Work from other authors has suggested B-cell rich infiltrate concentrated in 
the adventitia of AAA is an autoimmune response to specific tissue antigens129. 
Genetic analysis from the adventitia of the aortic wall demonstrated 











Fig 1.10 B-cell subtypes 
Haematopoietic stem cells (HSCs) are Lin-B220-KIT+SCA1+ fms related tyrosine kinase 3 (FLT3) -
CD34- cells. B-cells originate from lymphoid progenitors that are Lin-KITlowSCA1lowinterleukin-7 
receptor (IL-7R)+ cells. B-cell subsets are pre-pro, pre and pro B-cells that are delineated as per 
their cell surface markers. The pre cells are released from the bone marrow and differentiate 
in response to antigenic stimulation and T-cell interaction. This in turn leads to phenotypic 
change. In adults the stem cell activation factor (SCF) and receptor activator of nuclear factor B 
ligand (RANKL) are involved in formation of pre-B and immature B-cells.  ETP, early T-cell-











It is possible that the interaction of T and B-cells is important in monocyte 
recruitment, activation to macrophages and alteration of VSMC phenotype 
from elastogenic to elastolytic with increased breakdown of ECM (Fig 1.11). Of 
the immunoglobulin’s produced, IgG1, 3 and 4 predominate and may be 
responsible for classical complement activation (via C3)131,132. The presence of 
Ig heavy chains indicates a polyclonal B-cell population resident in the 





Fig 1.11 Mechanism of B-T-cells interaction 
The interaction of B with T-cells is important in leading to monocyte recruitment, macrophage 






Monocyte/ macrophages activation 
VSMCs 
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1.5.2.3 NK-cells  
NK cells represent subset of T lymphocytes that express T-cell receptor 
(TCR) and markers of NK cells  (NK1.1), CD122+ and CD56+. These cells are 
CD4-/CD8-133, 134. These cells are able to produce gamma interferon and IL-4 
and have been demonstrated in aneurysm wall134, 135. This might be the reason 
why Th1 T-cells predominate in aneurysms over Th2 phenotype. It is likely that 
these immune cells are responsible for effector action on VSMCs and through 
these actions influence the ECM in the aortic wall.  
 
1.5.2.4 Macrophages 
Monocytes and macrophage can infiltrate the aortic wall and release 
proteases, elastases and MMPs directly in the adventitia and tunica media and 
therefore compromise VSMC function, ECM production and hence wall 
integrity136,137. These cells also produce pro-inflammatory cytokines namely 
TNF, INF and IL694,95,137-139 that recruit inflammatory lymphocytes into the 
aortic wall. These processes precede aortic wall dilatation and are involved in 
the growth and rupture of aneurysms in animal models94,135-137. It has been 
suggested that macrophage derived angiopoietin-like protein 2 accelerates 
development of AAA138,139. Additionally decreased Notch1 protein protects 
against the formation of AAA by preventing macrophage recruitment and 
attenuating the inflammatory response in the aorta140. 
 
Macrophage infiltration appears in the adventitia and outer media of human 
AAA and correlate to aortic diameter136. In AAA with and without ILT 
macrophages are associated with a high degree of neovascularization137,138 . In 







Neutrophil polymorphs are found within the luminal layer of ILT that occurs in 
AAA at the interface with luminal blood. They are known to produce neutrophil 
elastases that are responsible for breakdown of ECM. The ILT rich in 
neutrophils are more likely to lead to aortic degradation with increased 
likelihood of aortic rupture144-146. ILT can store proteases147,148 including 
neutrophil derived proteases and these can lead to inhibition of platelet 
aggregation or activation and aneurysm enlargement. Neutrophils produce 
neutrophil chemotactic factors, including IL8 and thus amplify its own 
recruitment148. 
 
1.5.2.6 Mast cells 
Mast cells have been described in the adventitia of the aortic wall149. Although 
these cells are known for there involvement in chronic inflammatory and 
hypersensitivity allergic reactions there enumeration in the aortic wall might 
suggest a role in the development of aneurysms149. Mast cell deficiency has 
been associated to reduced aortic expansion in murine studies and infusion of 
bone marrow derived mast cells from WT subjects returned the aneurysm 
phenotype to TNF-α deficient animals149. Conversely mast cell deficient mice 
when infused with bone marrow derived mast cells from IL6 or IFN deficient 
mice did not form aneurysms149. There might be redundancy in cell 
phenotypes and it might be that mast cells act by producing IL6 and INF that 









1.5.3 Inflammation and neovascularisation  
Chronic inflammatory process in the aneurysm leads to an angiogenic response 
in the aortic wall90. The density of endothelial cells is 15-fold greater in 
aneurysms compared with the normal aorta and 3-fold greater compared with 
atherosclerotic aorta99. This is associated with histological medial 
neovascularisation, elastin degradation and chronic inflammatory cell 
infiltration. The increased aortic wall proteolysis, with caseinolytic serine 
proteinases and gelatinolytic MMPs and their inhibitors (TIMPs), are localised 
to the vasa vasorum150,151. It was suggested that aneurysm development 
occurs through progression of angiogenesis and inflammation from the base of 
the atherosclerotic plaque into the aortic media. It is likely, however, that the 
process starts peri-adventitialy and works its way down into the tunica media 
147-149. Neoangiogenesis might be important in allowing recruitment of 
activated inflammatory cell to the aortic wall90,152-155 and has been associated 
with sites of rupture151. MMP 8 and 9, that are associated with angiogenesis, 
are located in the aortic adventitia157,158. It is probable that the MMP activity in 
the aneurysmal wall facilitates neovascularisation leading to inflammatory cell 
recruitment and further dysregulated proteolytic degradation of the 
ECM145,153. Exposure of integrin binding sites in the ECM in the aortic wall leads 
to endothelial-cadherin endothelial cell-cell adhesion interactions. The 
resulting positive feedback loop leads to the generation of proangiogenic 
cytokines and increased neovascularisation from the tunica adventitia into the 
tunica media157,159. B-T-macrophage interactions result in the generation of 
cytokines that induce the expression of molecules such as Ephrin B1 and its 
cognate receptor EphB2160,161 effecting cell-cell interactions in the 







1.6 Extracellular matrix proteins 
1.6.1 Elastin 
Elastin is a key extracellular matrix protein that is critical for the elasticity and 
strength of numerous biological tissues. This includes blood vessels, lung, skin, 
tendons and cartilage. Elastin enables the artery to stretch and recoil and 
maintain a consistent blood pressure and also has a critical role in supporting 
and maintaining cell health162-167. Tropoelastin is a soluble 70kDa protein, 
produced by VSMCs and fibroblasts that is the key building block of all elastin. 
 
1.6.1.1 The elastin gene 
There is one tropoelastin gene (ELN), in contrast to other connective tissue 
proteins such as the collagens that are expressed by complex gene families165-
167. The human ELN gene possesses 34 exons, giving rise to multiple isoforms. 
The mRNA encodes for a 72kDA polypeptide depending on the splicing 
pattern168. Removal of a signal peptide leaves a 60kDa protein. There are at 
least 11 human tropoelastin variants dependent on alternative splice variants 
(domains 22, 23, 24, 26A and 33)169,170. ELN is expressed before birth with the 
vast majority of elastin synthesis and deposition occurring before birth and 
within the first few years of life169-172. From a young age there is a reduction in 
the elastin synthesis with extremely low-level expression by middle age.  
Thereafter, there is a slow turnover of elastin in tissues, with small amounts 
being deposited in response to degradation in various tissues. Elastin is 
therefore a highly durable and stable structural protein with a biological half-
life of approximately 74-years in man173.  
 
ELN gene expression is variable and the primary transcripts can be spliced in 
different forms that contain various introns and exons giving rise to slightly 
different forms of tropoelastin varying in protein sequence and therefore 
composition167,174. Certain exons such as 26A are not transcribed in healthy 
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tissues, but highly expressed in damaged tissues (e.g. in skin following UV or 
thermal damage)175, 176.  
 
Decreased LOX levels have been reported in human hypertension. Thus 
defective elastin cross-linking might lead to decreased distensibility and 
compliance precipitating the development of hypertension177. In mice LOX 
inactivated phenotypes develop aortic aneurysms and perinatal death178. 
Genes associated with microfibrillar proteins; fibrillin-1 and fibrillin-2 are linked 
to Marfan syndromes. 
 
The elastin content is decreased in aortic aneurysms from 35±3.2% to 
approximately 8%±3% of dry weight in the tunica media of the aorta178,179. The 
elastin fibres are disorganised with increased breaks and altered ratio of 
desmosines/isodesmosines. The serum elastin peptides and plasma alpha 1 
antitrypsin levels are elevated, that are considered markers of elastin 
degradation178,179. The result of a decrease in elastin content leads to 
decreased ability of the aortic wall to deal with haemodynamic shear stress 
with low aortic distensibility180. 
 
1.6.1.2 Elastin fibre formation  
Cross-linkage of tropoelastin molecules occurs through the action of lysyl 
oxidase (LOX), an amine oxidase catalysing the cross-linking process through 
oxidative deamination of the epsilon-amino group of specific Lys chains. 
Tropoelastin combines with other proteins including elaunin, oxytalan and 
Emilin1 to form elastin fibres 180,181. Tropoelastin undergoes post-translational 
modification and cross-linkage in the cell cytoplasm followed by release into 
the extracellular environment with further cross-linking to create insoluble 
mature elastin 168,183-185. Tropoelastin contains two domains that are important 
for its cross linkage. A hydrophilic domain consisting of lysine and alanine and a 
hydrophobic domain consisting of glycine, valine and proline. These alternate 
to form the cross-linked networks that comprise the elastin fibres. The splice 
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junctions and cross-linked regions are highly conserved, whilst the 
hydrophobic domains are variable. The C-terminus region is highly conserved 
being composed of two cystine residues joined by a disulphide bond. 
Disruption of this area leads to dramatically reduced ability of tropoelastin to 
form fibres. Elastin fibre formation also involves other molecules including 
microfibrils of fibrillin and fibulins-4 and -5186.  
 
Tropoelastin assembles into globules of several microns in diameter and is 
chaperoned from the endoplasmic reticulum to golgi apparatus and then to 
the cell membrane. The elastin binding protein (EBP) is responsible for this. 
Tropoelastin is rapidly assembled and cross-linked into fibres in the 
extracellular space. The monomers self assemble via. coacervation, aligning 
and concentrating the proteins into spheres prior to cross-linking187. The 
coacervate tropoelastin is attached to the cell surface collecting further 




Fig 1.12 Elastin fibre synthesis 
Tropoelastin is synthesised on the rough endoplasmic reticulum and captured by molecular 
chaperone proteins, preventing aggregation and its storage in the Golgi apparatus. It is 
released in vacuoles into the EC space. In contact with other elastin fibres the chaperone 
interacts with the galactosugars of microfibrils releasing the tropoelastin that is aligned and 
cross-linked by LOX.  There is irreversible polymerisation between fibrillin, laminin, emilin and 
integrins to form elastin fibres188. 
  
1.6.1.3 Elastin protein composition 
Once formed the tropoelastin amino acid sequence is divided into two major 
domains. The hydrophilic (lysine and alanine) and hydrophobic (glycine, valine 
and proline) residues. These alternate to form cross-linked networks 
composing elastin fibres. The splice junctions and cross-linked regions are 
highly preserved whilst the hydrophobic domains are variable. The C-terminus 
region is highly conserved being composed of two cystine residues joined by a 
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disulphide bond. Disruption of this area leads to dramatically reduced ability of 
tropoelastin to form fibres. Elastin fibre formation also involves other 
molecules including microfibrils of fibrillin and fibulins-4 and -5186. Recent 
studies have demonstrated further action of various other proteins, namely co-
operativity between fibulin-2 and fibulin-5, emilin-1 regulating oxytalan fibre 
formation186. Emilin-1 is a prototype of a newly discovered family of 
glycoprotein, EMILIN181,182. Emilin-1 forms fibrillar network in vitro and in the 
ECM in tissues and co-distributes with elastin, forming an important 
component of elastic fibres187. Emilin-1 is localised to the interface between 
amorphous elastin and the surrounding microfibrils, and is required for the 
correct deposition of elastin181,182. Emilin-1 interacts in-vivo close to cell 
surface. It is likely that emilin-1 interacts with integrins and elastin fibres to 
form the ECM188-190. Integrins are widely present heterodimeric proteins that 
are essential in cell adhesion, migration, cell differentiation and ECM 
formation. Integrin 3, a promiscuous RDG-dependent integrin is important 
in associations between fibrillin-1, 2, MAGP-2 and fibulin-5191-194. The protein 
folding leads to a structure including poly-proline II, compact ß turns and an 
organisation that produces a flexible protein configuration. 
 
1.6.1.4 Elastin expression, activation and turnover 
Tropoelastin is produced by VSMCs and fibroblasts. Tropoelastin assembles 
into globules of several microns in diameter and is chaperoned from the 
endoplasmic reticulum to golgi apparatus and then to the cell membrane. The 
elastin binding protein (EBP) is responsible for this. Once deposited the 
production of tropoelastin is reduced and little turnover of mature cross-linked 
elastin occurs over prolonged periods (Fig 1.12). Majority of elastin is laid in 
the late foetal and early neonatal periods195. 
In the event of injury the production of tropoelastin is recommenced. This is 
regulated by numerous cytokines and growth factors such as insulin like 
growth factor-1, interleukin 1ß, TNFα and TGF196. A set of proteases grouped 
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under elastases remodel elastin. MMP 2, 3, 9 and 12 are known to degrade 
elastin 91-93. 
 
1.6.1.5 Elastin assembly 
Tropoelastin is rapidly assembled and cross-linked into fibres in the 
extracellular space. The monomers self assemble via. coacervation, aligning 
and concentrating the proteins into spheres prior to cross-linking187. This 
process occurs optimally at 37°C at pH 7-8 in physiological electrolyte 
concentrations.  The coacervate tropoelastin is attached to the cell surface 
collecting further tropoelastin units until released to nascent elastic fibre. 
There is interlinking of the tropoelastin with integrin proteins, cross-linking 
with LOX and deposition to form microfibrils incorporated into mature elastic 
fibres188. 
 
1.6.1.6 Elastin organisation and turnover in the vessel wall 
Elastin represents 57% of the protein content of normal thoracic aorta and this 
decreases to 30% in abdominal aorta. Collagen represents 20% of the aortic 
extracellular matrix. Elastin is therefore responsible for providing resilience in 
the aortic wall, while collagen is characterised by its resistance to high pressure 
and provides tensile strength to the aortic wall. It is the lost of elastin from the 
aortic wall that leads to progressive aortic enlargement. The subsequent 
reduction in the tensile strength of the aorta relies increasingly on the collagen 
fibre mesh that comprises the adventitia. The increase strain of the expanded 
aorta exceeds the capacity of the elastin and collagen to resist expansion 
leading to rupture.  
The quantity of elastin varies with age, aneurysm development and segment of 
aorta. It is thought to be VSMCs that are responsible for elastin production and 
fibroblasts, endothelial cells and inflammatory cells that are responsible for 
turnover of elastin and collagen. Histologically the aortic wall is arranged into 
three layers, namely intima, tunica media and tunica adventitia (Fig 1.5). There 
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are two dense condensations of elongated elastin fibres that are present in the 
media. These are the internal and external elastic laminae. Endothelial cells 
line the intimal lining, the media being composed of elastin fibres. Elastin is 
organised as ‘lamellar units’ of abundant organised elastin fibres that are 
cross-linked. VSMCs are also present in the media and interplay with the 
elastin in providing resilience and distensibility with cardiac cycle. There is a 
decrease in number of elastic lamellae in the infrarenal abdominal compared 
to the thoracic aorta. The tunica adventitia is the outer most layer that is 
composed of a thin network of collagen fibres with a minimal elastin content. 
The durability of elastin has been demonstrated in in-vivo, and when extracted 
in-vitro to be decades173,197,198. Elastin is degraded in a variety of conditions in 
various tissues - aging in the skin, emphysema in lung parenchyma in and 
aneurysms in aortic wall. Once deposited the production of tropoelastin is 
reduced and little turnover of mature cross-linked elastin occurs over 
prolonged periods. The majority of elastin is laid in the late foetal and early 
neonatal periods195, but in the event of injury the production of tropoelastin 
recommences. This is regulated by numerous cytokines and growth factors 
such as insulin like growth factor-1, interleukin 1ß, TNFα and TGF196,197. 
Enzymes with elastolytic activity such as MMP 2, 3, 9, 12, cathepsins K, H and S 
that are present in aneurysmal wall degrade and remodel elastin91-95. 
 
1.6.1.7 The relationship between inflammation and elastin 
remodeling 
There is emerging evidence that elastin peptides might be responsible for 
immunomodulation in the aortic wall198,199. There is continuous degradation 
during the lifetime of elastin fibres. The elastin peptides (EP) that are produced 
might be able to exert chemotactic effects on neutrophils, monocytes and 
other immune cells by acting like chemoattractants such as C5a and formyl 
peptide (FMLP)200,201. Once at the site of EP degradation they are stimulated to 
produce oxygen free radicals, elastases and MMPs91,196,201-203. These 
interactions are balanced in the normal aortic wall, as there is extremely slow 
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degradation of elastin and therefore EP formation. There are also numerous 
protease inhibitors in the aortic wall such as -1 antitrypsin, secretory 
leukocyte protease inhibitor-binding protein (SLPI), skin-derived 
antileukoproteinase (SKALP) and TGF that inhibits elastin degradation by 
increasing the expression of tissue inhibitors of metalloproteases 
(TIMPS)204,205. In aortic aneurysm wall this balance between synthesis and 
degrading enzymatic milieu is altered. The reason for this is not known and it is 
this chronic antigen stimulation of the immune system in the aortic wall that 
leads to aneurysm generation. In some cases this is measurable with increased 
pro-inflammatory cytokines such as IL-6, IL1 or TNF206,207. It is also 
recognised that there is inverted CD4:CD8 ratio caused by expansion of the 
CD8+ cells leading to a chronic low-grade inflammatory process71,208. EP 
strongly induces oxidised LDL and therefore influences neutrophil polymorphs, 
monocytes and lymphocytes201,209.  
 
Previous experiments on plaques have demonstrated EPs activate the elastin-
laminin receptor and it is the CD4+ T-cells that are attracted to the arterial 
wall199,200. This process is thought to be responsible for osteogenic response in 
VSMCs and lead to arterial wall calcification. The Th1 polarisation mediated by 
the EP binding on S-Gal leads towards a Th1 phenotype from previously non-
orientated lymphocytes. This pre-orientation is preceded by production of IL-6, 
12 and MMP9202. These cytokines might stimulate the secretion of proteolytic 
enzymes further contributing to the inflammatory process. This role of EP in 
maintaining and modulating the inflammatory process in the aortic wall has 
not been investigated in aneurysmal disease.  
 
1.6.1.8 Elastin and aging 
The elastin concentration decreases with age in the aorta, but the content 
remains the same210-212. This is due to increase in other components such as 
collagen212. Age can effect the amino acid structure of elastin207. The cross-
linking amino acids desmosine and isodesmosine remain unchanged at 3/1000 
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amino acid residues, and start to decrease after the age of 63 reaching 2/1000 
amino acid residues when aged 86208. Other studies have shown continuous 
decrease in amino acid residues with age throughout adult life and the content 
of histidinoalanine increases208. Histidinoalanine is an important residue in 
senescent elastin fibres and forms cross-links between neighbouring acidic 
proteins, collagen and elastin and might be responsible for age related changes 
in aortic wall elastin208. There is fragmentation of elastin fibres with aging and 
in atherosclerotic aortas209-211. This is explained as a consequence of 
mechanical fatigue failure due to pulsatile wall strain experienced by the aorta 
over the number of cardiac cycles over a lifetime212-214. There is a chemical 
proteolytic degradation of the aortic wall by MMPs with a decrease in the 
levels of TIMPs. 
 
1.6.1.9 Distribution of elastin within the vasculature 
The elastin content is higher in the thoracic aortic wall with 60 lamellar units, 
with a decrease to approximately 28 in infra-renal abdominal aorta. The most 
marked decline occurs between descending thoracic and supracoeliac 
aorta214,215. There is a 50% decrease in elastin content between the supra-renal 
and infra-renal aorta. This reflects a corresponding change in blood pressure 
with decrease in arterial compliance216.  
 
1.6.2 Collagen 
Collagen is present in all tissues and provides a structural framework and 
strength. Collagen contains one or more domains of a triple helical structure 
composed of α-polypeptide chains that have a repetitive triplet sequence 
containing glycine (Gly-X-Y). There are more than 28 different collagen types 
that can be classified into five sub-families. 
i)    Fibril forming – Types I, II, III, V, XI 
ii) Network forming – Types IV, VI, VIII, X 
iii) FACIT (Fibril associated collagen with interrupted triple helices) –  
  Types IX, XII, XIV, XVI, XIX, XX, XXI 
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iv) Multiplexin (Multiple triple helix domains and interruptions) - Types 
  XV, XVIII 
v) Transmembrane - XIII, XVII 
Collagens that are involved in the basement membrane surrounding cells 
include collagen Type IV {[α1(IV)]3}, XV {[α1(XV)]3}, and XVIII {[α1(XVIII)]3}. 
Aortic wall contains Type I and III collagen along with the basement membrane 
components152,223,224. The aortic wall tensile strength is drawn from discrete 
fibrillar bundles of collagen that range from 10-200nm in diameter225-227. The 
collagen fibres are present between the elastic lamellae and the SMC in the 
tunica media and the adventitia. Although the histological appearance of these 
fibres is loose they are highly effective and provide tensile strength under 
pulsatile blood flow228,229. 
 
1.6.3 Extracellular matrix degradation in aneurysmal disease 
1.6.3.1 MMPs and their inhibitors 
These are a family of zinc dependent endopeptidases that were first described 
by Busuttil in 1985230 and have subsequently been implicated in the 
pathogenesis of aortic aneurysms45,93,99,231-237.  
 
MMP 2, 9, 13 are considered to be important peptides in aneurysm 
development 84,234,237,238. The degradation of medial elastin in the aortic wall 
appears to be an initial step in the cascade of event leading up to aneurysm 
development. Elastases (MMP2, 7, 9, 12) and collagenases (MMP1, 8, 13) can 
degrade elastin and collagen 46,232-240. MMP 13 is expressed in VSMCs in the 
aortic wall 71,72,234. Elevated levels of MMP1 mRNA and an increased MMP1 to 
TIMP-1 ratio are found in aneurysm wall compared to normal aorta 234,240. 
Real-time reverse transcriptase polymerase chain reaction (RT-PCR) 
quantification of gene expression has revealed MMP1 and 3 to be elevated in 
the aortic aneurysm wall compared to non-dilated regions of aorta 241. 
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Increased extracellular matrix degradation is characterised by increased gene 
expression ratio of MMP1 to TIMP1, 2, 3 and MMP3 mRNA to TIMP2 mRNA. 
 
Tissue inhibitors of matrix metalloproteinases (TIMPS) are a family of 4 
naturally occurring inhibitors of MMPs Cellular expression of TIMPs occurs at a 
transcriptional level with stimuli inducing concurrent MMP and TIMP 
production. As with MMPs, TIMP levels are increased in aortic aneurysms. 
Studies on normal and aneurysmal aortas have shown that MMPs are 
expressed in the presence of TIMPs212,151,242-244. TIMPs dampen the potential of 
widespread tissue damage of MMPs and enhancing their levels has been 
postulated for potential disease modulation (e.g. the adenoviral over 
expression of TIMP-1 in a mouse model of atherosclerosis leads to a reduction 
in lesion size251,252. Expression of TIMP-1 in rat aorta prevents aneurysm 
expansion and rupture247-249. TIMPs could therefore be specifically targeted in 
cardiovascular conditions such as aneurysms that involve excessive tissue 
remodelling234,250,251. TIMP3 is significantly up-regulated in aneurysm aortic 
wall and affect VSMC apoptosis232. It is likely it acts to inhibit the effects of 
MMP3 and stromolysin 1232.  
 
1.6.3.2 Cathepsins 
These are a potent group of elastolytic enzymes that have also been implicated 
in aortic aneurysm development252-254. Most cathepsins are serine proteases, 
although some such as cathepsin D are aspartic proteases. Cathepsins work 
best in intra-cellular lysosomes that provide an acidic environment and are 
important in peptide degradation and antigen presentation.  Macrophages are 
implicated in release of cathepsins in the extracellular space254. Cathepsins are 
inhibited by serine protease inhibitors, such as cystatin A, B and C255-257. 
Cystatins A and B are type I cystanins and are intracellular cathepsin inhibitors. 
Type II cystatins include cystatin C – that is the most potent cathepsin 
inhibitor259. Cystatin C shows the highest inhibiting properties to cathepsins L 
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and S, followed by B and H. Interestingly the proteolytic activity of some 
cathepsins is ten times more powerful than MMPs47. 
 
Aneurysmal wall is characterised by the up regulation of cathepsins and down 
regulation of cystatin C253. Cathepsins are involved in the formation of 
microvessels and VSMC apoptosis which characteristic of aortic aneurysm 
development. Levels of cathepsins B, D, and G are elevated in aortic aneurysms 
by 1.5 fold compared to normal aorta253. Levels of cathepsin C and L are also 
elevated in the aneurysm compared to the normal aorta47,252,253.  Aneurysm 
tissue had less serine protease activity compared to thrombus that had high 
activity compared to clot252. Intimal VSMCs and macrophages express 
elastolytic cathepsins S and K. Cultured human VSMCs expresses cathepsin S 
and K on stimulation with IL-1 or -interferon. An important limitation of this 
work is that the cathepsins levels are compared between aneurysmal and 
normal aorta, however the presence of atherosclerosis would confound the 
results, as it is associated with significantly elevated cathepsin B, H, L and S 
levels45,253,257,259. 
 
Cystatin C deficiency is associated with progression of aneurysms260. Genetic 
polymorphisms in the cystatin C signal peptide and the signaling peptide 
(+148G>A and -82G>C, respectively) demonstrate a slower growth rate for 
aneurysms than compared to the +148AA and -82C genotype48. The deficiency 
of cystatin C in ApoE-/- mice leads to the thinning of the tunica media and 
aortic dilatation. These effects are thought to be mediated as a result of the 








1.7 Diagnostic imaging 
Imaging of aneurysms has been carried out using a variety of techniques. The 
early techniques such as computer tomography provided anatomical detail, 
whilst more recently developed and used functional imaging techniques 
provide an analysis of the biological processes that are on going in the aortic 
wall. 
 
1.7.1 Chest radiography 
Many asymptomatic TAA are first detected on chest x-rays. Ascending aortic 
enlargement produces convex contouring of the right superior mediastinum. If 
the aneurysm is in the aortic root only, then the cardiac silhouette may 
obscure it. Aneurysms need to be large and AAA is not delineated (Fig 1.13).  
 
Fig 1.13 Chest radiograph of thoracic aortic aneurysm  





1.7.2 Ultrasonography and echocardiography 
Ultrasound and enhanced scanning for abdominal and echocardiography for 
thoracic aneurysmal disease are relatively portable tools that allows cheap, 
non-invasive diagnosis of acute aortic disease. In case of TAA, aortic valve 
pathology and detection of complications such as AD and IMH can be made. 
Transoesophageal echo (TOE) is the most accurate and reliable method of 
echocardiography for the thoracic aorta. It is limited by the views obtained, as 




Fig 1.14 Transthoracic echocardiogram of ascending aortic aneurysm 
Long axis view of the left ventricular outflow tract showing the dilatation of the aortic root and 
the proximal ascending aorta (Ao). The leaflets of the bicuspid aortic valve are visible (arrows).  
 
1.7.3 Computer tomography (CT) 
This is a widely used method for imaging of the vascular tree. It provides a 
quick and anatomically detailed assessment of the aortic size, extent and 
location of aneurysmal disease. Modern 256-slice scanners can acquire high-
resolution full body 0.7mm slice images in a single breath hold.  Not only do 
they help define the nature of the aneurysm, but they also diagnose any 
complications and development of acute aortic syndrome. Computer software 
programmes allow 3-dimensional (3D) reconstruction of the images that aid 
the surgeon in operative and endovascular planning, as the scans can be used 
to manufacture bespoke aortic endografts for the patients. The main 
disadvantage of CT is the need for intravenous contrast agent for optimal 
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spatial resolution. This may be contraindicated in patients who have contrast 
allergy or at a high risk of developing contrast induced renal failure. There is 
also the problem of radiation exposure form the scans. A single chest CT is 
equivalent to 400 chest x-rays, whereas an abdominal CT has the same 
radiation exposure as 500 x-rays.  For an aortic CT scan the radiation exposure 
is 9.9mSV (millisievert) with the average background exposure in the UK being 
1-3mSv per year.  
 
1.7.4 Magnetic resonance imaging (MRI) 
1.7.4.1 Basic principles 
This technique is based on the principle of electromagnetic activity (EMA) of 
atomic nuclei. The nuclei contain protons and neutrons that have specific 
spins. When the spin of neutrons and protons does not cancel each other 
fields, we are able to detect EMA. When performing a clinical MRI we utilize 
the protons in the hydrogen nucleus in water molecules. The quantity of water 
alters in various tissues with varying physiology and in pathological conditions. 
The hydrogen nuclei rotate around their own axis. A small magnetic field is 
created as a result of this rotation and called a magnetic moment. When we 
place a strong external magnetic field we align the hydrogen protons either in 
parallel or antiparallel directions to the z-axis of the field. The magnetic 
moments by themselves cancel each other out. There is however alignment of 
hydrogen nuclei after redistribution so that a greater proportion of the protons 
are aligned parallel to the field. This is the moment of the nuclei are 
magnatised. During this interaction the spinning nuclei wobble or precess. This 
occurs at a frequency that can be calculated by Larmor equation. At each 
particular frequency we can change the spin of the protons in the magnetic 
field allowing the signal to change.  
 
MR signal is generated because magnetization is a field with a vector quantity. 
This has a longitudinal component along the z-axis and transverse component 
along the XY-axis. The transverse magnetization processes around a receiver 
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coil induces a current (as per the Faraday principle of induction) and this 
current becomes the MR signal.  It is therefore the transverse magnatisation 
field that produces the MR signal. As the radiofrequency (RF) energy source is 
removed, the magnetization vector realigns with the axis of the external 
magnetic field and the spins of the protons returns the dynamic equilibrium. 
This time interval during which the longitudinal magnatisation increases or 
recovers is referred to as the T1 relaxation time (T1R denoted in milliseconds 
(ms)). The transverse magnetization delay is referred to as the T2 relaxation 
time. Individual tissues have different T1 and T2 values. For example water has 
a relatively long T1 and T2, whereas fat has shorter T1 and T2.  
 
1.7.4.2 T1 and T2 relaxation 
The longitudinal magnetization recovers as spinning nuclei release energy 
during the T1 relaxation. This phenomenon is also referred to as the spin 
lattice relaxation principle. The transverse magnetisation is dephased as the 
interaction between the spinning nuclei and their magnetic fields during T2 
relaxation. This principle is referred to as spin-spin relaxation. In case of T2, the 
magnetic field can be dephased as a result of inhomogenities that occur in the 
field. The magnetic field is not exactly the same everywhere as there is 
differential interaction of air, metals or indeed limitations of magnetic 
construction. This decay of the transverse magnetisation as a result of these 
factors is referred to as T2* decay.  While T2 is due to random motion of 
hydrogen nuclei moving within the moving water molecules. The T2* is the 
resultant field as the source is static but there are magnetic field 
inhomogeneities within the MR scanner. The T2* decay is therefore shorter 
than T2 and occurs rapidly in fat and water.  
 
1.7.4.3 Repetition time and echo time 
The tissue contrast created on the MRI is as a result of the differences in T1, T2 
and the proton densities. The creation of the MR image is due to the 
parameters referred to as a repetition time (TR) and echo time (TE). The TR is 
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defined as the interval between the two RF pulses (ms). TE is time between 
application of the RF pulse and the peak of the echo detection after this. The 
TR and TE affect the relaxation times in the different tissues allowing 
anatomical delineation. 
 
1.7.4.4 MR signal localization 
An MRI gradient is the application of linear variation in the magnetic field to 
detect a 3D location of the signal. This process is achieved by passing electric 
currents through specific ‘gradient coils’. This leads to protons within a region 
being excited by the RF pulse. The information that is detected about the 
phase shifts in spinning protons is stored within the MR system referred to as 
the ‘k-space’. Their location can be calculated using mathematical modeling 
using the inverse Fourier transform.   
 
1.7.4.5 Generation of MR sequences 
The pulse sequences formed as a result of the coil gradients and RF pulses are 
used to form a MR image. There is an RF pulses for each x-, y- and z- gradients. 
MR sequence generation is based on spin echo or gradient echo sequence. 
These can be 2-dimensional or 3-dimensional with volume of multiple sections 
that are obtained at a signal acquisition time.  
 
1.7.4.6 MR T1 and 3D T1-mapping 
Longitudinal relaxation time (T1) for each pixel (T1-mapping) has been 
hypothesised to provide additional information about the characteristics of the 
aortic wall262,263. Inversion recovery (IR) sequence is the gold standard 
sequence for T1 measurement. This needs a long acquisition time and is 
therefore clinically limited in utility. A modified Look-Locker sequence can be 
used to speedup the 3D T1-mapping. The importance of T1 quantification in 
detecting change in pathophysiology and directing therapy also needs further 
investigation. 
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1.7.4.7 MRI in aortic imaging 
MRI allows excellent contrast between soft tissues and blood flow can be 
visualised in the heart and aorta. Magnetic resonance angiography (MRA) 
requires the use of a paramagnetic contrast agent such as gadolinium or a 
technique called “flow-related enhancement”. The latter uses signal generated 
as a result of the movement of blood. Axial and sagittal oblique T1 weighted 
fast spin echo (FSE), axial “bright blood” gadolinium enhancement 3D MRA 
that is ECG-trigger gated is ideal. The advantages of MRA are that there is no 
nephrotoxic contrast agents or ionising radiation.  The disadvantage of this 
modality is that it is not as rapid as a CT. Even the fastest scans take 10-15mins 
compared with a single breath hold for a CT. 3D MRA can be rapid, however it 
does not provide information on aortic wall itself, therefore axial images are 
needed to delineate intramural dissections, wall thickening and other acute 
vascular pathology i.e. PAU, haematoma, adenopathy.  The scanners are noisy 
and very narrow a large minority of patients do not tolerate the scan. The need 
to remain still to reduce motion artifact in an elective compliant patient is not 
a problem, but in an acute clinical setting with critically ill patient that needs 
complex monitoring the scan is not possible. The presence of any ferric 
metallic prosthetics material in the patient also precludes from MRA. 
 
1.7.5 Positron emission tomography (PET) 
PET is a nuclear imaging technique that creates a 3D image of functional 
processes that occur in the body. The system detects pairs of gamma rays 
emitted indirectly from a positron-emitting radionuclide (tracer) that is 
introduced into the body on a biologically active molecule. Two photons result 
from the disintegration of the positron and are emitted in opposite directions 
(i.e. at 180 degrees from each other) and recorded in coincidence by the 
detectors surrounding the subject. A 3D image is created at the same time as 
the PET scan with the use of CT.  
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Depending on the radionuclide, a wide variety of physiological and 
pathological processes can be studied at the molecular level. However, in 
routine clinical practice, in the vast majority of PET studies, the most 
commonly used biologically active molecule for PET is fluroride-18 (18F) 
labelled deoxyglucose, creating the tracer fluorodeoxyglucose (18F-FDG). 18F-
FDG is injected into the body where it may accumulate in the tissues with high 
metabolic activity.  During the positive beta decay of 18F, a positron is emitted. 
This travels in tissue for typically less than 1mm during which time it loses 
energy and interacts with an electron. The encounter annihilates the electron 
and positron, releasing gamma photons that move in opposite directions. 
These are captured by a scintillator generating a burst of light that is detected 
by photomultiplier tubes.  
 
FDG is a glucose analogue, transported into cells using glucose transporters 
(GLUTs). Once inside the cells, FDG is phosphorylated to FDG-6-phosphate that 
cannot be hydrolysed by the enzymes of the glycolytic chain, and therefore 
accumulates in the cell. FDG-PET recognises increased metabolic activity and is 
mainly used for cancer imaging. Cellular glucose metabolism is significantly 
increased in most types of cancers because of increased expression of 
membrane transporters or increased hexokinase activity. Increased uptake is 
observed in many non-neoplastic physiological and pathological conditions. For 
example, when inflammatory cells are activated they have an increase in 
glucose metabolism and uptake264-267. This has been evaluated in various 
experimental settings, including induced inflammatory states, activation of T 
lymphocytes in bacterial abscesses or in B-lymphocytes after viral 
infection264,266-268. The lack of specificity for tumours provides a powerful tool 
for using PET to evaluate inflammatory and infectious conditions including 
monitoring of vascular graft infection268-270.  
 
The amount of 18F-FDG uptake correlates to metabolic activity measured by an 
indexed value – SUV (standardised uptake value)270-274. Therefore, rapidly 
dividing cells, active infection and inflammation will all be sites of high PET 
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tracer uptake. It is believed that proteolytic and inflammatory processes are at 
work in the development and propagation of aortic aneurysms and acute 
aortic syndrome.  There is therefore a scientific basis to use these scans for 
determining aortic activity and predicting aneurysm behaviour. It should be 
noted, however, that 18F-FDG uptake is often seen in the arterial wall, in the 
absence of any known inflammatory vascular disease269-271. 
 
18F-FDG-PET/CT has already an established role in oncology diagnosis 
confirmation and assesses response to therapy. It has also been used to assess 
stability of atherosclerotic plaques265,271-273.  High SUV in the setting of 
atherosclerotic plaques has been linked to cardiovascular risks, levels of 
inflammatory markers and macrophage infiltration into tissue271-274.  
 
Glucose uptake within cell in the aortic wall via facultative passive GLUT 
transporters is varied. The glycolytic activity in the aneurysmal versus normal 
aortic wall might be different. There have been data reported to suggest that 
glucose metabolism is increased in AAA patients related to MMP9 activity275.  
GLUT1 is the major isoform in most cells, whilst GLUT 3 is responsible for 
increased energy utilization as has high affinity for glucose. It is also the main 
GLUT subtype in immune cells such as neutrophils and macrophages276-278. 
Hence energy utilization by the aortic wall is a reflection of the various cells 
composing the aortic wall and their glycolytic activity. In AAA models the 
GLUT3 synthesis is dependent on MMP9 levels and this might be a reflection 
on macrophage aortic wall content. In ApoE-/- angiotensin II infused animals 
the expression of GLUT1 decreases in the aortic wall and GLUT3 increases 
which might be a reflection of immune cell infiltration (monocyte-
macrophages) in aortic wall279. GLUT10 deficiency is associated with 
upregulation of TGFβ pathway in the arterial wall, a finding in Loeys-Dietz 
syndrome and arterial tortuosity syndrome (an autosomal recessive disorder 
characterized by tortuosity, elongation, stenosis and aneurysm formation with 
elastic fibre disruption in aortic media. The identification of GLUT transporter 
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gene involved in arterial dilatation denotes a link between GLUT, aneurysm 
development and type 2 diabetes280. 
 
1.7.6 Single photon emission computer tomography (SPECT) 
This technique is very similar to PET, in its use of a radioactive tracer and 
detection of gamma rays. However, the tracer used emits gamma rays that are 
directly measured. During a PET scan the emissions or the coincident events 
provide more radiation events per unit of tissue therefore providing greater 
information on tracer uptake. PET therefore provides higher resolution than 
SPECT (which has a resolution of 1cm). SPECT is, however, quicker with a total 
scan time of 15-20 mins (compared with 60-90 mins for a PET scan) as two 
gamma camera’s can be rotated around the patient varying the angle by 3-6o 
with a full 360o rotation for a complete reconstruction.  It has been validated in 
myocardial perfusion scanning with the use of 99mTc-sestamibi or 99mTc-
tetrofosmin as a tracer. SPECT conducted after a stress stimulus reveals areas 
with relatively low blood flow when compared to previous images264,274,281,282. 
This technique is now being applied to aortic aneurysms in experimental work 
with novel tracers that are though to accumulate in inflammatory areas in the 
aorta264,274,282-286. 
 
1.8 Predicting aortic aneurysm behavior 
Clinical symptoms and aortic diameter dictate intervention for aortic 
aneurysms287-289. Multivariate regression analysis looking at factors responsible 
for increased risk of aneurysm rupture or dissection demonstrate that size 
above 5.5cm for abdominal and ascending aortic aneurysm and a size above 
6.5cm for descending thoracic aortic and aortic arch are associated with a five 
to ten fold increase in complications21,22,25,290. Female sex, connective tissue 
disease, smoking and COPD are all negative predictors of outcomes. The risk of 
rupture with time is 11 times worse with aortic size of 5.0 to 5.9 cm and nearly 
27 times worse with size of 6.0 cm or higher when compared to aneurysms less 
than 4cm diameter. Larger aneurysms have higher wall shear stress as dictated 
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by Laplace’s law. Leading to high rupture risk. It is also long been recognised 
that the presence of symptoms indicates an ‘unstable aortic wall’ that is likely 
to rupture291,292. Apart from these two parameters originally described 45 
years ago there is at present, no other way to predict the biological events 
going on in the aortic wall that are likely to represent aortic aneurysm 
expansion, rupture or dissection. Functional imaging aims to provide a 
mechanism to study the cellular and molecular events ongoing in the aortic 
wall that are likely to lead to a better understanding of aortic wall behaviour.    
 
1.9 Biological pathways for molecular imaging 
The main mechanisms that have been studied in human aneurysm 
development are aortic inflammation, angiogenic response, haemorrhage, 
elastin synthesis, proteolysis and thrombosis. The presence of inflammatory 
infiltrates (characterised by a mononuclear cell infiltrate that differentiates to 
tissue resident macrophages) and neovessels in complicated plaques were 
reported as early as the 1930s286-289,293. These neo-capillaries develop in 
complicated plaques at the interface of the lipid core, the cap and the media 
with ingress from the adventitia. They are thought to allow leukocyte 
diapedesis and accumulation of other inflammatory mediators into the aortic 
media. The development of these neo-vessels from the vasa vasora is linked to 
the extent of inflammation that follows, with subsequent haemosiderin 
deposition, propagation of inflammation and weakening of aortic wall144,293. In 
aneurysms, the breakdown of collagen, elastin, proteoglycan matrix is linked to 
an inflammatory cascade, vascular oedema and adventitial 
neoangiogensis144,294,295.  It is this proteolytic injury that weakens the aortic 
wall and leads to rupture113,294,295. ILT is generated at the blood luminal 
interface114,296-298. Luminal platelet activation and fibrin formation activates 
leukocytes propagating the aortic matrix degradation. These biological 
pathways explain the initiation, propagation and development of acute 
complications of aortic aneurysms. Any new imaging modalities will have to 
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specifically target the cells and molecules involved in these pathways to study 
aneurysm clinical expression.  
 
1.9.1 Activity based probes 
MMPs produced by macrophages, VSMCs and the endothelial cells are 
important in regulation of the ECM in the aortic wall. MMPs are also 
responsible in cardiac remodelling. MMPs can be coupled to 123I, 99mTc, 18F or 
gadolinium to enable imaging using SPECT-CT, PET and MRI296-300. Other 
molecular probes could depend on the enzymatic activity rather than simple 
expression of their targets. This allows for amplification of imaging signals. For 
example, an MMP probe that contains a substrate for MMP 2, MMP 3, MMP 9 
or MMP 13 conjugated to cyanine 5.5 for near infra-red fluorescence 131,287,288. 
If there is no MMP activity, the fluorescence is absent as the molecules are 
close together. If, however, there is peptide substrate that can be cleaved by 
MMP it leads to liberation of cyanine 5.5 leading to an up to 200 fold increase 
in signal137,261,300. The sites to which the probes are localised reflect sites of 
enzyme activity and therefore might represent metabolically active aortic wall.  
Similarly cathepsins that possess cysteine protease activity in lysosomes are 
important in ECM regulation. Normal human aorta has minimal cathepsin 
expression, however diseased aortic tissue expresses cathepsin S and 
K261,292,301,302. Attaching cyanine 5.5 to generate a probe that can be image 
using fluorescence tomography might allow cathepsin localisation in tissue301-
304. Near infra-red fluorescence localises to sites of disrupted elastin fibres in 
association with inflammatory cells expressing cathepsin302,303. This has been 








Functional imaging of aortic aneurysms with existing and novel PET and MRI 




1) To elucidate the association between 18F-FDG uptake and inflammatory cell 
composition of the aneurysmal wall 
 
2) To characterise the relationship between 18F-FDG uptake and of a novel 
elastin specific MR contrast agent (ESMA) to inflammatory cell composition 
in aneurysm wall in the ApoE-/- ATII model, and to use these to predict 
aneurysm behaviour 
 
3)  To use the ApoE-/- ATII model to determine the efficacy of treatment with 
an antagomir to microRNAs that regulate elastin turnover 
 
4) To investigate the interaction between tissue-derived inflammatory cells 
and VSMC function in order to determine whether specific inflammatory 









Chapter 2: Optimization of PET-CT, use laser scintigraphy 
and creation of 3D masks for aortic aneurysm biopsy 
 
2.1 Introduction  
PET creates high-affinity three-dimensional tomographic images of the 
distribution of positron emitting radionuclides that are injected into the body. 
These can be radiolabelled ligands, substrates, antibodies, drugs and other 
biomolecules that are tracers for specific biological processes. The resultant 
images are ‘functional’ as they demonstrate biochemical and/ or physiological 
activity of the underlying tissues. The initial and currently used PET study 
protocols focus on cerebral, myocardial and oncological metabolism. The most 
widely used substrate being flurodeoxyglucose (18F-FDG) as a marker of 
glycolysis. However FDG uptake is non-specific and is positive in any highly 
metabolically active cell. Within tumours and inflammatory lesions it is taken 
up by macrophages and other blood cells. It remains to be seen if 18F-FDG PET-
CT would provide useful information for the investigation of aortic aneurysms. 
In order to provide clinical utility the PET is coupled with a CT scan to provide 
anatomical information on the vasculature. The accurate image fusion to 
generate a precise three-dimensional map of the aorta with the PET uptake is 
vital for locating the aortic wall with the specific PET FDG uptake. The 
subsequent process is to translate this data into a 3D phantom that would 











1) Develop a protocol for performing aortovascular PET scans using 18F-
  FDG that would allow the most optimal vascular tracer uptake in the 
  aortic wall; 
2) Develop an imaging software protocol to allow accurate image fusion 
  of PET and CT data to generate hybrid fused PET-CT images to guide 
  surgical biopsy; 
3) Develop an anatomically patient specific and precise 3-dimensional 
  segmentation of the aortic vasculature with the PET data overlay; 
4) Develop a methodology to carry out accurate aortic biopsies from  
  sites of known 18F-FDG uptake using laser scintagraphy; 
5) Validate the aortic masks for accuracy using phantom scanning and 
  retrograde image reconstruction. 
 
2.3 Methods 
2.3.1 Patient preparation  
It is imperative to minimise the tracer uptake in normal tissues whilst 
maintaining a high uptake in target structure (aortic wall). Patients were 
therefore not allowed to consume glucose prior to the scan. Adequate 
hydration is important to ensure low 18F-FDG concentration in urine (as a 
radiation safety precaution post procedure) and therefore up to one litre of 
water was given 2hrs prior to the scan. The patients were kept seated post 18F-
FDG injection to prevent increased mobilisation of 18F-FDG in the muscles.  
 
Patients who were diabetic or those with impaired renal function with 
creatinine clearance of < 30mls/min/1.7m2 were admitted 12hrs prior to the 
scan for intravenous (IV) hydration. This was discontinued 4hrs prior to the 
scan. The scan was carried out late morning and the blood glucose values were 
normalised as much as clinically possible. All patients had their blood glucose 
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measured and if value was >7mmol/l the scan was rescheduled for another 
day. Care was also taken for patients on metformin that were due to get 
iodinated IV CT contrast medium. They required further IV hydration post scan 
and a baseline and post procedure renal function check prior to discharge. 
Patients were provided with patient information sheet that detailed the 
procedure as per the ethics, research and development protocols (appendix 1, 
page 333). 
 
2.3.2 Positron emission tomography  
As with PET scans carried out for investigating oncological, inflammatory and 
infectious processes, the patients were starved for at least 6hrs prior to the 
scan. This was to minimise background uptake from the gastrointestinal track 
that would obscure the abdominal aortic 18F-FDG uptake. Additionally when 
investigating inflammatory processes glucose loading significantly decreases 
glucose transporters expression and 18F-FDG uptake in inflammatory lesions.  
 
A net 3% accuracy of 18F-FDG activity was verified by the user. 18F-FDG (300-
400 MBq, 2.5 MBq/kg body weight ±10%) was injected through an indwelling 
catheter 60mins before the acquisition of the scan.  This is normally 90mins for 
oncological studies but was reduced for vascular imaging as this optimal 
vascular signal to background uptake. Images are then acquired with an 
emission scan photons collected from the patient and transmission scan (using 
an external gamma source). We carried out a classical acquisition from the 
skull base to the femoral heads over 30mins (Table 1 and 2, appendix 2, page 
343). The effective radiation dose being 0.025mSev/MBq. The sequences were 
recorded at each couch position for 3mins. Coronal, sagittal and transaxial 
images were based on ordered subset expectation maximisation iterative 




2.3.3 Computer Tomography  
The CT scan of the thoracic, abdominal or thoracoabdominal aorta was carried 
out using 64 x 3.75mm detectors, a pitch of 1.5 and 5mm collimation (150kVp 
and 30mA in 0.8s), using a Philips Brilliance 64 scanner (Philips Inc. US).  A 
scout CT scan was carried out with helical CT from the region of interest 
namely aortic arch to femoral head. A non-contrast and contrast CT scan was 
carried out following the administration of intravenous contrast agent. The 
initial CT was solely carried out for correction of attenuation, scatter and co-
localisation. The optimal tube current, voltage, slice thickness, rotation time 
and pitch were chosen to minimise radiation exposure for the patient. The 
diagnostic contrast CT was carried out post PET scan. We ensured that the 
patient was within the CT-AC field of view (FOV) and in the same position as 
during emission scanning. The breathing pattern and rate was monitored as 
deep inspiration at chest causes misintegration and artifacts compared to 
normal breathing. If CT quality was deemed not of diagnostic quality by the 
radiologist a repeat scan was carried out. The CT angiogram range is 
determined by the location of the aneurysm. The patient set-up, scan margins 
are outlined in Table 3 (appendix 2). The CT parameters used are outlined in 
Table 4 and the CTA parameters in Table 5 and 6 (appendix 2, page 343). 
 
2.3.4 Image acquisition  
The integrated PET/CT system allowed sequential acquisition of corresponding 
PET and non-contrast CT images with both data sets intrinsically co-registered 
providing that the patient did not move during or between the acquisitions. 
Both the CT and PET data sets were subsequently fused using the Hermes 
software system (Hermes Medical Solutions Ltd, UK). This allowed fused 
PET+CT data to be seen over the complete data set. A further IV contrast CT 
scan was acquired for aortovascular anatomical delineation. This data set was 
fused with the PET imaging using the Hermes or OsiriX software packages.  
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2.3.4.1 PET image reconstruction 
PET emissions information is corrected for detector efficiency and the 
geometric response, system dead time, scatter and attenuation, hence 
normalisation is carried out to account for these variables. Some of these 
corrections are carried out during the reconstruction process. This was done to 
obtain the quantitative information from the scan. The data present in 3D 
mode used to perform 3D reconstructions or rebinned in 2D format for slice-
by-slice display. We used the iterative reconstruction algorithms to perform 
the reconstruction with and without attenuation correction. This corrects for 
possible reconstruction artifacts that arise due to CT based attenuation 
correction. The reconstructed 3D volume data set is seen in transaxial, coronal 
and sagittal planes. Minimum and maximal intensity projections are also 
generated. All data sets were standardised at reconstruction to obtain the 
SUVmax and comparable resolutions. This is important, as the SUV values need 
to be interchangeable between the patients.  
 
2.3.4.2 CT image reconstruction 
Filter backed projection algorithm was used for image reconstruction. The 
images were in 0.625mm slice thickness. The slice overlap and filter were 
constant. The reconstruction kernels used modulate image characteristics 
within the slices such as spatial resolution, edge enhancement and signal to 
noise ratio. Longitudinal z filters were used to change the slice sensitivity 
profiles. The attenuation values were normalised to water density to assign 
device and time independent numerical value to the reconstruction. The z-
dimension is almost as high as transaxial resolution allowing high affinity image 
visualisation in coronal and sagittal views. The CT values were calculated as: 





2.3.5 Laser Scintagraphy 
This technique is used to fabricate a highly accurate scale model of the aortic 
aneurysm using three-dimensional computer aided design data. The PETCT 
DIACOM data sets were used to generate a 1mm manual segmentation of the 
aortic profile in Amira 5.3.3® software (Visage Imaging Inc. San Diego, CA). The 
PET data was overlaid on the mask to generate fenestrations corresponding to 
regions with varying 18F-FDG uptake as represented by SUVmax. The SUVmax 
ranges varied from patient to patient and upto 10 fenestrations were placed 
per aortic mask. These data files were transferred to be used in Magic v7.5 
(very-large-scale-integration layout tool, Magic Software Enterprises, US). This 
allows the files with the aortic model and the fenestrations to be subtracted to 
generate the final aortic model. This was given various thickness ranging from 
100 to 500µm, to best try the model that would allow aortic biopsies to be 
undertaken. To optimize process flows, laser sintering is carried out using the 
Formiga P100 (Eos GmbH, Germany), which can generate individualized masks 
of the aorta from a polyamide polymer. This material has high strength and 
good flexibility, is chemically inert and malleable. The turnover time for the 
production of this mask is less than 12hrs. The masks generated are washed 
and steam sterilized for 15mins at 121°C before use.  
 
2.3.6 Phantom generation and validation 
The aortic masks that were generated using the laser scintigraphy technique 
were tested for accuracy. PET and CT scans were carried out on the masks with 
sites of specific 18F-FDG uptake as points of fenestration marked with surface 
tracers. The tracers contained the CT contrast agent (Omnipaque350™, GE 
Healthcare, Canada), as well as 10MBq of 18F-FDG. The process was used to 
compare the accuracy of the mask generated and the sites selected from the 
fused PET-CT as fenestration points at sites of varying 18F-FDG uptake. This 
process acted as a validation tool; as once the mask was generated using the 
fused PET-CT DIACOM data sets, it was rescanned with the fenestrations 
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marked out and the image overlaid onto the previous PET-CT to “backtrack” 
for resolution and accuracy. 
 
 
Fig 2.0 Aortic mask generation and phantom testing  
A) Aortic mask generated for a patient used to place phantom radiotracer markers. B) Locating 
the radiotracers in 3-dimensional imaging of the aorta on PETCT scanning. C and D) Fused 
PETCT DIACOM dataset used to align and co-localise the tracer to specific areas of the aortic 
wall.  
 
2.3.7 Image analysis 
All the human images were pre-operatively analysed and reported by a senior 
nuclear medicine physician and a vascular radiologist on Hermes Medical 
Solutions platform (Nuclear Diagnostics AB, Stockholm, Sweden). All the scan 
data was also reconstructed and processed by the researcher in Hermes, OsiriX 
software (OsiriX Inc. San Antonio, Texas) and Amira 5.3.3® (Visage Imaging Inc. 
San Diego, CA). The slices were indexed at 3mm intervals with the PET data (Fig 
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2.1). Image registration was carried out with data fusion and the images were 
analyzed in axial, coronal and sagittal planes. Additionally, reformation of the 
data was carried out in 2-dimensional orthogonal multi-planar reconstructions 
(MPR) and 3-dimensional image reconstructions (Fig2.1 and Fig 2.2). 
 
 
Fig 2.1 2D orthogonal multi-planar reconstructions of ascending aortic aneurysm 
Axial, coronal and sagittal views of IV contrast aortic scan. Reconstructions were performed to 







Fig 2.2 3D multi-planar reconstructions of ascending aortic aneurysm 
A) Sagittal B) Coronal C) Axial D) 3D volume rendered reconstruction of the ascending aortic 
aneurysm.  
 
For human scans aortic CT data was used for manual segmentation of the 
aortic outline. This was done in the aneurysmal segments between two fixed 
anatomical landmarks. For ascending aortic/arch aneurysms the coronary 
arteries and the right brachiocephalic trunk formed the boundaries. For AAA, 
the renal arteries and the iliac bifurcation formed limits of segmentation. The 
PET scan data was superimposed on the segmented aortic phantom to 
generate a contour map demonstrating various areas of uptake. For the 
manual aortic segmentation the luminal and aortic wall boundaries were semi-
automatically segmented using the region growing method that utilises the 
perimeter of the lumen by seeking pixels of a selected range of intensities. The 
data was pre-processed using Gaussian filters to improve the signal-to-noise 
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ratio and improve the clarity. The segmented lumen and aortic wall contours 
were assembled in three dimension and the surfaces were constructed using 
cubic B splines (a mathematical function that provides minimal support with 
respect to a given degree, smoothness and domain partitions). 
To produce the aortic model this final surface underwent smoothing using the 
transformer manipulator. The volume rendered 3D projection was rechecked 
for accuracy with the PETCT data using the Canny Edge Detector tool and 
canny filtration applied for each label field. The surfaces generated would 
allow for finite element analysis of the aortic model as the statistical feature 
detection allows computational triangulation to be applied to the mesh of the 
surface generated.  
For the patients with abdominal aortic aneurysms that had intraluminal 
thrombus (ILT), this was also reconstructed. The presence of IV contrast agent 
in the lumen enabled clear delineation of the aortic wall, thrombus and lumen 
interfaces. The segmentation was carried out for each 0.625mm CT scan on a 
slice-by-slice basis. The segmented aortic masks were used as a basis to 
generate the high affinity aortic model with laser scintagraphy (videos 1 and 2). 
 
For each period of dynamic PET imaging, the mean maximum activity 
concentration (that is corrected for decay) was recorded and used to 
determine maximum standardised uptake value (SUVmax) that was inturn 
normalised to body weight of the patient. This is calculated using the formula 
below: 
 
   ROI decay – corrected activity (kBq/ tissue (mL) 
SUV  = _______________________________________ 
Injected 18F-FDG dose (kBq/body weight (g) 
 
The associated standard error (SE) (SD/√4) was calculated. This calculation is 
repeated in the patients to ensure that the mean SUVmax for the aortic wall and 
the lumen and the target-to-background (TAR) ratio is calculated. 
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2.3.8 Statistical analysis 
Analysis was carried out using ANOVA of repeated measures when comparing 
the uptake across the time points and using the Kolmogorov-Smirnov testing 
for normality. For paired data sets a 2-tailed t test was used to compare the 
differences in between the variables obtained at the time points and the alpha 




























The PET scan protocol that was followed allowed images to be obtained at 
resolution accuracy to within 3mm. This data was fused with the 0.625mm CT 
scan slices. For accuracy testing the phantoms were created from the hybrid 
PET-CT scan in 3 patients and over 30 biopsy sites were used of varying 18F-FDG 
uptake. In all patients 18F-FDG uptake was present in the aortic wall. The mean 
aortic wall SUVmax ranged from 1.0 to 3.380.44 (SE 0.11). The mean aortic 
lumen SUVmax was 1.0-1.620.4 (SE 0.1). The mean wall-to-lumen ratio (TBR) 
was 0.95-1.010.16 (SE 0.06). A significant difference in aortic wall SUVmax, 
luminal SUVmax and TBR (repeated measures ANOVA, P=0.02 and P=0.001) 
were observed (Fig 2.3 and 2.4, video 3).  
 
The image co-registration and manual segmentation of PET and CT data was 
within 1-3mm of the fenestration points. Each point was triangulated from 
three known fixed anatomical landmarks (e.g. coronary ostia, brachiocephalic 
branch, renal or iliac bifurcation). The validation of the phantom rescan 
showed a resolution accuracy of 1.50.55mm (range 1.3-1.7, 95% CI0.2-0.51). 
(Video 2, 3 demonstrating the fused anatomical PET aortic topography and 
generated co-registered aortic model). 
 
For SUVmax the voxel with maximum uptake was determined. Considering the 
volume of interest (VOI) equal to voxel with highest uptake in the aortic wall. 
The maximal uptake was defined on the original reconstructed PET images, 
without additional rebinning, resampling or smoothing. 2D peal ROI/VOI was 
used as well as the SUVmax. Hence the VOI was 1.2cm diameter fixed size circle 
containing the ROI that was 3-5mm in size. The 3D ROI/VOI was then 
determined where the 1.2cm diameter VOI was focused on the area with the 
maximal uptake. The 3D isocontouring was adapted for minimal, maximal pixel 
value, background uptake and the value best corresponding to aortic wall 
value to luminal blood was taken. It is important to note that when the aortic 
wall was adjacent to areas of high PET uptake there was a spill over effect from 
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the heart where there is a high background uptake. All these areas are visually 
checked close to or adjacent to the aortic wall (Fig 2.1, video 1). If the VOIs are 
non-correspondent visually to the aortic wall sites, than SUVmax was based on 





Fig 2.3 Fused aortic PET-CT  
A) A single slice PET image from the ascending aorta at the level of the pulmonary trunk with 
the corresponding non-contrast CT scan of the ascending aortic aneurysm both in the dynamic 
grey scale range. B) A fixed colour scale is added from SUV = 0 to 10, for interpretation of the 
co-registered images. Arrows mark the sites of moderate-high SUV uptake (Aortic wall SUV 














Fig 2.4 Image overlay of 3D fused PET-CT  
A) 3-dimensional reconstruction of a patient with aortic root and ascending aortic aneurysm. 
The 3D reconstructions allowed branch point identification and mapping aortic morphology to 
help plan the operative placement of the aortic mask. B) Topographical map of the 
myocardium and aorta demonstrating 18F-FDG uptake in the left ventricle and the aortic wall. 
C) Anterior aspect of the 3D aortic segmentation on Amira® demonstrating varying areas of 
18F-FDG uptake that have been marked as spots for fenestration in the aortic model that would 
be generated from this DIACOM dataset. D) Posterolateral aspect of the aortic wall 
demonstrating two different SUVmax that has been marked. The mask is generated within 1mm 
accuracy for CT data and 5mm resolution for PET scan. (Video 2 and 3 for 3D fly-through of 









Fig 2.5 A bespoke aortic mask  
An ascending aortic mask (200m) produced using laser scintigraphy. The fenestrations were 
marked out on the mask at the sites that represent different levels of tracer uptake and where 
aortic biopsies were to be taken.   
 
On validation of the model with backtrack scanning and image overlay on the 
previous fused PET-CT, the image accuracy at fenestrations was 1mm0.62mm 
at all sites (R20.88, P<0.05). All models tested at the same accuracy with high 
correlation to the initial scan used for model generation. The final model 
produced by laser scintagraphy as seen above was generated to be applied to 















18F-FDG uptake occurred within aortic wall and it was best quantified using the 
SUVmax. There was minimal uptake in the aortic lumen and ILT. Uptake was 
higher in thoracic aortic aneurysms than in abdominal aortic aneurysms. The 
optimal time to image vascular inflammation with 18F-FDG PET-CT was when a 
scout CT is performed to demonstrate the anatomical landmarks, followed by a 
non-contrast helical CT scan with a region of interest defined as aortic arch to 
femoral head. This was followed by a 60min post injection whole body 18F-FDG 
PET scan and an IV contrast CT.  Our previous data from multiple time point 
PET of arterial 18F-FDG suggests that uptake dose not significantly change at 
3hrs compared with earlier imaging. There were also minimal differences in 
the arterial wall SUVmax at 1 and 3hrs. The blood pool activity was significantly 
different and did not influence the TBR. There was therefore a minimal ‘spill 
over’ effect from 18F-FDG uptake in the blood to the aortic wall value. Given 
that we were using 18F-FDG uptake to assess vascular inflammation in the 
aortic wall, this is relevant to get accurate reading form the aortic wall alone. 
Delayed imaging of 18F-FDG uptake in the arterial wall results in increased 
variability because of tracer decay and a subsequent increase in noise 306. 
Therefore, although the time interval chosen was acceptable to patients, the 
benefits of delayed imaging are counter balanced by increasing noise and 
variable SUVmax measurements. As we were investigating low-level subtle 
changes in 18F-FDG uptake these factors might have influenced the outcome of 
results. The rationale for using the 60min protocol was influenced by the 
results of previous work that showed a decrease in the aortic wall uptake of 
FDG after 2hrs281,282,307.  
 
Although the PET scan is sensitive it is limited in its spatial resolution. The 
addition of CT (in the hybrid PET/CT) for image acquisition improves spatial 
resolution and allows anatomical determination of the 18F-FDG. This is 
important when evaluating the precise biological correlates from the aortic 
wall analysis from the site of 18F-FDG uptake. Clinically, it aids decision-making 
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regarding the management of the aneurysm. The intravenous contrast agent 
used to enhance the CT on arterial phase imaging allows the differentiation of 
the arterial wall uptake from the uptake in adjacent structures such as the 
lumen. This allows placement of ROIs, reduction of partial volume effects and 
calculation of SUVmax at precise anatomical sites. In the literature there has 
been inconsistent use of methodology when performing PETCT vascular 
studies. These differences in protocol and timings reflect numerous factors, 
such as logistical constraints, camera availability, radiotracer provision and 
local scanning personnel. Our protocol was determined using criteria that 
would allow optimal vascular imaging to guide clinical treatment of the 
patients and yield highly precise anatomical information.   
 
We also developed a novel methodology to reconstruct and generate a 3D 
volumetric model of the aorta that was segmented to allow construction of a 
patient specific aortic phantom. This was validated in phantom testing by back 
scanning the model and using radiomarkers to check the accuracy of the 
fenestrations placed at sites of known 18F-FDG uptake.  This demonstrated that 
the model generation was highly accurate in-terms of aortic anatomy and 













Chapter 3: 18F-FDG uptake in human aneurysms and 
biological correlates  
 
3.1 Introduction  
The cells responsible for the uptake of 18Flurodeoxyglucose in aortic aneurysms 
are not known. It is not clear what the purpose of these rapidly dividing or 
highly metabolically active cells would be in the aortic wall. From what is 
known about the aortic wall biology, the vast majority of cellular milieu is 
composed of VSMCs that are very slow growing in adults. These cells maintain 
a stable baseline metabolic activity, as they are responsible for maintaining the 
ECM in the tunica media. 
 
Multiple small retrospective clinical studies have demonstrated capability of 
18FDG-PET-CT to outline specifically the aortic wall in certain patients264,281,306. 
It might be that this is because of insulin-independent glucose uptake of 
activated lymphocytes and macrophages in diseased aortic segments that are 
responsible for the 18FDG signal specifically originating from aortic 
wall264,281,282,306-308. As chronic inflammation is known to be important in the 
development of aortic aneurysms and inflammatory cells are metabolically 
active, rapidly dividing and differentiating cells, we aimed to focus on these in 
the context of PET imaging. It is likely that the aortic signal for 18FDG uptake 
originates from the up regulated activity, synthetic function and division of 
these cells. As already discussed in section 1.5 (page 45) inflammatory cell 
activity is important in aneurysm development and the complex interaction of 
these cells lead to the cellular events that are responsible for aneurysm 
initiation, propagation and rupture. If the 18FDG uptake signifies inflammatory 
cell activity and function then accurate determination of the cellular events 
occurring in the aortic wall at sites of high compared with low 18F-FDG uptake 
could be informative of the likelihood of aneurysmal dilatation at those sites or 
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increased risk of rupture or dissection. This information would guide clinical 




1) Use the bespoke aortic mask generated using laser scintagraphy to 
  obtain biopsies from areas of low and high 18F-FDG uptake in the  
  aortic wall patients with aneurysms 
2) Isolate, quantify and characterise the immune cell populations in  
  normal aorta vs. aortic aneurysms in areas of low and high 18F-FDG 
  uptake 























Patients coming to St Thomas’ Hospital with aortic aneurysms that require 
open surgery were candidates for this study. Research committee approval 
was obtained (Ethics reference number 10/H0711/56). Patients were 
consented for a PET-CT scan at least 2-weeks prior to surgery for their 
aneurysm. All patients aged 18-75yrs were included. Pregnancy was the only 
exclusion criteria for this study. 15 patients were recruited for the study and 
their aortic wall analysed. 
 
3.3.2 Human aortic biopsy 
At time of open surgery for aneurysm repair, the mask was placed on the 
aneurysm after exposure and clamping of the aorta (distal aortic clamping for 
thoracic aortic repair and proximal and distal aortic clamping for AAA). The 
mask was fixed in place with Prolene® sutures using the anatomical landmarks 
of the coronary arteries proximally and aortic arch distally for the thoracic 
aorta (Fig 3.0A-B). The renal arteries and iliac bifurcation formed the fixed 
anatomical landmarks for the abdominal aorta (Fig 3.0C). In some instances the 
aortae were marked at points of fenestrations whilst in-situ, the aorta was 
resected and the biopsies taken ex-vivo with the aorta laid out within the 
mask. The fenestrated aortic sites were biopsied from the aorta and 
immediately stored in 0.9% saline on ice until the tissues were processed 
(within 1-hr). Prior to processing the aortic wall was thoroughly washed with 
sterile 0.9% saline at 4°C to remove any blood contamination. Biopsies of the 
artery wall (typically 4mm x 4mm) were obtained from regions with different 
SUVmax. Biopsies were processed for either flow cytometric analysis, fixed in 
10% formalin (or snap frozen in liquid nitrogen for frozen sectioning) for 
histological analysis or immunohistochemistry. 
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Fig 3.0 Aortic biopsies taken at open surgery for thoracic and abdominal aneurysm repair 
A) Aortic model generated using laser scintagraphy being used. Measurements are made to 
the fixed anatomical landmarks at replacement of ascending aorta B) Aortic mask applied onto 
the patients ascending aorta confirming to the aneurysm morphology and biopsies from the 
ascending and C) abdominal aorta are taken at open aneurysm repair.  The mask is fixed 
between the renal arteries and the iliac bifurcation. Fenestration seen in the mask to allow 
biopsies to be taken (arrows) (Courtesy of Mr Young, Mr Bapat and Professor Taylor) 
 
3.3.3 Isolation of tissue resident inflammatory cells for flow 
cytometry 
Human specimens underwent enzymatic degradation and cell harvest 
protocol. Tissue was cut into 2x2mm segments from each biopsy site and 
incubated in phosphate buffered saline (PBS, without calcium and 
magnesium), pH7.4 containing 0.5% bovine serum albumin (BSA), 1mM 
ethylenediaminetetraacetic acid (EDTA) with 1mg/ml collagenase D, 
100units/ml DNAase I and 500units/ml hyaluronidase IV-S (all Sigma Aldrich, 
UK). Incubation was at 37°C for 45mins. The sample was then filtered through 
a 100µm strainer (Falcon BD) into a 6-well plate and the undigested tissue 
mechanically dissociated in the enzyme suspension, using a plunger from a 
10ml syringe. The remnant tissue was washed with 5mls of PBS containing 
0.5%BSA and 1mM EDTA (PBS-BE). The cells were washed and centrifuged 
twice at 320g and 4°C with the supernatant discarded and the pellet 
resuspended in 1ml PBS-BE and incubated on ice for cell counting with 
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haemocytometer. The cells were fixed in 4% paraformaldehyde (appendix 3, 
page 347) for 10mins and subsequently washed and suspended in PBS-BE and 
stored at 4°C for up to 48hrs prior to staining for flow cytometry.  
 
3.3.4 Antibody staining of human inflammatory cells for flow 
cytometry 
The immune cell content of aortic tissue from sites of varying 18F-FDG uptake 
was quantified using flow cytometry. This was carried out in the following 
manner. Cell suspension in FACS buffer (500µl PBS with 1%BSA, 10% sodium 
azide, pH7.4, PBS-BA) from each aortic biopsy site was incubated with 20µl of 
human FcR blocking reagent (Miltenyi Biotec, 103-059-901) at 4-8°C for 15mins 
in a 15ml Falcon tube. The cell suspension was incubated with anti 
inflammatory cell type antibodies (Table 3.0) at 4°C for 30mins. To expose 
intracellular epitopes, 500µl of cell suspension from each aortic biopsy site was 
also permeabilised with 20% saponin (BD Perm/Wash buffer, BD Bioscience, 
554723) for 10mins at 4°C. The permeabilised cells were washed twice in the 
BD Perm/Wash buffer (1ml/wash) and re-suspended in 500μl of BD 
Perm/Wash buffer containing a pre-determined optimal concentration of a 
fluorochrome-conjugated antibody or appropriate negative control to detect 
the macrophage marker CD68+, the macrophage phenotype marker HLA-DR, 











Table 3.0 Primary flow cytometric antibodies for human immune cell typing 
(All antibodies were obtained from BD Biosciences) 
Cell Cell surface 
marker 
Fluorophores Concentration Code 
Leukocyte CD45 APC-H7 3µg/ml 560178 
NK CD56 PE 6.25µg/ml 555516 
T-cell CD3 FITC 15µg/ml 555339 
B-cell CD19 PeCy7 6µg/ml 557835 
Macrophage CD68 PE 6µg/ml 556078 
Macrophage HLA-DR PeCy7 15µg/ml 335830 
Neutrophil CD16 APC-647 5µg/ml 557710 
 
After incubation with antibody, the cells were washed twice with x1 BD 
Perm/Wash buffer (1ml/wash for staining in tubes) and resuspended in 1ml BD 
staining buffer prior to flow cytometric analysis. All the wash steps were 
carried out with centrifugation at 400g for 5mins. For non-permeabilised 
samples the cells were washed and kept in PBS containing 1%BSA. The 
permeabilised cells were always kept in the BD wash/perm buffer. Analysis was 
carried out using a FACS Canto II flow cytometer (BD Biosciences, UK). 
Leukocytes were selected according to forward (size) and side (granularity) 
scatter properties and final gating performed on CD45+, CD3+ and CD19+ 
leukocytes.  
 
3.3.5 Antibody staining for human lymphocyte subset markers 
The cell suspension sample from each aortic biopsy site was divided into three 
500µl aliquots in PBS-BA. Each 500µl of cell suspension in FACS buffer (PBS-BA) 
was incubated with 20µl of human FcR blocking reagent (Miltenyi Biotec) at 4-
8°C for 15mins. Cell suspensions were then incubated with combinations of 
fluorescently tagged antibodies against a variety of B/B-regulatory cell, T-cell 





Table 3.1 Primary flow cytometric antibodies for human immune cell subtyping 
(All antibodies were obtained from BD Biosciences) 
Cell Surface 
marker 
Fluorophores Concentration Code 
Early T-cell CD2 (T11/Leu-
5, LFA-2, LFA-3) 
PE 6.25µg/ml 561760 
Common T-cell  CD3 V500 10µg/ml 561416 
T helper cell CD4 PerCP-Cy5.5 0.2µg/ml 560650 
Active antibody 
producing B-cells  
CD5 PE-Cy7 6µg/ml 348810 
Active T-cell  CD7 APC 25µg/ml 561604 
Cytotoxic T-cell CD8 V450 50µg/ml 560347 
Highly activated T-
cells  
CD14 APC-H7 10µg/ml 641394 
Highly activated T-
cell 
CD16 APC-H7 20µg/ml 560195 
Common B-cell  CD19 PerCP-Cy5.5 6.25µg/ml 561495 
Common B-cell  CD20 PerCP-Cy5.5 6.25µg/ml 340955 
Plasma B-cell CD24 PE 12.5µg/ml 555428 
T regulatory cell CD25 (IL2) PE 12.5µg/ml 555432 
Memory B-cell CD27 V450 50µg/ml 560448 
Active B-cells  CD38 APC 6.25µg/ml 555462 
Common leukocyte 
antigen 
CD45 FITC 6.25µg/ml 555482 
Memory T-cell and T 
regulatory cell 
CD127 Alexa Fluor 
647 
6.25µg/ml  558598 
Active synthetic B-
cell 






3.3.6 Flow cytometric analysis 
The samples were analysed using a BD Canto II flow cytometer equipped with 
either a two (red and blue lasers with excitation wavelengths of 633nm and 
388nm respectively) or three lasers (red, blue and violet lasers with excitation 
wavelengths of 633nm, 388nm and 405nm respectively). Giving an option of 
either 6 or 9 colour cytometry. Florescence minus one (FMO-1) controls, in 
which one antibody at a time is left out of a particular antibody cocktail 
reaction was carried out for every experiment (gating controls), as well as 
single stain controls (compensation controls). Experimental controls were fully 
stained biopsy analyses from various sites with the patient sample (comparing 
areas of no, low, moderate and high tracer activity). Leukocyte content was 
gated according to their forward and side scatter and expression of the pan 
leukocyte marker, CD45. Doublets were excluded before the cells were 
phenotyped into subtypes and quantified. Unstained, fully stained and FMO’s 
were carried out to delineate populations and set gates for each sub-
population. Cell content was determined as either a percentage of the total 
CD45+ population or as an absolute number of CD45+ cells expressing sub 
phenotype markers per milligram-wet weight of biopsy. Data for all flow 
cytometric acquisitions was analysed using FlowJo v7.6.5 software (Tree Star 
Inc, USA). 
 
The number of cells was quantified using CountBright Absolute Counting 
Beads (Invitrogen, UK). The bead mixture was allowed to come to room 
temperature. The suspension was vortexed and 50l was added to the stained 
cells. The number of cells before the addition was noted. The sample was run 
on the flow cytometer with the forward scatter threshold low enough to 
include the microspheres on the forward scatter vs. linear side scatter plot (Fig 
3.1D). The beads were verified as on the highest scatter gate. When using 
CD45+ vs. log side scatter gating, the counting beads are easily distinguished as 
a separate population from the gated cells. Calculation of cell concentration is 
made using the following equation: 
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A/B x C/D = concentration of sample as cells/μl  
 
Where:  
A = number of cell events 
B = number of bead events 
C = assigned bead count of the lot (beads/50μl) 
D = volume of sample (μl) 
 
3.3.7 Tinctorial histology 
3.3.7.1 Sample preparation 
Biopsies were fixed in 10% formal saline (BDH, UK) for 24hrs and processed for 
paraffin impregnation using a VIP SE-F2 tissue processor (Tissue-Tek, UK). The 
tissues were then embedded in wax blocks and transverse sections (5μm) cut 
at 250μm intervals throughout their entire length. Sections were placed on 
salinized glass slides and placed in an incubator at 40oC overnight to bake the 
sections to the glass.  
 
3.3.7.2 Aneurysm general morphology by haematoxylin and eosin 
(H&E) staining 
Sections were warmed for 30mins at 60oC to soften the wax and de-
paraffinised in 2x5min xylene washes (BDH, UK). Sections were rehydrated 
through graduated alcohol (industrial methylated spirit, IMS, Genta, UK) 
washes (100% [x2], 95%, 70%, 50%) and rinsed in tap water for 5mins. Sections 
were incubated in Mayers haematoxylin (Clin-Tech, UK) for 5mins followed by 
5mins washing in running tap water. Staining was differentiated by incubation 
in 1% acetic acid: 99% ethanol for 3secs followed by a further 5min wash in 
running tap water. Sections were stained in eosin (Clin-Tech, UK) for 2mins. 
Sections were washed for 30secs in running tap water prior to dehydration 
through graduated alcohol, cleared in 2x5min xylene washes, mounted with 
cover slips in DPX medium (BDH, UK) and allowed to dry overnight. 
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3.3.7.3 Picrosirius red staining for collagen content 
Paraffin sections were rehydrated as described in 3.3.7.2, page 106. Picrosirius 
red staining was carried out as directed by the manufacturers instruction 
(Polysciences, USA). In brief sections were incubated with aqueous 
phosphomolybdic acid hydrate 0.2%(w/v) for 2mins and washed in distilled 
water for 5mins. Sections were incubated in 0.4%(w/v) Direct Red 80 diluted in 
a saturated picric acid solution for 1hr at room temperature, washed in 0.1M 
hydrochloric acid (HCL) for 2mins and subsequently dehydrated through 
gradated alcohols. Sections were cleared in two 5min xylene washes, mounted 
with cover slips in DPX medium and allowed to dry overnight. 
 
3.3.7.4 Accustain Trichrome Stains (Masson) for collagen 
Sections were deparaffinised and rehydrated as described in 3.3.7.2, page 107. 
Slides were rinsed in distilled water and placed. Mordant in preheated Bouin’s 
solution (Sigma-Aldrich, Inc. UK), at 56oC for 15mins. The slides were cooled in 
tap water in a coplin jar. The slides were washed in running tap water to 
remove the yellow colour from sections. The slides were placed in working 
Weigert’s iron Hematoxylin Solution (mixing equal volumes of Weigert's Iron 
Hematoxylin A and Weigert's Iron Hematoxylin B) for 5mins. They were 
washed in running tap water for 5mins. Rinsed in deionised water and stained 
in Biebrich Scarlet-Acid Fuchsin for 5mins. Rinsed in deionised water before 
being placed in working phosphotungstic/ phosphomolybdic acid solution (1 
part phosphotungstic acid and 1 part phosphomolybdic acid with 2 parts 
deionised water) for 5mins. The slides were placed in Aniline Blue solution for 
5mins placed in 1% acetic acid for 2mins, rinsed in tap water, dehydrated 





3.3.7.5 Verhoeff van Gieson staining for elastin 
Sections were deparaffinised and rehydrated as described in 3.3.7.2, page 107, 
placed in working elastin stain for 10mins (appendix 3, page 347). Rinsed in de-
ionised water and differentiated in working ferric chloride solution (appendix 
3, page 347). Sections were rinsed in tap water and checked microscopically, 
and if over differentiated returned to working elastin stain. This was followed 
by a rinse in 95% alcohol to remove excess iodine (present in the working 
elastin solution) and rinsed in de-ionised water. Sections were then stained in 
Van Gieson solution for 2mins, rinsed in 95% alcohol, 100% alcohol and finally 
xylene before mounting in DPX medium (BDH, UK). 
 
3.3.8 Immunohistochemistry (IHC) 
3.3.8.1 IHC analysis of leukocyte distribution in paraffin sections  
Sections were deparaffinised and rehydrated as described in 3.3.7.2. 
Endogenous peroxidase activity was blocked by incubating sections in 1%H2O2 
in methanol (3ml of 30% H2O2 in 87ml of 100% methanol) for 30mins. Antigen 
retrieval was carried out using citrate based retrieval solution at pH6.0 
(Menarini, UK) placed in a MenaPath access retrieval unit (Menarini, UK), for 
30secs at 125oC and 2secs at 90oC. The reservoir containing the sections was 
immediately placed on ice and the slides transferred to DPBS at room 
temperature. Sections were prepared for IHC, by removing from them one at a 
time (flicking off remaining DPBS), removing DPBS from around each section 
and drawing a ring around the section with a hydrophobic Pen 
(DakoCytomation, DAKO, UK). Each section was then quickly covered with 
Novocastra IHC blocking reagent (10min at room temperature) (Leica 
Microsystems, UK), placed in moisture box to prevent drying and immediately 
stained. Care was taken not to allow any section to dry prior to application of 
the antibody reagent. 
 
 110 
Sections of human tonsil were used as a positive control for leukocyte staining. 
A negative antibody control experiment was carried out each time using 
species-specific serum or isotype control IgG as negative controls. For the 
positive control staining, sections were retrieved by heat mediated antigen 
retrieval at 125°C for 1min in 10mM sodium citrate buffer (pH6.0) and then at 
80°C for 10mins.  
 
3.3.8.2 Co-localisation of leukocyte subtypes in aneurysm wall 
The antibody staining was carried out as per manufacturers instructions using 
EnVision Doublestain System, Rabbit/Mouse (DAB+/Permanent Red, Dako 
Inc. UK). Briefly, excess blocking reagent was removed from the slide by 
tapping off and wiping around the wax line surrounding each section before 
application of Dual Endogenous Enzyme Block (5mins at room temperature).  
The sections were rinsed gently with Tris-buffered saline wash buffer solution, 
pH7.6 (TBS see appendix 3, page 347). Care was taken to use buffer from a 
wash bottle (not focused directly on tissue) and the sections placed in a fresh 
wash buffer bath for 5mins. The sections were then incubated with antigen-
specific biotinylated-mouse or -rabbit primary antibodies (Table 3.2), 
appropriate negative IgG controls, or species-specific serum, for 10mins at 
room temperature.  
Table 3.2 Primary anti-human antibodies used for IHC 
Primary 
Antibody 





Anti-tropoelastin Tropoelastin Rabbit 1:200 1l/ml Abcam, USA 
Anti-CD3 Common T-cell  Rabbit 1:500 1l/ml Leica, UK 
Anti-CD20 Common B-cell Rabbit 1:1000 4l/ml Dako, UK 









Macrophages Mouse 1:1000 4l/ml BioLegend, USA 
Anti-CD68 Macrophages Mouse 1:500 2l/ml Dako, UK 
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Sections were washed in TBS (2x5min). Excess TBS was removed and sections 
incubated for 10mins at room temperature with the Envision 
Polymer/Horseraddish peroxidase reagent (extravidin-HRP complex), after 
which the sections were washed in TBS (2x5mins) and then incubated in DAB+ 
chromogen (1mL of Substrate Buffer with 1 drop of DAB+, 25-30µl) for 15mins 
at room temperature. The section was washed in deionised water (2x5mins).  
 
To stain for the second leukocyte antigen, excess water was tapped off and 
tissue sections incubated with Doublestain Block for 3mins at room 
temperature, followed by 2x5min rinse in TRIS buffer. Optimally diluted mouse 
or rabbit primary antibody or negative control reagent (same concentration as 
the primary antibody) was used to cover specimen for 10sec.  Excess wash 
buffer was tapped off and the slides wiped as before. Rabbit/mouse (LINK) was 
used to cover the specimen for 10mins followed by wash in TBS 2x5mins on. 
Excess wash buffer was tapped off and the slides wiped as before. 
Polymer/Alkaline Phosphatase (extravidin-AP) was used to cover the specimen 
for 10mins. Excess buffer was tapped off and slides wiped before Permanent 
Red substrate (100 parts of Permanent Red Substrate Buffer with 1 part of 
Permanent Red chromogen) was applied for 20mins. Specimen was washed 
2x5mins in deionised water. The specimen was immersed in hematoxylin for 
5mins for counterstaining followed by a rinse in deionised water. Tissue slides 
were immersed into a bath of 37mmol/L ammonia water and rinse gently in 
deionised water for 2-5mins. The sections were dehydrated in graded alcohols 
and finally xylene. Slides were mounted using DPX. Slides were left to dry for at 
least 12hrs in room temperature before imaging.  







3.3.8.3 Image acquisition and analysis of histology  
Slides were visualised using a light microscope (Leitz, Leica, UK) and images 
captured using a microscope-mounted camera (EXi Blue, QImaging). The 
complete slide surface area was digitised and the histological sections were 
captured and processed using image analysis software (Image Pro-plus, Media 
Cybernetics). Aneurysm cross-sectional area (mm2) was measured on van 
Geison and trichrome stained sections by computerized planimetry (ImageJ, 
NIH). Computer-assisted colour image analysis was used to quantify the area of 
staining in tinctorially stained sections for collagen (trichrome stain) and 
elastin (Verhoeff-Van Gieson), as well as IHC-stained sections. All staining was 
expressed as a percentage of the total aneurysm cross sectional area. 
Positively stained cells (DAB+/ Permanent Red Chromogen+) were in each 
section were counted and expressed as a percentage of total number of 
cells/section. Two independent observers carried out all image quantification 
and the inter-observer results correlated for agreement.  
 
3.3.9 Statistical Analysis 
Data was analysed in SPSS v21 (IBM Corporation, Data Collection, USA) and 
Prism v5.0 (GraphPad Inc., USA). Data are represented as mean ± standard 
error (SE). Parametric data was analysed using Student’s Paired T-test. Non-
parametric data was analysed using Mann–Whitney U or Wilcoxon rank sum 
tests. ANOVA was used for analysis of multiple grouped variables comparing 
two or more means and Bonferroni post-hoc test used to measure differences 
between specific groups. Where applicable univariate linear regression analysis 
was performed to model the relationship between a scaled dependent variable 
and one or more explanatory variables denoted. Correlations were carried out 
using linear regression and Pearson correlation coefficient analysis and 





15 patients with aortic aneurysms were recruited into the study. This allowed 
analysis of 152 aortic biopsy sites each representing a distinct SUVmax and 
hence varying 18F-FDG uptake. The patient co-morbidities and demographics 
are outlined (Table 3.3). 
 
Table 3.3 Demographics for patients involved in PET-CT imaging of the aortic aneurysms 
Number of participants N=15 







Thoracic aortic aneurysm (TAA) 
diameter (median, range) 
Abdominal aortic aneurysm (AAA) 











IV.Ischemic heart disease 
V.Aortic valve regurgitation 







2 Marfans Syndrome 
2 Bicuspid aortic valve 
Aortic pathology 10 Degenerate thoracic aortic aneurysms 
2 Degenerate juxtrarenal aortic aneurysms 
1 Mucoid medial degeneration 




3.4.1 Flow cytometry 
Sites with the highest SUVmax had increased number of B-cells (331±52, 
P<0.0001, 95%CI0.21-0.40) and T-cells (61±15.0 x102, P<0.0001, 95%CI0.2-
0.50) vs. sites of moderate SUVmax B-cell (145±31 x102, P<0.0001, 95%CI0.32-
0.44) T-cell (38±17 x102, P<0.0001, 95%CI0.10-0.64) and low SUVmax B-cell 
(18±15 x102, 95%CI0.11-0.92) T-cell (16±18 x102, 95%CI0.05-0.97). (Fig 3.2-3.3) 
 
Aneurysmal tissue had a greater B and T-cell content compared with normal 
aortic wall in the same patients. 58 biopsies were taken from normal aortic 
tissue and compared to aneurysm wall with no 18F-FDG uptake; B-cells number 
was 1±6 x102 vs. 18±15 x102, P<0.0001 95%±0.92 and T-cells count was 1±7 
x102 vs. 16±18 x102, P<0.0001, 95%CI0.23-0.97 respectively. 
 
 The number of NK cells was also significantly increased from aortic biopsy sites 
at varying SUVmax. At high (SUVmax >4.0) the NK cells numbers were 46±34 x102, 
p<0.001, 95%CI0.15-0.25. At moderate uptake (SUVmax 2.6-3.9) 26±34 x102, 
p<0.001, 95CI0.13-0.76 and at low SUVmax >2.5 the number of NK cells was 
19±12 x102, p<0.001, 95%CI0.24-0.92. (Fig 3.3-3.4) 
 
(The individual patient cell counts are summarised in Appendix 3, page 349. All 
patients are included in the appendix to show overall cell profiles for patients 








Fig 3.1 Flow cytometry of aortic wall  
A) Gating analysis of unstained aortic wall resident cell content on forward and side scatter 
profile. B) Doublet exclusion was done to remove adherent cell populations and debris and 
provide a clear cell population for analysis. C) Gating was carried out on CD45+ leucocyte cell 
fraction with exclusion of all other cellular types.  One sample was run without 
permeabilization and the cell surface markers analysed. The second sample run was a sample 
permeabilsed with Saponin. This was necessary to stain the intracellular markers for 
monocyte/ macrophages linage such as CD68+, HLA-DR staining. With and without 
permeabilisation there was no overall difference in the extracted CD45+ population and the 
cellular staining profile. D) The cells re counted using CountBright beads (Invitrogen, UK) 
these appear in the top right corner of the flow dot-plot. Calculation of cell concentration can 
be carried out as outlined in the methods section 3.3.6, page 106). 
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Fig 3.2 The flurophore spectral pattern and dot-plots analysis for CD45+ cells 
A-D) The first panels demonstrate differential flurophore patterns without overlap thus each 
immune cell phenotyped population could be determined accurately. There was no spectral 
overlap. A1-A3) Typical examples of flow cytometric dot plots of T lymphocytes (CD3+), B1-B3) 
B-lymphocytes (CD19+), C1-C3) natural killer cells (CD56+), D1-D3) macrophages (CD68+) and 
E1-E3) neutrophils (CD16+/HLA-DR+). The first dot-plot panel down (A1-E1) is from aortic wall 
biopsy site with low  (SUVmax <2.5). The second dot-plot panel down (A2-E2) is from moderate 
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(SUVmax 2.6-3.9). The third dot-plot panel down (A3-E3) is from site of high 18F-FDG uptake 
(SUVmax <4.0). The differential cell numbers are apparent in the dot-plots. The specific cell 
types are expressed as a percentage of total CD45+ leukocyte fraction. The cells from the 
different regions of the aortic aneurysm wall were therefore enumerated as a percentage/ 
fraction of the CD45+ cell population and additionally absolute cell numbers counted using the 
counting beads. This would allow us to determine the correlation between the cell populations 
and the SUVmax for discrete aortic biopsy sites for thoracic aortic and abdominal aortic 
aneurysms.  
 
Strong positive correlation was present between 18F-FDG uptake (SUVmax) and 
aortic wall resident CD3+ T lymphocytes (R2=0.85, P<0.0001), CD19+ B 
lymphocytes (R2=0.86, P<0.001) and CD56+ natural killer cells (R2=0.75, 
P<0.001). There were very weak correlations between 18F-FDG uptake and 
aortic wall resident CD68+ macrophages (R2=0.15, P=0.01) and CD16+/HLA-DR+ 
































































































































































































































































































































































































































































































Fig 3.4 Flow cytometric analysis of absolute human leukocyte counts (per mg-1 of tissue) 
using CountBright counting beads  
Cells were initially gated on CD45+ leukocyte cell fraction. There was a significant up-regulation 
in the aortic wall of resident B-lymphocytes with increase in SUVmax, (P<0.001, between the 
low moderate and high SUVmax values) and T lymphocyte numbers (P<0.001, between the low 
moderate and high SUVmax values). There was a smaller increase in the NK cell population at 
sites of moderate and high SUVmax (P<0.01).  There were no statistical differences when the 
macrophage and the neutrophil cell populations were analysed.  
N=4, 56 biopsy sites analysed, two way ANOVA with post hoc Bonferroni correction. Mean 










Lymphocyte populations were further subtyped into specific lineages 
according to the cell surface markers (table 3.4). The cell surface subtyping 
markers allowed the T-cells to be sutyped early T-cells (CD2+), naïve T-cell (Th0 
cell), helper T-cells (CD4+), cytotoxic T-cells (CD8+), mature activated 
phenotypes (CD7+, CD25+, CD38+) or T regulatory cells (CD25+, CD127+). B-cell 
phenotypes were subtyped to common B-cells (CD19+), memory B-cells 
(CD27+), class switched/ synthetically active B-cells (IgD), activated cells/ 
plasmablasts (CD38+).    
 
84 biopsies of aortic aneurysms, with a range of 18F-FDG uptake, were taken 
from of 8 patients.  The cells were stained for surface markers as delineated 
below. The gating profile and cell populations are as outlined in Fig 3.5 for T 
lymphocytes, Fig 3.6 for T regulatory cells and Fig 3.8 for B-cells including B 
regulatory cells.  
 
Table 3.4 The stained cell surface lymphocytic markers and the putative phenotype that the 
epitopes confer. 
 
Cell Marker Cellular phenotype conferred 
CD2 (T11/Leu-5, LFA-2, LFA-3) Early T-cell (thymic)/ NK cells 
CD3 Common T-cell antigen 
CD4 T helper cell 
CD7 B-T cell interaction 
CD8 Cytotoxic T cell 
CD19/20 Common B-cell antigen 
CD24 Plasma cell 
CD25 Activated T-B-cells; T regulatory cells 
CD27 Memory B-cell 
CD38 Activated B-T-cells 
CD127 T regulatory cell 
IgD Synthetic B-cell 
 Fig 3.5 Flow cytometry for T-cell subtyping  
A) The cells are gated on pan T lymphocyte marker CD3 and side scatter profile. After doubled exclusion as before, the CD3 population is gated upon and the T 
lymphocytes phenotyped. B) Staining for T helper cells (CD4+) against T cytotoxic (CD8+) cell populations. C-D) The cells expressing CD3+CD7+CD5- and CD3+CD7+CD5+ 
are likely to represent metabolically active cells responsible for B-T cell interaction which are either alpha beta or gamma delta phenotype. E) T-cells modulating 
active inflammation express CD3+CD7+CD38+ F) Increase in CD38+ expression delineates likely differentiation to NK type phenotype and antigen presentation. G) 
Human CD25+low vs. F) CD25+high cells are likely to represent T regulatory phenotype. I) CD3+CD25+ cells are further subtyped into CD127+ and CD127- T regulatory 
phenotype of cells. J) Two distinct populations, CD127low and CD127high cells can be seen.  
  
 
Fig 3.6 T regulatory lymphocytes from human aortic aneurysm wall analysed by flow 
cytometry  
A) Cells were gated on the CD45+ (leukocyte) and CD3+ (pan T-cell marker). B) The cells were 
selected to ensure that they were CD4+. This is likely the T regulatory cell population in the 
tissue. However due to unreliability in human T regulatory cell mapping we further looked for 
the expression of CD127high/low populations C) The CD3+CD4+ CD127low and D) CD127high 
populations are determined to effectively phenotype the IL7R T regulatory cells.  
 
At sites of no 18F-FDG uptake or at sites of low 18F-FDG uptake cytotoxic (CD8+) 
and helper T-cell (CD4+) populations were predominantly resident (Fig 3.6 and 
3.7). There was a drop in their population at sites of increased 18F-FDG uptake 
(P<0.001). At sites of moderate to high 18F-FDG uptake there was a switch to 
activated T-cells, memory and effector T-cell types. The highest fold change 
increase was for T regulatory cells phenotypes (P<0.001), followed by activated 





































































































































































































































































































































































































The B-cells populations were gated for the common B-cell (CD19+), 
synthetically active CD38+ cells that may produce antibodies (IgD/ IgM) and/or 
interact with T-cells, CD19+CD24+ cells that are plasma type involved in cell-cell 




Fig 3.8 B-lymphocytes subsets phenotyped by flow cytometry 
A) The cells population on forward and side scatter profiles was identified B) Gating performed 
on CD45+ CD19+ cells. C) After doubled exclusion the CD19+ cells expressing CD5 were 
identified. These denote B1 cells the subset likely to secrete IgM and are synthetically active. 
D) The CD19+CD5+ cells were also assessed to the ability to stain for IgD expression, which 
constituted less than 5.5% of this population. E) The expression of CD24+ denotes cell adhesion 
ability for plasma cells. F) The CD27+ cells are differentiated memory B-cells. G) The memory B-
cells were phenotyped as IgM producing cells. H) Activation marker CD38 was phenotyped to 
delineate active B-cells that interact with T lymphocytes.  
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At no or low 18F-FDG uptake the common B-cell antigen was expressed with 
very low level expression of activation, mature B-cell and memory B-cell 
markers with these populations accounting for less than 10% of the overall B-
cell fractions (P<0.001). However at sites of high 18F-FDG uptake there was a 2-
3-fold increase in the populations of mature CD19+CD24+ cells, memory 





Fig 3.9 B-cell subtype distribution in the aneurysmal aortic wall in association with the 
18F-FDG uptake 
The aortic aneurysm wall from sites of no 18F-FDG uptake had pre B-cell markers mostly being 
CD19+CD127+ lymphocytes. As the 18F-FDG uptake increased there was an increase in the 
synthetic B regulatory cell population CD19+CD5+IgD+ along with activated phenotypes 
expressing CD38+ epitopes as well as mature B-cells (CD24+) and memory B-cells that express 









3.4.2 Tinctorial histology and IHC 
The aortic aneurysms from a range of SUVmax were stained for elastin, collagen and 
presence of tropoelastin. Initially all aortic tissue was stained with H&E to determine 
aortic morphology (Fig 3.10). The EvG stained tissue can be seen to delineate the 
elastin fibers in the aortic wall and the degree of organisation of the fibres can be 
analysed (Fig 3.11). This is for fibre organisation, lamellar structure, number of fibre 
breakages, degree of staining with EvG and the fibre surface area when compared to 
the total aortic wall surface area (Fig 3.11-3.12).  
 
Fig 3.10 Haematoxylin and eosin stained aortic wall 
A) Normal aortic wall with preserved aortic architecture and morphology B) The aortic 
aneurysm wall from low 18F-FDG uptake showing predominantly preserved aortic architecture. 
Early features of ECM degradation C) Aneurysm wall from high 18F-FDG uptake demonstrating 
increased vacuolation of the aortic wall and ECM deterioration throughout the tunica media 
and adventitia. Scale bar 100μm. 
 
There is predominately preserved aortic architecture in the H&E stained 
sections with only sites of highest 18F-FDG uptake having disrupted aortic 
media and adventitia. On EvG staining the normal aortic architecture is typified 
by 60-70 lamellar units of elastin in the tunica media and adventitia. These are 
break free (Fig 3.11 A1, A2). On IHC analysis with tropoelastin specific antibody 
(Fig 3.11 B1) there is increased tropoelastin synthesis at discrete sites in the 
tunica media. Tropoelastin synthesis is highest at the tunica media adjacent to 
the adventitia in the perivascular zone (Fig 3.11 B2). When this is compared to 
an aneurysm wall biopsy site that is from the same patient but a high 
SUVmax>4.5 (C1) there is a marked loss of the elastin in the aortic wall with 
haphazard EvG staining. Loss of lamellar structure, weak staining, that is 
C B A 
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predominantly in the tunica media (Fig 3.11 C2). The elastin fibres are no 
longer in the lamellae and the internal and external elastic lamellae are lost. 
The corresponding tropoelastin stained sections can be seen to stain extremely 
highly for tropoelastin (Fig 3.11 D1) with dense regions of tropoelastin staining 
present in the tunica media adjacent to the adventitia. There is marked 
increase in the capillary density in the aortic adventitia. There is concomitant 
staining for Mac-2 expressing macrophages demonstrate that these cells are 




Fig 3.11 Staining for elastin and tropoelastin in aortic aneurysm wall  
A) The aortic aneurysm wall from site with low 18F-FDG uptake (SUVmax <2.5).  The near normal 















organised elastin in the tunica media and adventitia is seen (A2).  A few breaks become visible 
in the elastin (A2). B) IHC analysis of tropoelastin in aneurysm wall from area of low tracer 
uptake (B1). The tropoelastin content is highest in the tunica media adjacent to the adventitia 
and in the adventitia (black box). The increased magnification (B2) demonstrated the 
perivascular zone at this site with regions high in tropoelastin content. C) Elastic architecture in 
aneurysm wall with high tracer uptake (SUVmax>4.5) in the same patient (C1) there was a 
marked loss of the elastin in the aortic wall with haphazard EvG staining. Loss of lamellar 
structure, weak staining, that was predominantly in the tunica media (C2). The elastin fibres 
are no longer in the lamellae and the internal and external elastic lamellae are lost. D) The 
corresponding tropoelastin stained sections can be seen to stain strongly for tropoelastin (D1) 
with dense regions of tropoelastin staining present in the tunica media adjacent to the 
adventitia. Concomitant staining for Mac-2 expressing macrophages demonstrates that these 
cells are present in the adventitia (red stained cells, red arrows) at the sites where there is 
increased tropoelastin present (D2).  Bars represent 50m and 100m 
 
The elastin surface area markedly decreased from 39.8% of total aortic wall 
area to 25.8% at moderate aortic 18F-FDG uptake. The elastin expression 
decreased to 15.6% of surface area at sites of highest 18F-FDG uptake (P<0.007, 
ANOVA). The tropoelastin uptake followed an inverse pattern with an increase 
in tropoelastin expression from low to high 18F-FDG uptake. The expression 
levels increased from 9.8%, 17.8%, 21.9% and 36.8% of vessel wall surface area 
(P<0.007, two-way ANOVA). 35 biopsy sites analysed from aortic aneurysms in 
7 patients. The mean coverage in sections taken at 4 different levels per biopsy 






Fig 3.12 Histomorphometric quantification of the aortic aneurysm stained for elastin and 
tropoelastin stained aortic aneurysm wall. 
There is a decrease in the elastin content with increasing SUVmax with an increase in collagen 
content, P<0.007 Two-way ANOVA, with post-hoc Bonferroni test P<0.04. 
 
On analysis of the aortic wall collagen content the histomorphometric 
assessment demonstrates an increase in collagen content in the tunica media 
as the 18F-FDG uptake increases. The mean level of collagen content increased 
from low to high SUVmax (Fig 3.14). Mean collagen percentage area increased 
from 19.8% to 67.6%. There was a significant upregulation of collagen content 
in the aortic wall, P<0.04, 95%CI1.2-1.65, OR 0.34 (Two-way ANOVA, with post-




Fig 3.13 Collagen staining (Massons Trichrome) of aneurysmal wall (blue stain)  
A) Low 18F-FDG uptake aortic wall (A1) demonstrating collagen expression (blue) 
predominantly in the tunica media/ adventitia boundary. At 100x magnification the collagen 
expression is seen with early fragmentation of the aortic ECM (arrows). At 200x (A3) there is 
low-level expression of collagen seen in between the elastin fibres. B) High 18F-FDG uptake 
aortic wall (B1) demonstrating increased collagen in the ECM. This is present in the tunica 
media (B2) despite the increased breakdown of the aortic wall. At 200x the increased 
expression of collagen is visible in the aortic wall between the elastin fibres. N=7, 35 biopsy 
sites analysed with 4 sections per biopsy; 140 slides analysed at high power field with 
complete slide area covered by two independent observers.  
 
Fig 3.14 Histomorphometric quantification of collagen content in the aortic aneurysm wall in 
association with 18FDG uptake 
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There is an increase in the vessel wall collagen content as a percentage of wall surface area 
and this is statistically significant (P<0.07 across the SUVmax, two-way ANOVA, with post hoc 
Bonferroni test <0.01) 
 
The immunohistochemical analysis of immune cell infiltration in aortic 
aneurysm wall from varying 18F-FDG uptakes demonstrated increase in the 
number of CD3+ T-cells and uptake of this tracer in the aneurysm wall 
(P<0.001, paired T-test). The greatest T-cell numbers was found in wall at 
SUVmax>4.5, with >175cells/mm2 aortic wall, compared with >70cells/mm2 at 
SUVmax <4.5, P<0.001. The cells were particularly prevalent at the aortic media/ 
adventitial boarder at sites of perivascular infiltration (Fig 3.15). Mac-2 
expressing macrophages were also co-located to these sites. The number of 
mac-2 expressing cells was highest in aortic wall with highest SUVmax (P<0.05, 
















Fig 3.15 Immunohistochemical staining for CD3+ T lymphocytes and Mac-2+ macrophages 
in association with 18F-FDG uptake  
A) Low 18F-FDG uptake (SUVmax<2.5) aortic aneurysm wall with IgG negative control staining 
(A1). CD3+ T lymphocytes stained brown with DAB staining present (brown cells, brown 
arrows) in the aortic adventitia in the perivascular zone (A2). CD3+ cells were present focally in 
the adventitia and the outer media ingressing into the aortic wall. There was no macrophage 
(CD68) staining visible in aortic wall with low 18F-FDG uptake. B) Aortic aneurysm wall from 
high 18F-FDG uptake (SUVmax>4.5) in the same patient. Control IgG staining (B1) and the 
corresponding CD3+-stained T-cells (B2, brown DAB stained cells, brown arrows) and CD68+ 
macrophage staining (red cells and arrows). The cells were present in an infiltrative pattern in 
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the tunica media and tunica adventitia, predominating in the perivascular zone, rich in vasa 
vasorum. They were present and surround arterioles infiltrating in from the adventitia into the 
media. C) There were significantly more T lymphocytes (P<0.001) and macrophages (P<0.05) in 
the aortic wall with SUVmax >4.5 (mean of 4 sections per biopsy from 40 biopsies obtained from 
10 aneurysms – a total of 160 slides analysed by two independent observers).    
 
The CD3+ T-cells were co-localised with CD19+ B lymphocytes. Both lymphocyte 
subsets were co-located within the outer third of the tunica media and tunica 
adventitia at sites of increased neovascularisation. The B-cell numbers were 
linearly related to 18F-FDG uptake.   
 
Fig 3.16 IHC staining for CD3+ T lymphocytes and CD20+ B lymphocytes 
 A) Low 18F-FDG uptake (SUVmax<2.5) aortic aneurysm wall stained with negative control with 
IgG (A1). Aneurysm wall section stained for CD3+ T lymphocytes (brown cell and brown arrow). 
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These cells were found mainly in perivascular zones in the adventitia, with some ingress into 
the media (A2). No B lymphocytes were found  in wall with low 18F-FDG uptake.  
B) Aortic aneurysm wall from high 18F-FDG uptake (SUVmax>4.5) in the same patient. The 
negative IgG staining control is seen in (B1). CD3+ T-cell (brown cells and arrows) and CD20+ B 
lymphocyte staining (red cells and arrows) (B2). The cells were present in an infiltrative pattern 
in the tunica media and tunica adventitia, predominating in the perivascular zone, rich in vasa 
vasorum. Cells were found around what morphologically looks like arterioles infiltrating in 
from the adventitia into the media. C) On quantification of the cells by cell counting there was 
a significant increase in the number of B lymphocytes (P<0.001) in the aortic wall with 
increasing SUVmax (mean of 4 sections per biopsy from 40 biopsies obtained from 10 aneurysms 
– a total of 160 slides analysed by two independent observers). Two-way ANOVA <0.001, with 





























3.5.1 18F-FDG uptake in the aneurysmal wall 
We have shown that there is focal uptake of 18F-FDG in the aneurysmal wall 
and that this is heterogeneous in nature (i.e. highly variable from site to site in 
the aortic wall). Regions of aortic wall within millimeters of each other can 
have highly variable 18F-FDG uptake. This confirms existing data from 
longitudinal retrospective human studies that shows episodic focal uptake at 
different sites in the aortic wall281,306,309. This uptake changes over time at the 
same anatomic site in the aortic wall.  
 
To date, few studies have examined the long-term outcomes of patients with 
increased vascular 18F-FDG uptake, with most studies having small numbers 
and described as pilot or early feasibility studies. The 18F-FDG uptake seen in 
the majority of these studies may be influenced by their patient selection. For 
instance, in order to carry out a PET/CT scan one needs an optimal time 
window of at least 2-3hrs between injections of the tracer and scans. This 
lengthy time and the geographical separation of the scanners in most 
institutions, gives rise to pre-selection bias of patient groups that are medically 
stable and compliant, with clinically unstable patients or patients requiring 
immediate therapy being excluded from the study. It is this precise group who 
need appropriate, timely investigation and intervention to improve outcomes. 
Future development of a range of more bespoke PET tracers that are specific 
for biological processes on going in the aorta wall is needed to facilitate rapid, 
accurate, specific and sensitive scanning, thus enabling PET/CT examination of 
acutely unwell or haemodynamically unstable patients. 
 
Another limitation of PET is that despite its sensitivity it has limited spatial 
resolution, making it difficult to accurately localize the radiotracer uptake in 
the aortic wall. The addition of CT hybrid techniques for image fusion and 
registration has sought to circumvent this problem. The anatomical 
information on 18F-FDG uptake helps differentiate the wall uptake from the 
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uptake by adjacent tissues such as luminal blood or surrounding soft tissue.  
The use of ROI, reduction of partial volume effects, SUVmax, mean SUV and 
TBR all allow for correction of this problem. An unenhanced CT scan is 
technically more difficult to interpret as intraluminal thrombus (ILT) in the 
abdominal aorta and soft tissue artifact make arterial wall distinction difficult. 
There is difficulty in delineating the aortic wall from the luminal blood. 
Intravenous contrast is therefore essential to enhance the image; followed by 
the PET scan timed at least 1-3hrs post tracer injection. Before there is 
widespread application of this technique in evaluating patients with aneurysms 
and with AAS, there needs to be agreement on the visual assessment of FDG 
uptake (absolute SUVmax, SUV thresholds and TBR). The imaging times need to 
be consistent and a uniform methodology developed for arterial 18F-FDG 
studies. A recent study on 18F-FDG PET advocates dual time point 
imaging264,274,270,281,308, which provides better lesion to background reading on 
PET visual assessment. This involves identifying the most intense area of aortic 
wall uptake and drawing regions of interest around the wall and lumen. The 
maximum activity concentration for each area is then recorded in each 2min 
frame. For each period of dynamic imaging (4 x 2min frames), the mean 
maximum activity concentration (decay corrected) is then recorded and 
converted to SUVmax that is normalized to body weight.  
 
Once optimisation of the technical aspects of the fused PET/CT scan has been 
considered the next problem to overcome is clinical presentation. The protocol 
that we developed for the PET-CT study was designed to optimize the 
anatomical detail that the CT scan provided for operative planning, with 
accurate 18F-FDG localization in the aortic wall to facilitate tissue biopsy of 
regions of varying tracer uptake. Symptomatic aneurysms are reported to have 
higher tracer uptake compared with aneurysms in asymptomatic patients and 
healthy controls131,264,275,288. These findings are in keeping with the fact that 
aneurysm formation and rupture are active metabolic processes that are 
highlighted by 18F-FDG uptake. There was however no correlation between 
aneurysm size and uptake. This could be partly explained by the small patient 
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sample size in these studies. Another possible explanation would be that 
aneurysm growth is not linear with rapid growth followed by quiescent phases. 
Hence the 18F-FDG uptake would vary from week to week and over time in the 
same site in the same patient. We sought again to evaluate this in the murine 
model of aneurysm development. We additionally aimed to correlate the 
tracer uptake with aneurysm expansion and growth rates, rather then a static 
diameter reading. Of the two patients who had chronic aortic dissection, there 
was increased 18F-FDG uptake in the flap tissue suggesting metabolically active 
immune cell content in the dissected aortic wall. 
 
3.5.2 Biological correlates of 18F-FDG uptake 
The results of this study also show that there is a relationship between specific 
inflammatory cell subtypes and 18F-FDG uptake in aneurysmal thoracic and 
abdominal aortic wall. 18F-FDG uptake was strongly, positively correlated with 
a B, T and NK cell infiltrates. This is contrary to reported observational data 
which postulated that monocyte/ macrophage infiltrates were responsible for 
18F-FDG uptake136,264,308-310.  It is possible that these biological correlates are 
specific to large degenerate aneurysms, as these were the aneurysms that 
were amenable to open repair and were therefore included in this study. All 
patients included in the study were asymptomatic and the aetiology of the 
aneurysms was degenerate aneurysms, connective tissue disease and 
complicated chronic aortic dissection in an aneurysmal aorta. There was more 
18F-FDG uptake in the thoracic aortic wall compared to abdominal aortic wall in 
the patients, however the uptake correlated to the same cell populations in 
the aortic wall. The intensity and range of 18F-FDG uptakes was no different in 
the thoracic and abdominal aneurysms.  
 
18F-FDG-PET has been used to assess atherosclerotic plaque in the vascular 
tree311-313 where it has been reported that unstable atherosclerotic carotid 
plaque takes up 18F-FDG and this correlates with levels of circulating matrix 
metalloproteinase 1 (MMP-1). Others show that the level of 18F-FDG tracer 
uptake into at risk atherosclerotic plaque increases with degree of plaque 
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instability 311,312. It has been suggested that monitoring metabolic activity as a 
surrogate of inflammatory activity in plaques may be used to assess the 
efficacy of drugs aimed at modifying the stability of plaques. This postulation is 
supported by the finding that assessment by 18F-FDG PET-CT is informative of 
the beneficial effects of statins in limiting atherosclerotic plaque inflammation 
and attenuating aneurysm formation in animals 311-314. Increased 18F-FDG 
tracer uptake is associated with macrophage numbers in plaque, with tracer 
accumulation in the regions of the plaque with the highest density of 
macrophages311,312. 18F-FDG uptake is well-recognised in inflammatory 
vasculitis. Takayasu's arteritis and giant cell arteritis both show significant 
metabolic activity314,315. Furthermore, 18F-FDG uptake has been found in 
mycotic aneurysms that are metabolically active as a result of infection and 
inflammation130,314-317. 
 
The processes on-going in the aortic wall that delineates 18F-FDG uptake in the 
aneurysm are, however, not known. The presences of inflammatory cells (B 
and T lymphocytes and NK cells in the adventitia might be implicated as 
suggested by our current work. The underlying biological mechanism for the 
presence and role of inflammatory cells remains to be elucidated and will form 
part of further work in this project. Intimal atheroma and adventitial 
inflammation are features of aortic aneurysms that have been previously 
described. In almost half the patients with aneurysms lymphoid follicles are 
observed in the adventitia along with B-cells101, 107-111,134. Other authors have 
placed T-cells with increase CD4/CD8 ratio in aneurysmal tissue and CD19 B-
cells in all pathological cases101,107,134,135,316. The intensity of the inflammatory 
immune response has led some authors to consider if aneurysmal disease is a 
reaction to local aortic wall damage. Initial wall shear stress and mechanical 
load leads to aortic wall injury that could expose antigens, such as oxidised LDL 
and cellular proteins, which is then followed by an immunophenotypic 
response to elastin fragments, collagen fibres and ECM proteins leading to 
aneurysm formation107,108,126,320-324.  
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Characterisation of the T and B-cell subtypes in the aortic aneurysms was 
based on expression of pan B-cell markers (CD19/20) and T-cell marker (CD3). 
CD8+ cytotoxic T-cells predominated, with CD4+ T-helper cells in the aneurysm 
wall. As the 18F-FDG uptake increased there was an increased preponderance 
of CD25+, CD38+, CD25+CD127+ cells. This represents an activated cell 
phenotype that is responsible for T-B interactions, further complex 
immunomodulation and T regulatory cell function. Previous studies have not 
found T lymphocytes that demonstrate this phenotype in the aortic wall 96,306. 
Some authors have shown T-cells that demonstrate memory phenotype 
CD45RO+ CD45RA- indicating T-cells are migrating in the aortic wall in response 
to a yet unknown antigenic trigger107,324,326-328. The B-cells in these studies have 
been defined as a CD5- population. This is a polyclonal B-cell type that 
produces and expresses kappa and lambda chains107,318. Additionally these B-
cells expressed CD27+ for the CD19+ population which represents a specific 
memory cell phenotype319. Also expression of the surface Ig heavy chains 
expresses memory status onto these B-cells. In the aortic aneurysm wall there 
has been a large amount of IgA expression described in certain studies. This is 
predominantly in AAAs. The reason for this might be due to mucosa associated 
gut priming of B-lymphocytes319-320. Interestingly there might also be 
differential expression of adhesion molecules on the aneurysm surface. These 
include the β1, β2, β7 integrin subfamily, members of the Ig super family, and 
CD44320,321.  
 
Vast majority of AAAs have been also shown to have B-cell rich infiltrates in the 
adventitia that are not an autoimmune response to limited repertoire of tissue 
antigens128. There is a presence of lymphoid follicles and plasma cells in the 
adventitia with expression of immunoglobulin heavy chains133. The 
inflammatory changes were non-specific and macrophages and B-cells were 
present. Same studies identified gelatinase A, MMP2 and MMP9 activity to be 
increased in aortic aneurysms322. The recruitment of the B-cells into the 
adventitia with subsequent elaboration of the MMPs including gelastinase A 
and B may contribute to rapid growth and rupture of large aneurysms322. 
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The initiation, development and propagation of aneurysms is complex and 
several biological processes may be involved including lipid deposition, 
coagulation, tissue hypoxia and angiogenesis, and protease activity (all of 
which are involved in atherosclerosis, a disease that occurs concomitantly with 
aneurysmal disease). Specifically novel tracers could target these processes. It 
may be possible, for example, to target endothelial epitopes associated with 
leukocyte transmigration, leukocyte adhesion molecules, angiogenic growth 
receptors, tissue hypoxia and bespoke synthetically designed radiotracers that 
are coupled to enzymes or their respective inhibitors (for instance MMPs and 
TIMPS). These may provide better targets to study aneurysm development and 
their potential to rupture322,323. 
 
Novel 4D PET-CT tracer targeting macrophages has been used in clinical trial to 
identify chronic inflammation in the asymptomatic abdominal aortic 
aneurysms324-325.  No aortic uptake was recorded on the visual inspection, 
neither with [(11)C]-PK11195 nor with [(11)C]-d-deprenyl (the two agents 
used).   
 
One of the main criticisms of 18F-FDG is that its uptake may vary within the 
same patient with time as a result of the non-linear growth of aneurysms.  The 
inherent weakness of any imaging modality assessing metabolic activity is that 
it may miss the rapidly expanding phase, which may last from days to weeks at 
a time326. New animal data suggests that there are other molecular imaging 
compounds that might be better at identifying vulnerable areas of aortic wall. 
It is important to consider the interaction of intraluminal thrombus with aortic 
wall. Autopsy studies have demonstrated that most aortic ruptures occur at 
site of ILT under the aortic wall321,326,327. These sites may be thinner and 
weaker with increase inflammatory cell infiltrate, proteolysis and ECM 
breakdown327,328. The relationship between size of ILT and risk of aneurysm 
expansion is controversial146,326-328. It might be that increased thrombus 
volume in expanding aneurysms leads to rupture but it could be that large 
aneurysms have increased risk of rupture and contain thrombus140,317,318.  
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Studies indicate that annexin V it may be able to determine the development 
of ILT in aneurysms thus providing a new potential diagnostic marker to image 
aneurysm development and expansion as ILT increases. Annexin V binds to 
activated platelets and apoptotic cells and 99mTc-annexin-V has been used for 
SPECT in humans and animals to demonstrate acute and chronic thrombi. 
Using platelet activation induced fibrin formation, 99mTc-annexin-V may mark 
the interface between aortic wall and ILT and therefore represent biologically 
active aneurysms329-332. The role of ILT in AAA progression has been suggested 
by links between plasma markers of thrombotic thrombin-antithrombin 
complexes 332 and fibrinolytic plasmin-antiplasmin activity332. The ILT is 
biologically active component with continuous turnover linked to platelets and 
phosphatidylerine in the luminal part of the thrombus333. This stores PMNLs 
that are responsible for cellular apoptosis and adhesion332,333. The PS exposure 
on platelet membranes is the mediator linking platelet vesicles to thrombin 
formation and fibrinolysis329,334. 
 
Abdominal aortic aneurysms (AAA) are structurally characterized by parietal 
extracellular matrix degradation attributable to activated matrix 
metalloproteinases,46 cell disappearance334,336 and presence of a mural 
thrombus333,334. The role of the thrombus in aneurysm progression has been 
suggested by early observations of a link between plasma markers of 
thrombotic (thrombin-antithrombin complexes)333 and fibrinolytic (plasmin-
antiplasmin) activities336,337 and aneurysm evolution338. Furthermore, this 
relationship has been documented at the tissue level334,338-340. Recently, the 
AAA thrombus was found to be biologically active involving permanent 
renewal linked to platelet activation and phosphatidylserine exposure in the 
luminal part at the interface with the circulating blood329,341,342. The luminal 
part of the thrombus stores polymorphonuclear leukocytes (PMN), which 
spontaneously disappear by apoptosis after adhesion; in this context of arterial 
mural thrombus, phosphatidylserine exposed on platelet membranes is the 
mediator linking platelet vesicles to thrombin generation and fibrinogenesis 
329,341-343. 
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Annexin V specifically binds with nanomolar affinity to PS, which is exposed to 
the surface of activated platelets and apoptotic cells329. Therefore, 
radiolabeled 99mTc-annexin-V (ANX) has been previously used for in vivo 
scintigraphic imaging of both apoptotic cells in animals and humans, and acute 
platelet-rich thrombi in animals329,344-346. Nevertheless, the ability of ANX to 
assess renewal activity in chronic mural thrombus, at the interface between 
circulating blood and mural thrombus has not yet been reported. 
 
Another novel compound called lacadherin may be able to mark out platelets 
and cell apoptosis by binding to αvβ5 and αvβ3 integrins. Its role as a novel 
marker remains to be determined. Other proposed tracers include 99mTc-
Apcitide as this ligand binds to the platelet GPIIb/IIIa receptor331,347,348.  The 
platelet infiltration of the intraluminal thrombus might positively modulate the 
immune cell infiltration into the aortic wall and thus dictate aortic aneurysm 
behavior and expansion349.  
 
The studies that have investigated the role of 18F-FDG PET-CT in acute aortic 
syndrome (AAS), have yielded significantly higher tracer levels at sites of 
penetrating aortic ulcers, intramural haematoma and aortic 
dissections143,310,347,348. 18F-FDG seemed to correlate to unfavourable clinical 
outcomes. The pathophysiological changes that characterise these arterial wall 
changes are degeneration of the elastic fibres in the tunica media, loss of 
collagen and accumulation of fibrin, loss of vamps, adventitial hypertrophy and 
accumulation of a pro-inflammatory infiltrate and proteolytic enzymes. It is 
believed that these immune cells surround areas of medial degradation and 
with the involvement of MMP’s, lyse aortic proteoglycan matrix. Several 
studies report higher 18F-FDG uptake correlated to immune cell content (mainly 
macrophages) in the aortic wall138,309. 18F-FDG accumulation in aortic dissection 
may stem from increased macrophage density indicating aortic inflammation 
and correlation with worse short term outcomes for aortic dissection. 
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One third of patients with AAS had 18F-FDG uptake suggesting active 
inflammatory activity348,349. There was a trend to an association between 
higher uptake of radiotracer and poorer clinical outcomes. Other studies 
demonstrate that in patients with aortic aneurysm, given the SUV mean cut-off 
value of greater than 3, 18F-FDG PET had a substantial predictive value for 
discriminating unfavourable from favourable aortic dissection 
patients108,347,348. These authors also report, macrophages in the aortic media 
in both patients with aortic dissection and aneurysms. However, greater 
numbers of macrophages are present in the dissection patients, accounting for 
differential uptake between aneurysms and dissection.  
 
The classically known determinants of aortic dissection are the aortic 
aneurysm diameter, female sex, older age, partial thrombosis of a false lumen. 
Identification of an aorta before it ruptures or dissects is the ultimate goal for 
non-invasive vascular inflammatory imaging. 18F-FDG uptake and its association 
to AD is unknown. Functional data on aortic wall will determine the usefulness 
of 18F-FDG PET-CT for risk stratification among aortic dissection patients. 
Indeed the one patient that had chronic type A dissection in this study 
demonstrated a high 18F-FDG uptake in the aortic dissection flap. Analysis of 
this flap tissue on flow cytometry demonstrated intense B and T-cell infiltrate. 
This suggests that the flap is a metabolically active tissue with immune cell 
infiltration that is modeling and interacting with the aortic wall. 
 
Performing 18F-FDG PET-CT imaging provides a snapshot of immune cell activity 
in the aneurysm wall at a specific time. We are unable to tell how the immune 
cell activity and content changes with aneurysm growth, at various aortic 
diameters and if there is a variation within the same aneurysm with time. An 
aneurysm model would allow better characterisation of the biological 
correlates of the immune cell content in the aortic wall. We aimed to carry this 
out next. 
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Chapter 4: 18F-FDG uptake in murine aneurysms and 
biological correlates  
 
4.1 Introduction 
Angiotensin II is the primary bioactive peptide of the renin angiotensin system 
that plays a critical role in cardiovascular pathology. Subcutaneous injection of 
angiotensin II into ApoE-/- mice leads to the development of aortic 
aneurysms62,153,279,349,359. Similar to human aortic aneurysms, the angiotensin 
II-exposed mice exhibit progressive aortic wall changes and clinical    
complications of aortic aneurysm dissection and rupture352 as well as the 
development of intraluminal thrombosis353. Angiotensin II-induced mice 
develop aneurysms in the suprarenal aorta, which differs from the most 
common locations of aneurysms (the thoracic and abdominal aorta) in 
humans. The reason for this is unknown, but the peri-aortic tissue around the 
suprarenal aorta in mice contains an abundant source of leukocytes and pro-
inflammatory cytokine following angiotensin II infusion that might be 
responsible for the development of an aortic aneurysm in this location352. Also 
the haemodynamically induced wall shear stress is different in the murine 
model and may influence the site of aneurysm development. This model of 
aneurysm development is thought to accurately recapitulate the disease in 
man with aneurysm development associated with inflammation, tissue 
modeling, up-regulation of matrix-degrading proteinases, ECM degeneration, 
altered VSMCs function, formation of ROS and thus aneurysms350, 352,353, 354. 
Using the ApoE-/-ATII model we sought to investigate the relationship between 
18F-FDG uptake and aortic wall expansion, maximum aortic diameter, rupture 
risk and early aortic death. We also sought to understand the biological events 







1) Generate aortic aneurysms in ApoE-/- animals by angiotensin II (ATII) 
 infusion and to determine the natural history of aneurysm 
 progression in this model 
2) Carry out contrast enhanced 18F-FDG PET-CT in the ApoE-/--ATII model 
  and determine the natural history of aneurysm progression with 18F-
  FDG uptake 
3) Determine the association between aneurysm growth rate, aortic  
  diameter and risk of rupture to 18F-FDG uptake in aortic wall 
4) To characterise the immune cell infiltrate associated with 18F-FDG     
                 uptake in murine suprarenal aneurysms  
5) Quantify the immune cell populations and define the subtypes  
  present in the normal aorta vs. aortic aneurysms vs. aortic aneurysms 
  from different 18F-FDG uptake sites 


















4.3.1 Murine ApoE-/--ATII model of aortic aneurysms 
All procedures on animals were carried out under a project license from the 
ANIMALS SCIENTIFIC PROCEDURES ACT 1986 (PPL 70/7097) and personal 
license (PIL 70/22677) granted by the Home Office. ApoE-/- mice mutant strain 
(Jackson Laboratory, Bar Harbor, ME, USA) were used for the aortic aneurysm 
model. The animals were housed in a 12-hr light/12-hr dark cycle at 18-23oC 
with 40-60% humidity. The ApoE-/- mice were given normal chow 8-11% fat 
with water available at all times (SDS, Essex, UK).  
 
Alzet osmotic mini-pumps (Durect Corporation, Cupertino, CA, USA) loaded 
with 107μl of a 12μg/μl Angiotensin II (Sigma-Aldrich, Saint Louis, MO, USA) 
solution in sterile normal saline. Under 4% isoflurane anesthesia, the pumps 
were implanted subcutaneously in the dorsal region of 12-14 week-old male 
ApoE-/- mice, to achieve a delivery rate of 1µg/kg/minute over the course of 6-
weeks as previously described62,153,279,349,359. The skin was closed with 4/0 
polydiaxonone (Ethicon, UK). Buprenorphine (2µg/g body weight) was 
administered subcutaneously for post-operative analgesia. An aortic aneurysm 
was defined as a 2-fold increase in the aortic diameter from the baseline. 
Abdominal aortic aneurysms in the supra renal and descending thoracic aorta 
were generated (Fig 4.0).  
 
4.3.2 Detection and quantification of 18F-FDG on PET-CT 
The animals previously implanted with the subcutaneous pumps for 
angiotensin II release were anesthetised with isoflurane/oxygen 4% via a face-
mask at a constant flow rate of 1.5L/min. One of tail veins was cannulated with 
a 30-gauge needle. Exitron Nano1200 (Miltenyi Biotec, GmbH, Germany) was 
used as a blood pool contrast agent delivered through a 100µl injection. 18F-
FDG was injected at a dose of 10MBq at the same sitting. CT scan images were 
acquired at 60mins post injection and the PET images at 90mins without 
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moving the animals on the gantry. Haemodynamic parameters for the animal 
were monitored using telemetry system that informed of pulse and respiratory 
rate. Animals were continuously monitored visually whilst in the scanner. At 
the end of the scan session animals were allowed to recover in the preparation 
room in a warm dim environment. The animals were recovered for imaging at 
later time points in a longitudinal fashion; or animals were culled using 
exsanguination (direct cardiac puncture). The spectral Nano PET/CT scanner 
(Medisco, Bioscan Inc. Washington, US) was used for image acquisition. The 
PET detector comprised of 12 arrays of 85x39 LYSO crystals on 
1.12x1.12x13mm3 at a packing fraction of 92%.  The helical CT scan allowed 
data acquisition at 1.2mm CFOV with a 250-750keV window. CT scan images 
were acquired from the aortic arch to the iliac bifurcation at maximum FOV, 
360 projections at 1600ms, voltage setting of 65keV with 1:4 binning at a pitch 
of 0.5 (Fig 4.1-4.2). The PET and CT system shared the same axis of rotation 
enabling real time accurate image fusion without the errors of quantification 
or due to partial volume effects. This also allowed minimisation of the artifacts 
caused due to non-uniform sampling from the field of view (Fig 4.2).  
 
Viscover™ ExiTron™ nano (Milteny Biotec, Bergisch-Gladbach, Germany) was 
used as the intravenous alkaline earth metal–based nanoparticulate (110nm) 
contrast agent for the preclinical CT imaging. On intravenous injection, ExiTron 
nano circulated in the bloodstream till finally taken up by the 
reticuloendothelial system. The ExiTron nano 12000 gave density of 12,000 
HU. 100µl was injected per mouse (25g) corresponding to a dose of 1200 mg 
iodine/kg body weight. The imaging was typically performed 60mins post 
injection of the contrast agent. 
 
4.3.3 Image analysis of PET scans 
The scans were analysed using the Hermes, OsiriX software (OsiriX Inc. San 
Antonio, Texas) and Amira 5.3.3® (Visage Imaging Inc. San Diego, CA) software 
as for human scans described in section 3.3. Additionally the murine scans 
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directly transferred and analysed at a dedicated workstation using Bioscan 
InvivoScope™ imaging suite. This allowed PET-CT fusion and image registration 
to be performed. Images were reconstructed to give the maximal field of view 
(FOV) and co-locate 18F-FDG into aortic tissue (Fig 4.3). 
 
4.3.4 Murine aortic biopsy 
Mice had induction anesthesia with 3% isoflurane, which was maintained with 
1% isoflurane at 2l/min of oxygen. Aseptic techniques were used throughout 
the time of open surgery: a median sternotomy and midline laparotomy was 
carried out to expose the entire length of aorta. The aorta was dissected from 
the aortic root, along with the aortic arch vessels down to the iliac bifurcation 
using an operating microscope (Leica Microsystems ltd, UK). The entire aorta 
was harvested and sectioned into ascending, aortic arch, descending thoracic, 
suprarenal and infra-renal aortic segments. The affected aneurysmal segment 
was removed and segmented as per imaging data for analysis. Prior to 
processing the aortic wall was thoroughly washed with sterile normal saline at 
4°C to remove any blood contamination. Aortic segments were obtained from 
regions with different SUVmax (18F-FDG uptake). Biopsies were processed for 
either flow cytometric analysis, homogenised for PCR/ELISA analysis, or fixed in 
10% formalin/snap frozen in liquid nitrogen for histological analysis. 
 
4.3.5 Isolation of tissue resident inflammatory cells for flow 
cytometry 
Murine aortic specimens underwent same enzymatic degradation and cell 
harvest protocol as in section 3.3.3. Tissue was cut into 1x1mm segments from 
each site and incubated at 37°C for 30mins in phosphate buffered saline (PBS, 
without calcium and magnesium) containing 0.5% bovine serum albumin (BSA), 
1mM ethylenediaminetetraacetic acid (EDTA) with 1mg/ml collagenase D 
(Sigma Aldrich, UK), 100units/ml DNAase I (Sigma Aldrich, UK) and 500units/ml 
hyaluronidase IV-S (Sigma Aldrich, UK). The tissue and dissociated cells was 
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filtered through a 100µm strainer (Falcon BD) into a 6-well plate and the 
undigested tissue mechanically dissociated in the enzyme suspension-using 
plunger from a 10ml syringe. The remnant tissue was washed with 5mls of PBS 
(0.5%BSA, 1mM EDTA). The cells were washed and spun twice at 320g at 4°C 
with the supernatant discarded and the pellet resuspended in 1ml 
PBS/BSA/EDTA and incubated on ice. The cells were fixed in 4% 
paraformaldehyde for 10mins at room temperature, washed (x1) and 
suspended in PBS (0.5%BSA, 1mMEDTA) and stored at 4°C for 48hrs prior to 
staining for flow cytometry.  
 
4.3.6 Antibody staining for murine inflammatory cell markers 
Murine samples (normal and aneurysmal) were obtained at 5, 10, 15, 25 and 
33 days post-aneurysm induction. For the murine PET-CT experiments n=15 (3 
from each time point) tissue samples were obtained at each time interval. 
Aortic samples were segmented according to anatomical location to ascending 
aorta including aortic arch, descending thoracic aorta, suprarenal abdominal 
aorta and infra-renal abdominal aorta. The aneurysmal segment was divided 
into segments depending on the degree of tracer uptake. The complete 
aneurysmal segment was excised and cut into anterior, posterior, lateral and 
medial aortic wall segments as per regional tracer uptake. Tissue underwent 
enzymatic degradation and cell harvest protocol as described in Section 4.3.5.   
 
Inflammatory cell content of tissue resident cells from murine aortic wall was 
quantified using flow cytometry. This was carried out in the following manner. 
500µl of cell suspension in FACS buffer (PBS with 1%BSA, 10% sodium azide) 
from each aortic biopsy site was incubated with the antibodies resulting in the 
following concentrations (Table 4.0). 
 
Analysis was carried out using a FACS Canto II flow cytometer (BD Biosciences, 
UK). Leukocytes were selected according to forward (size) and aide 
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(granularity) scatter properties and final gating performed on CD45+, CD3+ and 
CD19+ leukocytes. 
 
Table 4.0 Primary flow cytometric antibodies for murine immune cell typing 
(All antibodies obtained from BD Biosciences) 
Cell Cell surface 
marker 
Fluorophores Concentration Code 
Leukocyte CD45 PE 0.25 µg/ml 553081 
NK NK1.1 APC-Cy 0.1 µg/ml 560618 
T-cell CD3 PE-Cy 0.1 µg/ml 552774 
B-cell CD19 APC 0.25 µg/ml 550992 
Monocyte CD11b APC-Cy 0.25 µg/ml 557657 
Macrophage F4/80 PE-Cy 0.5 µg/ml 123114 
Neutrophil Ly6c FITC 0.25 µg/ml 553126 
 
4.3.7 Antibody staining for murine lymphocyte subset markers 
The cell suspension sample was split into three subsets for staining. These 
were for B-cell, T-cell and T regulatory cell surface markers. Each subset 
contained 500µl of cell suspension in FACS buffer from each aortic biopsy site 
that was incubated with the antibodies resulting in the following 
concentrations (Table 4.1). Flow cytometric analysis was carried out as 









Table 4.1 Primary flow cytometric antibodies for murine immune cell subtyping 
(All antibodies were obtained from BD Biosciences) 
Cell Cell surface 
marker 
Fluorophores Concentration Code 
Common T-cell CD3e PerCP-Cy5.5 0.2µg/ml 551163 
T helper cell CD4 APC-H7 0.2 mg/ml 560181 
Active antibody 
producing B-cells  
CD5 (Ly-1) FITC 0.5 mg/ml 553020 
Cytotoxic T-cell CD8a (Ly-2) FITC 0.5 mg/ml 553030 
Common B-cell  CD19 PerCP-Cy5.5 0.2 mg/ml 561495 
Common B-cell  CD20 APC-H7 0.2 mg/ml 641396 
Plasma B-cell CD24 PE-Cy7 0.2 mg/ml 560536 
T regulatory cell CD25 (IL2) PE 0.2 mg/ml 558642 
Memory B-cell CD27 V450 0.2 mg/ml 560448 
Active B-cells (B-T 
interaction/ adhesion) 
CD38 APC 0.2 mg/ml 555462 
Common leukocyte 
antigen 
CD45 V450 0.25 mg/ml 560501 
Active B plasma cell CD138 
(syndecN-1) 
APC 0.2 mg/ml  558626 
Active synthetic B-cell Anti IgD PE 0.2 mg/ml 553511 
Synthetically active B-
cell 
Anti IgM PerCP-Cy5.5 0.2 mg/ml 550881 
Highly active T-cell  CD14 APC-H7 0.2 mg/ml 641394 










4.3.8 Tinctorial histology and immunohistochemistry 
This was carried out as described in Sections 3.3.7, page 107 and 3.3.8, page 
109, using the primary anti-mouse antibodies described in Table 4.2 and the 
same secondary antibody staining system.  
 



























Macrophages Mouse 4l/ml BioLegend, USA 
Anti-
tropoelastin 
Tropoelastin Rabbit 1μl/ml Abcam, MA 
 
4.3.9 Statistical analysis 
Data was analysed in SPSS (IBM Corporation, Data Collection, USA). Data are 
represented as mean ± standard deviation (SD). Parametric data was analysed 
using Student’s Paired T-test. Correlations were carried out using linear 
regression and Pearson correlation coefficient analysis and represented as the 









The -/-ApoE/angiotensin II murine model was used to evaluate the 18F-FDG 
uptake in 15 animals that underwent 20 scans in total at 5 time points (day 5, 
10, 25, 25, 33). Some animals developed aortic dissection and rupture as 
complications in this model (20% of number used, Fig 4.0). 
 
The model mimicked not only the characteristic development of aortic 
aneurysm but also all the complications that can arise as a consequence of 
aneurysm development, namely aortic rupture and/ or dissection. To image 
the aorta at various stages of aneurysm development computer tomography 
(CT) was used to delineate the aorta. The non-contrast CT as in humans was 
not helpful as lack of intraluminal vascular contrast agent meant aortovascular 
anatomy could not be seen compared to surrounding tissues (Fig 4.1). This was 
the case when assessing mediastinal and abdominal vasculature and it was 
technically challenging to follow the aortic tree in the abdomen with 





Fig 4.0 ApoE-/--ATII infused animals at day 35 with suprarenal aortic aneurysms (SRA) 
A) The supra-renal aorta can be seen to dilate to more than x4 its normal diameter in this 
animal with a normal thoracic aorta (TAo). The aneurysm typically terminates above the renal 
arteries B) This ApoE-/--ATII animal developed an aortic dissection and died at day 14. The 
haemorrhagic change can be seen in the adventitia of the SRA C) This SRA at day 35 had ILT 
present around the aortic wall when opened up longitudinally. This typically characterises an 
advanced aortic aneurysm. D) ApoE-/--ATII infused animal developed acute aortic rupture of 
the thoracoabdominal aorta and was found dead at day 15. A post-mortem examination 
showed haematoma in the left pleural space and the retroperitoneum.  
SRA 
vTAo 










Fig 4.1 Non-contrast enhanced murine CT 
A) A transverse slice taken through the mid-thoracic section of the chest where the heart is 
visible in the middle mediastinum. The aorta or the cardiac structures cannot be delineated 
clearly due to lack of contrast. B) The transverse section taken through the abdominal aorta at 
the level of the liver. There is unclear soft tissue opacification and none of the vascular 
structures seen. C) This is a coronal section through the murine chest and abdominal cavities. 
The soft tissue and solid organs are just visible. Lungs appear as dark opacities in the upper half 
of the image with the live seen under the diaphragm. D) A sagittal section through the chest 
and abdomen again delineating poorly the heart and the aortovascular details are absent 
 
The intravascular contrast agents were therefore used to determine the 
aortovascular tree. After intravenous administration of ExiTron nano 12000 
(Miltenyi Biotech, Bergisch-Gladbach, Germany), the alkaline earth metal-
based nanoparticulate contrast agent specifically circulated within the vascular 
tree and maximally delineated the aortic vascular tree 60mins post intravenous 
injection. The blood pool agent is eventually taken up by the Kupffer cells and 
renal excreted but till then allowed excellent intravascular visualisation of the 
aorta (Fig 4.2). This allowed aortic wall lumen to be delineated and thoracic 
and abdominal aortic aneurysms to be visualised (Fig 4.2) as well as all the 
thoracic, visceral, renal arterial branches and the vascular arcades.  
 157 
 
Fig 4.2 Contrast CT scan performed 60mins after intravenous blood pool agent ExiTron nano 12000 
A) The coronal section shows the thoracoabdominal aorta and its branches in a day 7 ApoE-/--ATII mouse. Early dilatation of the suprarenal segment can be seen (*) 
B) Sagittal section MPR showing the abdominal aorta, IVC, and visceral branches. C) Transverse mid-thoracic section demonstrating cardiac chambers. D) Ascending, 
arch and descending thoracic aorta with arch branches seen. Proximal descending thoracic aneurysm (red diamond). 
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The PET scan using 18F-FDG was performed 90min after the radiotracer 
injection (Fig 4.3). Extremely high metabolic activity was seen in the 
myocardium, followed by the kidneys and increased renal pelvic washout of 
the 18F-FDG into the urinary bladder. The 18F-FDG uptake varied 
heterogeneously within the murine model. Overall there was an increased 
uptake of the 18F-FDG in the animals over the time course of the experiment 
with a statistically significant higher uptake when day 5 animals were 
compared to day 15 (P<0.01). However there were no differences between the 
groups when compared on weekly basis. The uptake was localised to certain 
sites but was heterogeneous (Fig 4.3B) and plateaued in its intensity from day 
15 to day 33. Uptake was predominately present in the aneurysmal segments 
compared to the normal aortic wall. There was no correlation between 
aneurysm size or growth and the 18F-FDG uptake (Fig 4.4). Uptake varied from 
site to site at various time intervals within the same animal when serially 
imaged and the equivalent sequences and slices were compared.  
 
A cohort of serially imaged ApoE-/-ATII (n=16) allowed determination of the 
natural history of aneurysm development. 70% of the cohort developed an 
aortic aneurysm and off these 20% developed aortic dissection or rupture 
within the time course of the study. The mean aortic diameter was 
210m38.3m and this increased in all animals with time. The maximum 




Fig 4.3 A fused PET-CT image, CT scout and 18F-FDG uptake  
A) The increased uptake of the 18F-FDG can be seen in the myocardium and the urinary 
bladder. There is minimal 18F-FDG uptake in the aorta in this animal. B) This is an example of 
focal but heterogeneous uptake of the 18F-FDG in the suprarenal aortic wall of an aneurysm at 
day 15. The SUVmax ranged upto 4.5 in this instance. The renal outline can be seen at the lower 
pole of the aneurysm. C) The SUVmax represented in the suprarenal aortic aneurysm with time 
in any specific region of interest selected in the SRA wall. There is significantly more 18F-FDG 
uptake in the aortic wall at day 5 compared with day 15 (P<0.01, paired T test n=9). Thereafter 
there are no statistically significant differences between the uptakes at the time points out to 
day 33. Thus there was plateau of 18F-FDG uptake within the aortic wall at difference sites from 





Fig 4.4 The individual growth rates of the ApoE-/-ATII aneurysms 
The growth rates of individual animals (depicted by a different graph colour) are plotted in a 
longitudinal temporal manner for n=16 animals. The mean aortic diameter at 5days after ATII 
infusion was 21038.3m and this increased in 70% of animals over time to 812250.8m at 
35 days. The rate of aneurysm induction was 70%. Of the animals that developed aortic 
aneurysms the risk of complications increased with time. There was a 20% mortality associated 





Fig 4.5 No correlation between the maximal aortic diameter on IV contrast CT and the 
SUVmax on PET scan 
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There was no correlation between maximal aortic diameter and the 18F-FDG 
uptake (n=16) R2=0.0003. Multiple murine aortic diameters taken from all the 
time points were compared to the SUVmax readings taken for those aneurysms. 
There was an intense focal uptake at certain sites in all aneurysms even at 
small aortic diameters. The SUVmax varied from site to site at all the varying 
time intervals. Different sites had intense 18F-FDG uptake followed by 
quiescent phase, independent of increase in aortic diameter.  
 
The extracted cell suspensions from sites of specific 18F-FDG uptake were used 
for flow cytometric analysis to determine the immune cell content and 
correlate this to radiotracer SUVmax. The immune cell content was gated 
according to their forward and side scatter properties (Fig 4.6) and further 
gating was performed on CD45 expression. The immune cell content was 
quantified in all samples (Fig 4.6). Aortic tissue from sites of varying 18F-FDG 
uptake was quantified according to SUVmax (Fig 4.3). Cellular content was 
quantified per microgram of tissue (Fig 4.6-4.8). Sites with the highest SUVmax 
had increased number of B, T lymphocytes and NK cells (Table 4.3).  
 
Table 4.3 Immune cell content as assessed by flow cytometry at sites of varying SUVmax   
(N=10, 50 biopsy sites, two way ANOVA with post hoc Bonferroni correction) 
Immune cell Mean cell number per mg wet wt.  Aorta ± 
S.E.M 
95%CI± P 
 SUVmax<2.5 SUVmax2.5-3 SUVmax>3.1   
B-cell 77±42 258±85 550±51 0.38 <0.001 
T-cell 35±20 170±75 330±70 0.43 <0.001 
NK cell 10±8 23±14 74±23 0.45 <0.01 
Macrophages 6±25 10±23 11±18 0.22 0.12 






Fig 4.6 Examples of flow cytometric analysis of the suprarenal aortic aneurysm at site of 
low SUVmax and high SUVmax 
A) The over all cell distribution when gating is performed of CD45+ leukocyte fraction against 
SSA. B and C) After doublet exclusion on FSC and SSA the cell population subsets are analysed 
for immune cell quantification. D-I) Upper panels demonstrates the suprarenal aortic 
aneurysm (SRA) with high 18F-FDG uptake characterised by SUVmax >3.5 in the aortic wall 
compared to the bottom panels where SUVmax <2.0. There is increased expression of T 
lymphocytes (CD3+), B lymphocytes (CD19+), NK cells (Nk1.1), slight increase in macrophages 
(F480+), but not neutrophils (CD11b/Ly6C). (N=10 patients and 50 biopsy sites). 
 
Once the high expression of lymphocytes was determined at sites of high 
SUVmax. These cells were subtyped according to the cell surface markers to 
determine the lymphocyte population resident in the aortic aneurysm wall (Fig 
4.7). The cells were subtyped according to CD45+ expression, and the leukocyte 
fraction further gated on the common T-cell antigen (CD3+). The CD3+ T-cell 
fraction was subtyped to T helper CD4+, cytotoxic CD8+ cell fraction, activated 
T-cells CD25+ that interact with B-cells and T regulatory cells FoxP3+ with 




Fig 4.7 Flow cytometry immune sub-typing of the CD45+CD3+ T-cell population 
The cells extracted from the normal and aneurysm sites with varying SUVmax were 
characterised on FSC and SSA profiles. B) After doublet exclusion gating. C) The CD45+CD3+ 
cells were gated and counted (C1) with CountBright beads (Invitrogen, UK). This population 
(C2) and sub-typed as D) the CD8+ cells as expressed a high and low expression group. E) The 
CD4+ T helper cells along with CD8+ cytotoxic T-cells. F) The activated cell phenotypes 
expressing CD25+ cell surface marker and G) the identification of T regulatory cell population as 






Fig 4.8 Flow cytometric analysis of T-cell fractions as a percentage of total CD3+ cells. (N=6, 32 aortic segments with P<0.001, 2-way ANOVA and post hoc 




































B-cells were subtyped after initially gating on the CD45+ leukocyte population. 
The cells were gated on the common B-cell antigen CD19+. The cells were 
subsequently typed according to the presence activated B-cells CD25+, 
synthetically active plasma cells that produce IgD and IgM producing 
populations (Fig 4.9). 
 
 
Fig 4.9 B-lymphocytes subsets were phenotyped on flow cytometry 
A) The cells population on CD45+ and side scatter profiles was identified. B) Doublet exclusion 
gating. C) Gating on CD45+ CD19+ B-cells. D) The CD19+CD25+ synthetically active population of 
B-lymphocytes. E) The expression of CD25+IgD denotes cell adhesion ability for plasma cells. F) 
The memory B-cells were phenotyped to IgM synthetically active IgM producing cell type.  
 
Site of no 18F-FDG uptake only expressed CD19/20+ pre-B-cells (Fig 4.10). 
Increasing tracer uptake was associated with increase in the mature B-cell 
phenotype with CD24+ expression. This was across the biopsy sites with the 
SUVmax increase from low, moderate to high levels. The proportion of 
CD27+IgM+ and CD5+IgD+ memory and active B-cells increased markedly 
compared to the no uptake sites (P<0.001). There were no statistically 
significant differences between the no, low, moderate uptake sites; however, 
when there was very high SUVmax there was up-regulation of the cells 
expressing CD27+, CD5+ and IgM (P<0.001).  
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The flow cytometric cell presence was confirmed and the cellular 
histomorphometric location determined on immunohistochemistry. T-cells 
(CD3+), B-cells (CD19+), macrophages (Mac2+) were found in the outer two-
thirds of the tunica media co-localising in the same regions and in the tunica 
adventitia. There was a smaller infiltration with NK cells (NCAM1) at this site. 
The immune cell content could only be seen in immunohistochemical analysis 






Fig 4.10 The immune cells phenoytped to B-cell subsets from aortic wall with varying 18F-FDG uptake 







































Fig 4.11 The immunohistochemistry of immune cell content in the aneurysm wall 
A) T-cells (CD3+) from site of high SUVmax>3.5. A1) There are T-cells in media and 
adventitia (brown stained cells, black arrows); A2) The negative control sample has 
absent staining B) B-cells (CD19+) at high SUVmax>3.5. B1) There is B-cell infiltration in the 
aortic adventitia and media (brown stained cells, black arrows); (B2) The negative control 
sample has absent staining. C) NK cells (NCAM1) at high SUVmax>3.5. C1) There is little NK 
cell staining in the aneurysm in the tunica media; C2) The negative control sample has 
absent staining. D) Macrophages (Mac-2) at high SUVmax>3.5. D1) Macrophage staining in 
the aortic wall is adjacent to the lymphocyte staining at the same sites increasing from 
the adventitia to the tunica media; D2) The negative control sample has absent staining. 
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Aortic aneurysm progression was associated with a breakdown of the 
extracellular matrix (ECM) and decrease in the elastin lamellar content. There 
were increased breaks seen in the elastin fibers with increased vacuolation of 
the aortic tunica media, suggesting VSMC loss from the aortic wall. There was 
no correlation between the immune cellular infiltrate and the ECM 
degeneration that was more pronounced in aortic wall from larger aneurysms 
harvested at later time-points (Fig 4.12-4.13). As early as day 5 there were 
certain animals that had segments of aortic wall with decreased elastin 
staining, loss of lamellar structure of the tunica media with progresses through 
to the time-point at day 33. There is increased vacuole formation in the tunica 
media that represents loss of VSMCs. There is a loss of collagen in the aortic 
wall at certain sites (Fig 4.12B) however there are regions of the aortic wall in 
advanced aneurysms where there is a corresponding increase in the collagen 
content as assessed with masons trichrome staining (Fig 4.12C). These sites 
might represent active aortic remodelling response to the injury. The 
complications of loss of aortic matrix are seen (Fig 4.13A) where there is an 
aortic dissection. The lower aortic wall has normal aortic lamellar structure 
with intense black staining within the tunica media (black arrows). The upper 
aortic wall has decreased staining throughout. There are multiple areas with 
breaks in the elastic lamellae (red arrows) with a start of vacuole formation 
signifying loss of the homeostatic VSMCs. There are two aortic lumens, a clear 
true lumen that has been washed of from blood contamination and a partially 
thrombosed false lumen, that stains red due to fibrin and organized matrix 
deposition in the clotted lumen. The intimal flap (green arrows) is seen. As 
aneurysms progress there is generally thinning of the aortic wall with a global 
decrease in elastin content, decreased lamellae, lamellar breaks, vacuole 
formation (Fig 4.13B) and that would eventually lead to aortic rupture. This 
matrix degradation was thus present as common final consequence of 
inflammatory cell wall changes across all aneurysms. 
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Fig 4.12 Massons Trichrome stained aortic aneurysm wall 
A) Day 5 suprarenal aortic wall with organized lamellae of thick elastin bands (red) with organized collagen (blue) in between. B) Day 15 suprarenal aortic aneurysm 
with thinning of the aortic wall, increased vascoulation, decreased number and thickness of the elastin in the lamellae and loss of collagen staining. C) Day 33 
suprarenal aorta with haphazard aortic wall architecture and elastin degradation. There is increased collagen present at this stage as compensatory mechanism to 
modulate aortic wall. (20x; Scale bar 50µm)  




Fig 4.13 Verhoff van Geison stained aortic wall 
A) Day 5, there is preserved segments of the aortic wall (black arrows) where the elastic 
lamellar structure is preserved in the tunica media. The opposing wall is thinner with increased 
breaks in the elastic lamellae (red arrows) and decreased elastin staining. There is an aortic 
dissection present with a true lumen (T) and a partially thrombosed false lumen (F). The green 
areas mark the intimal flap (20x) B) Day 33, aortic aneurysm with marked loss of elastin 












The mouse model of aortic aneurysms was highly reproducible with (>70%) 
aneurysm induction and a mortality rate of 20% caused by aortic dissection or 
rupture. The aneurysms generated were similar in structure and composition 
to the human aneurysms. The natural history of aneurysm development was 
analysed with longitudinal serial CT scanning of the aorta. This allowed us to 
determine the mean growth rate, maximal aortic diameter and volume with 
time. This was subsequently compared to metabolic uptake using 18F-FDG. By 
day 10 over 50% of the animals have aortic aneurysms and the maximal aortic 
diameter reached was 5 times normal aortic diameter. The growth rates were 
non linear and varied widely as in humans. The mean growth rate in the 
suprarenal segment was 26µm/day. There was however no correlation 
between aortic aneurysm diameter or growth rate to aortic wall metabolic 
activity (SUVmax). The 18F-FDG uptake was focal at certain sites within the aortic 
wall at any one time point. It varied from site to site over the course of serially 
imaging the animal to different sites within the aneurysm. It was thus 
heterogeneous and varied widely within an animal and from animal to animal. 
Although there was an overall trend to increased individual ROI SUVmax 
readings at later time-points there was no statistical significance between the 
SUVmax readings obtained from day 10 onwards till the termination of the 
experiment where the majority of the animals had large advanced aneurysms. 
The 18F-FDG uptake was higher in the aneurysm wall compared to normal aorta 
at all time points.  
 
The focal aortic wall tracer uptake is a novel finding in the murine model as 
there are few previous studies to have used 18F-FDG in this model to assess 
aneurysm formation136,281,282. We confirmed in our murine studies that there 
are spurts of highly heterogeneous increased 18F-FDG uptake that occur whilst 
the aneurysms grow and expansion. This is in contrast with some human 
studies, which have shown an inverse trend between 18F-FDG uptake and 
human aneurysm expansion281-283.  
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The murine model allows investigation of the aneurysm through the stages of 
initiation, propagation and expansion, as well as the development of 
complications. It allows comparison of aneurysm size to aortic wall biochemical 
activity. It is, however, unlikely that the animal model of aortic aneurysms truly 
replicates the conditions that lead to aneurysm development in humans. The 
ApoE-/-ATII aneurysm develops over the course of 3-6weeks, while in man the 
natural history of the disease is usually over many years to decades 
10,22,279,340,358. Other models use mechanical injury, direct enzymatic wall 
destruction and photochemical injury to generate aortic aneurysms 358,359 and 
have their own limitations. This the murine ApoE-/-ATII model provides the 
most physiologically and pathologically related model to assess human aortic 
wall behaviour. The immune cell infiltrates that are identified in the human 
and murine aortic wall are very similar in relation to metabolic uptake as 
assessed by flow cytometry including subtype analysis of the precise 
lymphocyte populations. The histomorphometric location of the immune cells 
was also identical in the aortic wall in the model and human aortic wall, along 
with the changes seen in the pattern of ECM degeneration. 
 
When we analysed the biological correlate of the 18F-FDG uptake in the aortic 
wall, it was clear that immune cells present at the sites of highest metabolic 
activity had a different cellular signature when compared to sites of moderate 
or low activity. Analysis of these immune infiltrates in the mouse model reveals 
that the proportion of B and T-cells accounting for the total immune cell 
content of aorta is greater in 5-10-fold greater in aneurysmal wall with the 
highest metabolic uptake compared with wall from low uptake regions. Normal 
aorta had very low levels if non existent population of inflammatory cells. This 
is a finding that is recapitulated from our human data.  In the aortic aneurysm 
with no metabolic activity there is a preponderance CD4+ T helper and CD8+ 
cytotoxic populations. These are virtually absent at sites of high metabolic 
activity with a clonal shift to mature activated CD7+CD38+ T-cells and the rarer 
population of CD25+CD127+FoxP3+ T regulatory cells. Mature activated Th17 
lineage of CD4+ cells is typically responsible for proinflammatory cytokine 
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signal and classic inflammatory aortic wall degradation360-367. IL-17A produced 
by activated T-cells is a marker of Th17 lineage and induced Th17 CD4+ 
activated T-cells are responsible for tissue destruction. The large number of 
the activated T-cells seen might be involved in immune mediated vascular 
inflammation and an autoimmune component of aneurysm development364-
366.  αβTCR+CD4+ T-cells are the best investigate source of IL-17A, other cell 
populations such as γδTCR+ cells, NK and NKT-cells also produce IL-17364,365. In 
vitro studies have previously shown that combination of cytokines produced by 
the activated T-cells including IL-1, IL-6 and TGFβ in mice and humans361,366,367. 
At the same time as the activated T-cell populations CD4+ CD7+ CD38+, the 
subset signal is from the T regulatory cells. These have not been previously 
recognised to be present in the aortic aneurysm wall. FoxP3+ T regulatory cells 
are known to be a major modulator of immune regulation and homeostasis by 
immunosuppressive function. The have opposing action to the activated T-cell 
subtypes from which they clonally arise368. IL-17FoxP3+ cells resemble the IL17 
cells but under complex cytokine signaling and simulation have pleiotropic 
functions including positive and negative gene transcription368. T regulatory 
cells have suppressive function that dampens the immune response368. The T 
regulatory populations in-vitro can inhibit the activated T-cell phenotypes thus 
providing a mechanism of self-regulation and self-tolerance369-370. We sought 
to differentiate between the CD127high vs. CD127low as this is a negative Treg 
marker for IL-7 receptor. CD25+ expressed by CD4+FoXP3+Tregs is a marker for 
functional Tregs. The aortic wall resident population would be induced Tregs 
(iTregs). These upregulate in the periphery following antigen exposure and 
stimulation by TGFβ359. These cells can alter gene transcription and perform 
numerous epigenetic modifications to alter overall T and B-cell function372,373.  
 
This immune inhibitory role could be through contact dependent cell surface 
receptor inhibition, competition for finite growth factors with the 
metabolically active CD4+CD25+ populations, hydrolysis of the extracellular 
nucleotides (CD39, CD73) and specific induction of apoptosis or zymogenic 
secretion374,37563. The iTeg populations can in specific niche microenvironments 
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skew the complete expression profile of T effector cells. This transcriptional 
regulation permits homing to a specific inflammatory mediator. The 
transcription factors such as T-bet, Irf3, STAT3 modulate the iTeg suppression 
of Th1, Th2 and Th17 mediated inflammation372-373.  
 
Importantly, there was also evidence of B-cell activation and production of 
IgM. These B-cell(s) are responsible for B-T interaction and chemotactic 
attraction of cytotoxic T-cells and NK cells to the tissues they are resident in 376-
378. This phenotype might also confer a memory B-cell phenotype that might 
be resident in the aortic wall after an antigenic trigger. The immunoglobulin’s 
production and IgM hexamer formation might affect VSMC synthetic activity 
and therefore influence ECM production. Tissue resident B-cell populations can 
be similar to T-cells very heterogeneous and constantly changing phenotype. 
The B-cells expressing CD19+CD27+ constitute memory B-cells. This is a 
population of cells with an extremely long life span, which when stimulated are 
primed for rapid response on repeated exposure to the antigen. These cells are 
normally resident in the lymphoreticular system or the bone marrow. They 
have a high affinity for surface immunoglobulins and this enables their 
activation by lower levels of cognate antigen compared to the naïve B-cells.  
CD24+CD38+IgMhigh cell population could represent an extremely differentiated 
Bregulatory cell population. This would depend on the cytokine signal given by 
the cells as Bregs would produce IL-10 and TGFß as pose inhibitory function in 
immune modulation378,380. There might be an additional population of Breg 
cells that are phenotyped as CD24hiCD27+ that is related to memory B-cells381. 
This population has however never been previously described in the aortic 
wall. The accurate characterisation of the B-cell populations is difficult as there 
are numerous shared cell surface and transcription markers381.  The role in the 
aortic tissue could be pathogenic if the cells are producing antibodies leading 
to targeted tissue damage382. However the autoantibodies that are made may 
have a protective role in the protection of the aortic wall by removing 
apoptotic cells and decrease autoantigens that have been produced locally in 
the microenvironment383. B-cell populations can act as antigen presenting cells 
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leading to activation and amplification of the naïve and activated CD4+ T-
cells372-374.  There is increasing evidence that the B-cells can modulate a B 
effector 1 response with the T-cell interactions and lead to either Th1 
associated proinflmmatory cytokines to be expressed including TNFα, IFNγ and 
IL12. Conversely B effector 2 responses would be responsible for Th2 activation 
with production of IL-4 and IL-13377. However B-cells that illicit IL10 or TFGß 
might lead to immunological inhibition of inflammation. The two Breg subsets 
can produce IL10 that suppresses the production of Th1 cells (IFNγ and TNF-
α)378,379. It has also been shown that the longer the contact time between 
CD4+CD25+ cells and the IL-10 producing B-cells, the T-cell responses are 
altered380. Also IL4 and IL12 production by B-cells has been shown to alter the 
balances between Th1 and Th2 cellular responses381-383.  
 
Breg populations are shown to interact with iTreg populations when treated 
with CD40 to effectively induce CD4+CD25+FoxP3+ cells and suppress the 
cytotoxic CD4+CD25- T-cells389. This might explain the lymphocyte population 
subsets in the metabolically active aortic wall.  Other authors have also shown 
that CD40L stimulation of the lymphocytes induces a CD19+CD24hiCD38hi B-cell 
population that inturn suppresses Th1 differentiation, implicating CD40 in Breg 
activation mechanisms390-391. As well as Th1/Th2 responses the Breg 
population modulates FoxP3 and IL-17 Th populations and thus Tregs392-395. 
Bregs have recently been shown to decrease pulmonary inflammation by 
modulating Treg responses396. Also IL-10 producing B-cell deficient murine 
model has increased activation of the Th1/Th17 pro inflammatory cells and 
decreased levels of Th17 and Treg populations390,397. There is likely complex 
interaction between the B and T-cell sub-populations that constantly modifies 
and modulates responses in the aortic wall microenvironment. There are 
always competing populations of cells that are homeostatically balancing pro 
and anti-inflammatory activities.  
We aim to further study, characterize and elucidate the B-T cell interactions 
that are responsible for the VSCMC modulation, ECM degradation and aortic 
wall function. These influences are important in not only understanding the 
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pathophysiology of aneurysm generation but might provide future targeted 
therapeutic targets. For instance, the pro-inflammatory state is known to be 
responsible for activation of the JNK pathway in the VSMCs with down stream 
phosphorylation to p-JNK114. Inhibition of c-Jun N-terminal kinase has been 
shown to cause regression of AAA in murine models399,400. 
 
Further studies in this thesis will focus on determining the possible role of the 
lymphocytic infiltrate in the areas of high tracer uptake in the aortic wall. The 
final aim being to delineate the downstream signaling pathway responsible for 




















Chapter 5: Magnetic resonance imaging (MRI) of novel 
elastin peptide uptake in mouse model 
 
5.1 Introduction 
Elastin is an abundant ECM component of the aortic wall and its degradation 
through inflammatory processes is thought to be involved in the pathogenesis 
of various cardiovascular diseases including aortic aneurysm and 
atherosclerosis88,401-405. The process of elastogenesis is complex, involving an 
orchestration of a number of proteins, with VSMCs as the key regulators. 
Elastin deposition occurs early during embryogenesis and the process is nearly 
complete by postnatal life204,406-408.  Elastin is a stable protein with a low 
turnover rate. Its concentration remains predominantly unchanged in adult 
life, which makes it an attractive molecule to target in longitudinal imaging 
studies409,410.  
 
Increased expression of elastin is however seen during atherosclerotic plaque 
development399,400 and this has resulted in its use as target for imaging plaques 
by MRI. Plaque burden can be characterised on the basis of the different 
elastic fiber ratios256. 
 
MRI represents an attractive investigative tool, as it is non-invasive (no 
radiation exposure) and allows delineation of soft tissue detail in high 
resolution. It enables detection of subclinical disease and arterial 
remodelling412. Numerous studies have used MRI to determine aortic wall 
dimensions and wall thickness, most using black blood sequences414-414. Long-
term and recurrent imaging has been affected by long scan times even if slice 
gaps are present in the imaging protocol414. ‘Molecular’ or ‘functional’ MRI is a 
technique that allows the detection and quantification of specific targeted 
probes with high resolution in the aortic wall. The recently used novel 
gadolinium based elastin specific magnetic resonance contrast-agent (ESMA) is 
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an example of this268,269,417. This agent is currently only available for use as a 
research tool and we sought to investigate the biological correlates of the of 
ESMA tracer uptake in ApoE-/-ATII murine model of aortic aneurysms. 
 
5.2 Aims 
1) To characterise the temporal uptake of EMSA using the ApoE-/-ATII 
 infusion model to characterize the natural history of aneurysm 
 progression. 
 
2) Determine the association between aneurysm growth rate, aortic  
  diameter and risk of rupture and ESMA in aortic wall. 
 
3) To characterize the cell populations resident in the aortic wall at sites 
  of high and low ESMA uptake by flow cytometry and   


















5.3.1 Murine ApoE-/-ATII infusion model of aortic aneurysms 
This was as described in section 4.3.1 on page 146.  
 
5.3.2 Magnetic resonance imaging of murine aortic aneurysm 
5.3.2.1 In-vivo MRI protocol at 3T 
In vivo MR imaging of aneurysms was carried out using a 3T Philips Achieva MR 
scanner (Philips Healthcare, Best, The Netherlands) equipped with a clinical 
gradient system (30mT m–1, 200mT/m/ms) and a single–loop surface coil 
(diameter = 47 mm). Anesthesia was induced with 5% and maintained with 1 - 
2% isoflurane during the MRI experiments. Mice were imaged in prone 
position at 5, 9, 12, 19, 26 and 33 after angiotensin II infusion. Following a 3D 
GRE scout scan, arterial and venous time of flight angiography (TOF) as follows: 
arterial TOF with TR=40ms, TE=6.2ms, flip angle=60º, FOV=20x33x17mm, 
acquired matrix=68x110, slice thickness=0.6mm, resolution=0.3x0.3mm, 
reconstructed resolution = 0.1x0.1mm, slice number=50, averages=2, 
duration=7.5min and venous TOF with TR=50s, TE=6.2ms, flip angle=60º, 
FOV=20x33x17mm, acquired matrix=68x110, slice thickness=0.3mm, 
resolution=0.3x0.3, reconstructed resolution=0.13x0.13mm, slices=50, 
averages=2, duration=9min. The maximum intensity projection images were 
used to visualize the abdominal aorta, the renal and iliac bifurcations (Fig 5.0). 
These images were used for planning of the subsequent magnetization 
transfer, diffusion weighted, and delayed-enhancement scans. 
A 2D-Look-Locker sequence planned perpendicular to the ascending aorta, was 
used to determine the optimal inversion time (TI) for blood signal nulling. 
Acquisition parameters were: TR=19, TE=8.2ms, FOV=30x30mm, acquired 
matrix=76x75, slice thickness=2mm, resolution=0.39x0.40, reconstructed 
resolution=0.27x0.27mm, TR between subsequent IR pulses=1000ms, and flip 
angle=10°. Subsequently, an inversion-recovery-3D-fast-gradient echo 
sequence (IR) was acquired before and 2h post intravenous injection of the 
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elastin-targeted gadolinium contrast agent (8 μg/kg, tracer) and was used for 
DE-MRI and visualization of contrast uptake. Imaging parameters were: 
TR=28ms, TE=8.2ms, flip angle=30°, FOV=30x30x8mm, acquired 
matrix=304x304, slice thickness=0.5mm, resolution=0.1x0.1mm, reconstructed 
in-plane resolution=0.06x0.06mm, slices=32, averages=2. TR between 
subsequent IR pulses=1000ms. T1 mapping was performed using a sequence 
that employs two non-selective inversion pulses with inversion times ranging 
from 20ms to 2000ms, followed by 8 segmented readouts for 8 individual 
images. The two imaging trains result in a set of 16 images per slice with 
increasing inversion times. For T1 mapping the acquisition parameters were: 
TR=9.0, TE=4.6ms, flip angle=10°. FOV=36x22x10mm, acquired 
matrix=180x102, measured slice thickness=0.5mm, resolution=0.2x0.2, 
reconstructed in-plane resolution=0.1x0.1mm, slices=20, averages=1. A 3-
dimensional T1 mapping sequence was acquired with two-inversion recovery 
prepared modified look-locker sequence. The sequence started with a non-
selective inversion pulse using specific inversion times followed by eight 
segmental read outs for eight images. Inversion time (T1) is the time from 
preparation pulse to acquisition of the k0 profile in k space. Low-high k space 
ordering with 500ms delay between image acquisition was performed to 
minimise the saturation effects and allow accurate quantification of T1 values. 
The imaging planes were acquired at FOV = 18 x 36mm, matrix = 180 x 151, 
measured voxel size 0.2 x 0.2 x 0.5mm, TR/TE = 9.8/5.1ms, flip angle = 8° and 
acquisition window = 157ms. T1 values were computed pixel-wise with a 
three-parameter curve fitting procedure of the longitudinal magnetization 
Mz(TI) including a T1 correction 418. 
Mz(TI) = M0*- (M0+M0*)e-(TI((1/T1)-(1/TR)ln(cos alpha))) 
T1 then can be calculated as described previously in 417,418 
T1 = T1* (((M0+M0*)/(M0*)) – 1) 
M0 is the equilibrium of magnetization; this is sampled during the recovery, as 
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the recovery is affected by constant RF-pulses that leads to apparent 
relaxation time T1* (T1* < T1; RI=1/T1; 1/T1=T/T1+1/T1looklocker) and 
decreased equilibrium magnetization M0*. 
 
5.3.2.2 Gadolinium bound elastin specific magnetic resonance 
agent (ESMA) 
The ESMA agent (Lantheus Medical Imaging, North Billerica, Massachusetts) is 
a low-molecular-weight contrast agent (molecular mass, 855.95 Da)262,419. It is 
a D-phenylalanine linked to gadolinium diethylenetriamine pentaacetic acid 
(Gd-DTPA) chelate. This agent specifically binds to elastin and has a short half-
life comparable to the current gadolinium based MR contrast tracers. The 
contrast uptake in the aortic wall in the setting of the atherosclerotic model 
shown to be specific and low in other areas such as heart, lungs and muscles 
with a rapid removal from the body262. Like all gadolinium-based agents, the 
contrast is metabolised and cleared by the kidneys, whilst the hepatic 
concentrations remain low. The agent is known to have a longitudinal relaxivity 
of 15.1 mM-1s-1 when imaged in rabbit aortic wall at 1.5T thus yielding a high 
target to background signal ratio. The vessel wall ESMA uptake has a 
favourable pharmacokinetic arterial wall profile making it suitable for aortic 
wall imaging262. 
 
In order to make sure that the signal arose from the specific ESMA rather than 
gadolinium scans were initially carried out using intravenously administered 
MAGNEVIST® (Gadopentetate dimeglumine, Bayer, UK). Injection is the N-
methylglucamine salt of the gadolinium complex of diethylenetriamine 
pentaacetic acid (Fig 5.1). MAGNEVIST Injection contained a 0.5-mol/L solution 
of 1-deoxy-1-(methylamino)-D-glucitol dihydrogen [N,N-bis[2-
[bis(carboxymethyl)amino]ethyl] glycinato (5-)] gadolinate(2-)(2:1) with a 
molecular weight of 938, an empirical formula of C28H54GdN5O20, and has 
the following structural formula:  
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5.3.2.3 Image analysis of MRI scans 
MR images were analyzed using Osirix (OsiriX Foundation, Geneva, 
Switzerland). MRI slices spanning through the region of blood obstruction, as 
seen on the TOF arterial- angiography, were used for the analysis. Regions of 
interest (ROI) encompassing the aneurysm were manually segmented on the 
images acquired without MT pre-pulse and then propagated on the images 
acquired with the MT-prepulse, and the diffusion weighting. The mean signal 
intensity (SI) and area (cm2) of each ROI was recorded. Aortic aneurysm maps 
were generated based on formula using an Osirix plug-in for visualization of 
the areas protein-rich within the aneurysm. The same ROIs were used to 
calculate the apparent diffusion coefficient (ADC) based on the equation 
ADC=ln (S0-S1)/b1-b0 (mm2/s). T1 values were computed on a pixel-by-pixel 
basis using an in house Matlab software420-422. 
 
5.3.3 Histological analysis  
Aneurysm cross-sectional area (mm2) was measured on trichrome stained 
sections by computerized planimetry (ImageJ, NIH). Computer-assisted color 
image analysis was used to quantify the collagen area on trichrome stained 
sections and the positive areas for elastin on Verhoeff-Van Gieson and 
immunohistological sections, which were expressed as percentages of the total 
aneurysm cross sectional area. 
For registration of the in vivo MR images and histological sections, the distance 
of the proximal end of each segment, the gross morphology, and internal 
aneurysmal landmarks visible on both the MR images and histology were used 
as references. 
 184 
5.3.4 Isolation and staining of tissue resident inflammatory cells 
for analysis by flow cytometry 
16 animals underwent MRI using the elastin peptide at 6 time points totaling 
18 scans (day 5, 9, 12, 19, 26 and 33). 4 animals also underwent control MRI 
contrast scan using gadolinium based contrast medium. Murine aortic 
specimens underwent same enzymatic degradation and cell harvest protocol 
(Section 4.3.5, page 149).  
 
Flow cytometry Murine aortic tissue from areas of no, low, moderate 
and high elastin peptide uptake was obtained at day 5, 9, 12, 19, 26 and 33 
(n=12, 2 from each time point). Aortic samples were segmented according to 
anatomical location to ascending aorta including aortic arch, descending 
thoracic aorta, suprarenal abdominal aorta and infrarenal abdominal aorta. 
The aneurysmal segment was divided into segments depending on the degree 
of tracer uptake. The complete aneurysmal segment was excised and cut into 
anterior, posterior, lateral and medial aortic wall segments as per regional 
tracer uptake. Tissue underwent enzymatic degradation and cell harvest 
protocol as mentioned immediately post harvest.  Inflammatory cell content of 
tissue resident cells was quantified using flow cytometry using antibodies and 
protocols described in section 4.3.5, page 148 and 4.3.6 page 149).  
 
5.3.5 Tinctorial histology and immunohistochemistry 
This was carried out as described in section 3.3.7, 3.3.8 and 4.3.8 pages 









5.3.6 Statistical analysis 
 
Data were presented as mean±standard deviation (SD), standard error or the 
mean (SEM) and analysed in SPSS v21 (IBM Corporation, Data Collection, USA). 
Parametric data were analysed using Student’s Paired T-test. Correlations were 
carried out using linear regression with Pearson correlation coefficient analysis 



























There was no delineation of the aortic wall on gadolinium (gadopentetate 
dimeglumine; Magnevist®, Bayer, UK) only scan. The aortic wall and lumen 
could be clearly visualised in all animals with ESMA. The aortic diameter, aortic 
volume and aortic wall thickness was determined for each animal at each time 
point (Fig 5.0).  
 
 
Fig 5.0 Comparison of MRA with MAGNAVIST® and ESMA 
The aorta was not visible with MAGNAVIST (A1, red arrow), but is clearly visible with the 
suppression of the blood pool signal with ESMA (A2). The aortic diameter could be measured 
and the aortic dimensions followed longitudinally (days 5-33) with the aneurysm development 
(B). Along with the increase in aortic diameter the aortic wall thickness and therefore elastin 








5.4.1 Assessment of the aortic wall dimensions using ESMA 
Imaging of aneurysms in ApoE-/--ATII infused animals was carried out at days 5, 
9, 12, 19, 26 and 33  (n=24, Fig 5.0). Continuous infusion of ATII at 1000 
ng/kg/min) resulted in the formation of typical aneurysms in ApoE-/- mice. The 
aneurysms were clearly visualised using MRA (Fig 5.0). This is the region known 
to generate aneurysms and is therefore the region that we performed the 
detailed scan, followed by the thoracic aorta in certain animals. In order to 
make sure that the signal arose from the specific ESMA rather than gadolinum 
we initially performed scans using IV MAGNEVIST® (Gadopentetate 
dimeglumine, Bayer, UK). Injection is the N-methylglucamine salt of the 
gadolinium complex of diethylenetriamine pentaacetic acid (Fig 5.1A). 
 
On the magnetic resonance angiogram and TOF images high-resolution 
anatomical detail was visualized to see the renal, visceral vessels and the aortic 
termination. This allowed the correct supra renal segment for detailed MRI. 
(Fig 5.1) The transverse sections showing the aortic lumen on the angiogram 
allowed measurement of the maximal aortic diameter, aortic volume and 






Fig 5.1 MRA of a suprarenal aortic aneurysm in a 5-day post ATII infused ApoE-/-animal 
 
The images were reconstructed using 3D MPR, MIP and volume rendered 
reconstructions created (Fig 5.2). Aortic diameter, volume, aneurysm 





Fig 5.2 2-dimensional cross section imaging of the aorta, multi-planar reconstruction 
(MPR), minimal intensity projections (MIP) and 3-dimensional reconstructions 
Transverse section through single slice aortic MRA sequence to visualise the maximal aortic 
luminal diameter (A). The MPR images (B) allowed sagittal and coronal reconstructions (C) of 
the aortic aneurysm for determination of aortic volume. The aortic wall could be delineated on 
the ESMA scan with suppression of the blood pool signal (D) and the level of aortic wall elastin 
tracer uptake in the aortic wall calculated as the area between the inner diameter and outer 
diameters drawn. The 3D volume rendered reconstructions that allowed the aortic 
morphology to be determined and differentiated between aneurysms (E, F). 
 
5.4.2 In vivo detection of the aortic disruption sites and aortic 
repair processes 
The quantification of the ESMA aortic wall uptake in normal aortic wall 
segments and aortic aneurysms was visualised using image fusion protocols 
that allowed addition of false colour per pixel value of the ESMA activity on 
magnified aortic aneurysm luminal views (Fig 5.3). This allowed visualisation of 
breaks in the aortic wall.  
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Fig 5.3 Determining maximal aortic diameter and vessel wall ESMA content 
(A) Aortic luminal diameter expanding with time from day 5 through to a small aneurysm at 
day 12 and a large aneurysm at day 24 with increase in diameter by up to 5-fold. (B) The 
corresponding ESMA fusion images demonstrate a near uniform low-level uptake of the agent 
in the aortic wall at day 5. By day 12 when the aneurysm was present there was increased 
signal in different regions of the aortic wall, and increased numbers of breaks in ESMA uptake. 
These breaks increased in size and distribution so that by day 24 ESMA very low ESMA uptake 
was present (seen in the 9-11o’clock position).  (Upper Scale bars 1mm, lower scale bar 
250µm) 
 
There was increased aortic wall remodelling as shown by increased EMSA 
uptake in the area proximal to aortic aneurysm development, with adventitial 
tissue remodelling clearly visualised in the proximal aneurysm sequences on 
the magnified transverse sections of the aorta (Fig 5.4). Increased aortic 
luminal expansion was seen the continuous AT II infused groups and a 
corresponding steady and significant increase in adventitial tissue remodelling 
in the regions proximal to the areas of luminal expansion on the ESMA image 
fusion sequences. As the maximal aortic diameter increased the ESMA uptake 
increased at certain sites in large aortic aneurysms. There was focal high ESMA 
activity surrounded by regions of the aortic wall with no ESMA uptake. We 
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compared the MR elastin content in the vessel wall to histologically assessed 
elastin and tropoelastin content in the aortic wall at all time points.  
 
 
Fig 5.4 Determining the maximal aortic diameter, elastin breaks and ESMA up-regulation 
A) T2 blood pool suppression ESMA images for the corresponding TOF angiogram sequences 
(given in Fig 5.3). The vessel wall ESMA content was visualised on the magnified non-colour 
enhanced sequences. B) The same transverse slices as shown in panel A, with enhancement on 
the false colour fusion reconstruction software that allows equal pixel voxel colour coding of 
ESMA uptake. Increasing deposition of elastin in the aortic wall with the increased aortic 
aneurysm diameter at day 12. This active aortic remodelling and increased ESMA signifies 
increased elastin and tropoelastin content in the aortic wall. By day 24 there was loss of ESMA 
aortic wall at certain sites signifying loss of elastin/tropoelastin. (Upper scale bars 1mm, lower 
scale bar 250µm) 
 
  
The focal but heterogeneous nature of aortic aneurysm development was 
apparent on functional imaging. When the complete aortic aneurysm was 
analysed on slice-by-slice basis there was large aortic wall variation in the 
ESMA uptake seen from segment to segment as demonstrated in Fig 5.5. As 
the aortic aneurysm progresses the aortic wall ESMA uptake increases at 
certain sites. This is likely to represent active positive remodelling. The areas 
that have decreased ESMA uptake are likely to represent sites of active 
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inflammatory aortic wall degradation and decreased ECM content. This pattern 
on ESMA uptake fits the natural history of aortic aneurysm development with 
episodes of positive aortic remodelling (characterised with high ESMA uptake) 
followed by periods of quiescence and sites of no ESMA uptake signifying 
increased water content in the aortic wall (inflammatory immune cell infiltrate) 
and decreased elastin. 
 
Fig 5.5 MRA demonstrating the heterogeneous nature of aortic wall ESMA content 
A) TOF angiogram fly through of the aortic aneurysm. The red lines represent imaging plane of 
two different transverse planes atleast 50m apart. B) The first transverse slice taken 
demonstrates high specific aortic wall ESMA uptake on the blood pool suppressed sequences. 
86% of the aortic wall surface area is seen on the transverse section. C) The image fusions 
sequence with the angiogram now allows determination of the aortic diameter and the aortic 
wall thickness and elastin content. D) The transverse slice taken shows a similarly dilated aortic 
wall but at this level there is decreased aortic wall ESMA content at this level in the aortic 
aneurysm. E) The corresponding fusion ESMA sequences with the angiographic views show 
little or no ESMA in the aortic wall of the aortic aneurysm. 23% of the aortic wall contains 




5.4.3 Aortic aneurysm diameter, ESMA content and T1 mapping 
The increase in aortic diameter is noted with time across the ApoE-/-ATII 
aneurysm on the MRA. After administration of ESMA, a gradual increase in R1 
values was measured in the aortic wall starting from week one to four of ATII 
infusion (Fig 5.6-5.8). The temporal association in T1 and R1 values were in 
agreement with the quantification of elastin and tropoelastin in the aortic wall 
sections (Fig 5.6-5.8).  
 
 
Fig 5.6 Aortic aneurysm assessment using ESMA MRA 
A) The aortic diameter is not increased at day 5 imaging with a baseline level of 162±33m in 
the supra renal aortic segment. The red line represents a typical single transverse slice taken at 
that specific level for the purposes of illustration B) Transverse aortic wall segment taken on 
pre-contrast imaging before the Gd-ESMA tracer is given. The aortic wall is not visualised. C) 
60mins post IV injection of the Gd-ESMA tracer, the aortic wall is clearly seen with near 
uniform uptake of the ESMA specifically in the aorta. There is no luminal blood pool signal that 
is suppressed and minimal signal to noise artifacts. D) The ESMA fusion sequence where the 
blood pool suppression T2 image is overlaid onto the TOF angiogram to allow determination of 
the aortic wall luminal diameter and the ESMA uptake in the aortic wall. E) The corresponding 
T1 map of the transverse aortic slice that allows numeric quantification of the ESMA uptake in 
the aorta. 
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Using ESMA along with increased maximal aortic diameter we can image the 
aortic wall ECM (elastin and tropoelastin) composition, content and the 
presence of acute immune cell infiltrate in the aortic wall (sites where there is 
no ESMA signal). The calculation of the T1 values allows numeric quantification 
of the relaxivity and this can be correlated to the aortic wall ECM. Certain 
aneurysms loose the aortic wall ESMA signal at an earlier rate with multiple 
breaks in the aortic wall and this correlates to histological changes in the 
matrix content (elastin and tropoelastin) in the aortic wall. (Fig 5.7-5.8) 
 
Fig 5.7 In vivo assessments of aortic disruption sites with aortic dilatation in a day 24 aortic 
aneurysm 
A) Three dimensional MR angiogram volume rendered reconstruction of the murine aorta from 
the taken at day 24. The red line represents an example of transverse slice taken for analysis 
through the middle of the aneurysm. B) This demonstrated the aortic wall delineated using 
ESMA and near uniform high level of ESMA in the aorta. There is a small site at 6 o’clock 
position where there is a break in the ESMA uptake C) Axial fusion image of the contrast 
angiogram demonstrating the presence of ESMA in the same position suggesting an aortic 
break with likely decreased elastin/ tropoelastin content at a single site on that slice. D) 
Measurement of T1 relaxation times of the aortic wall to determine the quantification of the 
ESMA uptake.  
 
 195 
In some cases (n=6) aortic disruptions of ESMA uptake were seen prior to 
dilation of the aorta.  
 
 
Fig 5.8 In vivo assessments of aortic disruption sites with aortic dilatation in a day 33 aortic 
aneurysm 
A) Three dimensional magnetic resonance angiogram volume rendered reconstruction of the 
murine aorta from the control group taken at day 33. The red line represents an example of 
transverse slice taken for analysis through the middle of the aneurysm. B) Transverse section 
taken through the aortic wall using ESMA showed a decrease in the aortic wall tracer content 
from 6 o’clock to 9 o’clock position with a further break at the 12 o’clock site. C) Axial fusion 
image of the contrast angiogram demonstrating the presence of ESMA in the same position 
suggesting multiple areas of aortic breaks with likely decreased elastin/ tropoelastin content at 
a the 6 o’clock to 9 o’clock position. D) Measurement of T1 relaxation times of the aortic wall 
to determine the quantification of the ESMA uptake.  
 
Aortic aneurysm propagation and maturation therefore depend on a 
continuous homeostatic balance between ECM degradation and formation, 
with tropoelastin synthesis and elastin fibre organisation being the key 
regulatory steps in maintaining aortic wall stability. Histologically there is 
increased elastin expression in the periadventitial regions of the aortic wall in 
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correlation with ESMA uptake whereas at sites where there is no ESMA 








Fig 5.9 Histomorphometric assessment of the aortic wall on Gd-ESMA MRA and its 
correlation to elastin and collagen content  
A) The Gd-ESMA uptake in the aortic wall at day 5 (A1). Collagen content (Masson’s Trichrome) 
(A2). There was high vessel wall collagen content in sections taken from the aortic wall at day 5. 
The vessel wall elastin content was analysed from sites of high ESMA uptake and high EvG 
staining (A3) was seen with organised elastic lamellar structure. B) On analysis of the aortic wall 
at sites of moderate ESMA staining at day 12 (B1) there was reduced collagen staining (B2) and 
decreased EvG staining with loss of the lamellar structure (B3) C) Aortic wall analysis from larger 
aneurysms with no ESMA uptake in the aortic wall at day 24 showed increased collagen uptake 
(C2) and little elastin content on EvG staining. There was loss of elastic lamellar structure, 
increased breaks in the elastin lining and fragmentation of the aortic wall with vacuolation and 















5.4.4 Comparison of in vivo and ex vivo aortic aneurysm wall ESMA, 
elastin and tropoelastin content 
 
The histomorphometric assessment of the aortic wall showed that after day 12 
there was progressive maturation of aneurysm with increased elastic fibres in 
and ex vivo. The active aortic remodelling response to aneurysm generation 
adjacent to the lumen is likely to represent compensatory mechanism to enable 
stabilisation of the aortic wall. This process could be visualized and quantified 
both in vivo on ESMA-MRI and ex vivo on corresponding histological sections. At 
late stages of aortic aneurysm development there is either a very strong signal 
at extremely specific sites or a complete loss of the signal. It is likely that this 
will be the site of the aorta that will be the site of rupture or dissection.  
 
There was a significant positive correlation between EMSA uptake and elastin 
content of the vessel wall as measured by histology. On aortic wall imaging prior 
to administration of ESMA (pre-contrast) and after administration of ESMA 
(post-contrast) the R1 values from T1 maps in the aortic wall in all mice was 
observed (Fig. 5.10). After administration of ESMA, a gradual increase in R1 was 
measured in the aortic wall. The trends R1 were in agreement with 
quantification of elastin on histological sections (Fig. 5.10). To exclude contrast 
effects resulting from Gd-DTPA in the second imaging session, additional pre-
contrast scans were performed in 2 mice on day 5 and 9. No significant 
difference (P>0.05) in vessel wall enhancement was measured between pre-




Fig 5.10 The relationship between EMSA uptake and elastin content in the aneurysmal wall 
on EvG staining 
Respective average R1 values derived from T1 maps after ESMA administration and correlation 
with EvG-stained histological sections.  
 
The percentage area ex vivo when assessed using tropoelastin specific antibody 
staining for aortic wall tropoelastin content that increased with the aneurysms 
increasing diameter on in vivo imaging (P<0.05). There was a strong positive 
correlation of the R1 values (ESMA uptake) and the corresponding vessel wall 
tropoelastin content. R2=0.78, P<0.05 correlation coefficient (Fig 5.11).  
 
 





















Fig 5.11 The relationship between EMSA uptake and tropoelastin content in the aneurysmal 
wall on IHC staining 
Respective average R1 values derived from T1 maps after ESMA administration and correlation 
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5.4.5 Immunohistochemical assessment of the aortic wall 
immune cell content in aortic aneurysms with varying ESMA 
uptake 
Immune cell content was assessed from sites of aortic aneurysm wall that had 
ESMA uptake vs. sites of no ESMA uptake. When stained for CD3+ T-cells, CD19+ 
B-cells, NCAM1+ NK cells and Mac-2+ macrophages there was increased uptake 
suggesting immune cell infiltration in the aortic wall at the tunica media and 
tunica adventitial boarder in the periadventitial vascular zone. Similarly there 
was expression of immune cells in the tunica media at sites of no ESMA uptake. 
The immune cell infiltration seems to arise from the vasa vasora from the 
outside of the vessel wall and move in. The cells were morphologically typical of 





Fig 5.12 Aortic wall immunohistochemical analysis from sites of no ESMA uptake 
A) On staining for CD3+ T lymphocytes (A1) there is cell infiltration in the aortic adventitia (DAB+ 
brown cells, black arrows). Negative control (A2) B) On CD19+ B-cell staining there are B 
lymphocytes in the aortic adventitia (brown cells, black arrows) infiltrating into the tunica 
media. (B2) Negative controls. C) NK cells, NCAM1 (brown cells, black arrows) (C1) staining in 
the aortic wall adventitia. Negative control staining (C2). D) Macrophage (Mac2) staining in the 
aortic wall (DAB+ brown cells, black arrows). Negative staining (D2). (Scale bars 50µm). 
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When IHC analysis was similarly carried out at various sites in the aortic wall 
when there was a clear signal from the ESMA in the complete section of the 
aorta, there were occasional immune cells. Almost all immune cell markers 
tested for were negative apart from the presence of B-cells (Fig 5.13). 
 
Fig 5.13 Aortic wall immunohistochemical analysis from sites of ESMA uptake 
A) On staining for CD3+ T lymphocytes (A1) there are no cells seen (A2) Negative control B) On 
CD19+ B-cell staining there are occasional B-cells in the aortic adventitia (brown cells, black 
arrow) infiltrating into the tunica media. (B2) Negative control. C) NK cells, NCAM1  (C1) no 
staining in the aortic wall media or adventitia. (C2) Negative control staining. D) Macrophage 





On semi-quantitative analysis there is an increase in the T, B, NK and Macrophage number in 




Fig 5.14 IHC quantification of immune cells 
The immune cell quantification on immunohistochemistry dependent on EMSA uptake in aortic 
aneurysms. There is an immune cell infiltration in aneurysm wall when there is no ESMA uptake 
(P<0.001, paired T-test for all cell types comparing no ESMA to ESMA uptake) 
 
5.4.6 Flow cytometric assessment of the aortic wall and 
aneurysm immune cell content at sites of high vs. no ESMA uptake 
The immune cell content was quantified in all samples from high and no ESMA 
uptake (Fig 5.15). Aortic tissue from sites of varying elastin uptake was 
quantified according to T1 relaxation times. Cellular content was quantified per 
microgram of tissue. At regional aortic wall sites in the absence of the ESMA 
uptake there was an increased number of B-cells (63.8±13.0, P<0.001, 
95%CI0.54-0.66) and T-cells (82±9.8, P<0.001, 95%CI0.24-0.64) versus sites of 
ESMA binding where there was a low expression for B-cell (19.4±14.1, P<0.001, 
95%CI0.54-0.78) and T-cell (57.8±8.9, P<0.001, 95%CI0.64-0.73). The number of 
NK cells, was not significantly altered across the two sites. There was an inverse 
































significantly higher in the ESMA uptake group compared to the no ESMA uptake 
group (93.8±4.8 vs. 81.7±4.0, P<0.01, 95%CI0.2-1.2) (Fig 5.15, 5.17, 5.18). 
 
When normal aortic wall was compared to ectatic or aneurysm wall, there was 
minimal immune cell activity in the aortic wall with 10.3-14.4% of the total cell 
fraction being CD45+. This was in marked contrast to aneurysmal aorta which 
typically had >50% CD45+ cell fraction and these predominantly were of T and B-
























Fig 5.15 Representative flow cytometric assessment of the normal, ectatic aorta and aneurysmal aortic wall for immune cell content 
A) Aortic wall was segmented into either normal aorta typically the thoracic aortic segment or infra-renal aortic segment and analysed here at day 24 where 
there was a markedly low expression of B, T lymphocytes and NK cells. The proportion of macrophages and neutrophils was exceptionally low B) Ectatic 
suprarenal aorta was defined as an increase in diameter to 1.5x normal diameter and this occurred at typically day 5-12. This suprarenal aortic wall followed 
an intermediate phenotype with increasing degrees of lymphocyte and NK cell infiltration in the aortic wall. C) Supra renal aortic segment taken at day 24 
post ATII infusion when the aorta is over twice the normal starting diameter, typically over 5x normal aortic diameter. As the severity of the aortic aneurysm 






















Fig 5.16 Representative flow cytometric assessment of the aortic wall immune cell content in aneurysms with and without ESMA uptake 
Aortic aneurysm was segmented into A) without ESMA uptake B) with ESMA uptake. There was marked difference in the immune cell content of the 
aortic wall. Increased immune cell content was present typified by B (CD19+) and T (CD3+) lymphocytes, NK cells (NK 1.1) and macrophages (Mac-2) at 




Fig 5.17 Flow cytometric aortic wall analysis from suprarenal aortic aneurysms with and 
without ESMA uptake 
The SRA sites without ESMA uptake had higher total leukocyte content compared to SRA with 
ESMA uptake (P<0.001). There was no difference in the normal aortic leukocyte content 
(CD45+) expression with overall low level of immune cells present in the aortic wall. (N=16, 48 




Fig 5.18 Flow cytometric analysis of suprarenal aortic aneurysm with immunophenotyping 
When the CD45+ fraction is analysed according to SRA ESMA uptake, sites of low ESMA uptake 
had higher T-cells (CD3+), B-cells (CD19+), (P<0.001) and macrophages (F4/80+) had an inverse 
pattern (P<0.01). There was no difference in the NK cell-staining pattern  (N=16, 48 aortic 


























Our MRI studies have shown specific uptake of a gadolinium bound elastin 
tracer in aortic wall in the murine model of aortic aneurysm. This elastin tracer 
uptake was focal but heterogeneous in the aortic wall and occurred at sites 
with the highest concentration of elastin and tropoelastin. There were 
increasing breaks in the ESMA uptake in the aortic wall associated with an 
increase in diameter of the aorta and at sites preceding the aneurysm 
expansion. Flow cytometric analysis of the aortic wall confirmed a high 
immune cell infiltrate in the regions that had no ESMA. This was typified by 
CD45+ leucocytes that are predominantly B-cells (CD19+), T lymphocytes (CD3+) 
and NK cells (NK1.1+). Macrophages (F4/80+) were conversely more likely to be 
present at sites of higher ESMA activity. This immune cell expression pattern 
was confirmed on immunohistochemial staining for the specific cell marks with 
the immune cell infiltrate localised to the tunica adventitia and tunica media.  
Specifically histological assessment of the extracellular components including 
elastin, tropoelastin and collagen demonstrated a highly significant correlation 
between elastin and tropoelastin content and the aortic wall ESMA uptake 
(calculated with the expression of the R1 value). At specific aortic wall 
segmentation from regional areas with and without ESMA uptake 
demonstrated a decrease in the aortic wall elastin and tropoelastin content at 
sites of no ESMA uptake. There was however increased tropoelastin turnover 
seen at other sites as aneurysms progressed.  
 
It is likely that the functional imaging with ESMA is delineating two processes 
ongoing in the aortic wall. At sites of no ESMA uptake the aortic wall is 
undergoing inflammatory cell infiltration and decrease in the ECM in the vessel 
wall. This is followed by expansion and reparative phases where there is an 
attempt to stabilise the aortic wall. This is demonstrated by the ESMA signal in 
aneurysm wall. It is clear that the aetiology of the signal is the ESMA binding to 
elastin fibres and tropoelastin in the aortic wall.  
 
 211 
The MR techniques can monitor aneurysms through morphological 
measurements, assessment of the thrombus (its organisation and structure) 
and leukocyte uptake with specific contrast agents (SPIO/USPIO).  MR has been 
validated to show adequate morphological detail when compared with CTA 
403,413,422,423. Along with this anatomical detail, MR allows evaluation of tissue 
composition. In the absence of macroscopic accumulation of fat in the 
thrombi, it is suggested that fibrinolysis or haemorrhage occur in the aortic 
wall and this correlates with high levels CD66b (neutrophils), CD68 
(macrophages), MMP-2, MMP-9 and pro-MMP-9 activity that are known 
markers of proteolysis in the aortic wall281-283,437. MRI T2 images in the same 
study showed multilayered thrombus suggesting that it had formed in stages in 
line with aneurysm growth cycles. This was particularly clear on T2 relaxation 
imaging, while SPIO uptake resulted in significant signal reduction in the 
subluminal layer and deeper thrombus tissue252,328,341,343. This suggests that 
functional imaging with MR is picking up leukocytes (likely macrophages) 
trapped in thrombus and therefore represents an unstable aortic wall that is 
expanding and is prone to rupture418,437. From the clinical point of view the 
utility of MR lies in assessment of aneurysms morphological properties and 
correlating these to the biological data obtained from ILT. The use of contrast 
agent further enhances this by deeper assessment of ILT aortic wall 
interaction. The use of paramagnetic iron particles does, however, have 
limitations. These include clearance of these particles by the liver that might 
reduce their sensitivity and lead to a relatively poor uptake in vasculature. It is 
not possible to quantify these particles in the inflammatory cells, as the 
leukocyte turnover at the luminal surface of ILT is unknown. The variable time 
interval between imaging and treatment results in uncertainty in location of 
the SPIO engulfing macrophages. Also, because of the small number of 
patients in these studies it is unclear as to the precise nature of the 
relationship between MR signal and intensity of cellular infiltration and a cut 
off value of noise to signal in ILT. The analysis of SPIO uptake will be further 
complicated as the ILT is heterogeneous with varying ages of thrombus present 
that takes up SPIO in differential layers. The subluminal thrombus may have 
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low signal intensity and with the increase in circulating blood pool signal with 
SPIO injection means that signal measurement might be biased.  
 
The clinical utility of the MR data is from providing the biological correlates to 
the anatomical data and the likely proteolysis changes occurring in the aortic 
wall as aneurysms develop. MR has the advantage of exposing the patient to 
no ionising radiation. Serial imaging with MR using these contrast agents is 
needed to characterise the natural history of aneurysm growth. Therefore MR 
could provide clinically critical information on risk of rupture. Currently it is 
predicted that SPIO uptake signifies high-risk aneurysms that have abundant 
inflammatory cells, proteolysis and this implies an unstable aortic wall.  
 
T2 weighted imaging along with Gold-DTPA enhancement on T1 imaging to 
visualise the fibrous cap and ILT correlate with cellular changes in the 
aneurysm wall322,426-427. The authors concluded that MR could identify plaques 
that are vulnerable to rupture. There is a need for validation of these findings 
in larger studies as MR may be critical in assessing risk of rupture and therefore 
influence clinical decision-making. 
 
Imaging that can better predict the progression of aneurysms and 
development of complications would be of great clinical benefit. Additionally if 
we understand the chronic inflammatory processes that underlie the 
pathophysiology of aneurysm development we could target specific drugs to 
augment aneurysm growth. The development of novel radiotracers and MR 
agents allows functional imaging of aortic aneurysms to yield potential 
physiological, biochemical and cellular correlates to events occurring in the 
aortic wall as aneurysms progresses. The main immune signal is from the B and 
T lymphocytes. From characterisation of the lymphocyte subtypes we have 
defined two different overall populations. The synthetically active lymphocytes 
express CD5+, CD24+, CD25+, IgD and IgM phenotypes.  It is possible that as yet 
unknown antigenic trigger activates the B-cells to be attracted to aortic wall 
and produce immunoglobulins. Through MHC class II peptide antigen 
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presentation CD4+ T-helper cells would be recruited to the region. These would 
in turn activate CD8+ cytotoxic T-cells that are responsible for cytokine release 
and further interaction with B-cells to produce plasma cells427,522. There is 
subsequent recruitment of macrophages in the aortic wall as a result of 
lymphocyte activation and B-T interaction. The role of T and B regulatory cells 
in the pathogenesis of aneurysm is as yet not elucidated. The interaction 
between B and T lymphocytes and their influence VSMC’s is yet not fully 
understood. This is a second population of immune cells that are present in the 
aortic wall and are likely involved in remodelling responses to the aortic wall. 
This B and T memory cells and regulatory cells are likely responsible for 
dampening the inflammatory response followed up by upregulation of 
tropoelastin content in the aortic wall. 
 
It is known that pro-inflammatory cytokines, mechanical stress and oxidative 
state activates the c-Jun N terminal kinase (JNK) pathway that increases 
activation of activating protein (AP-1), increases expression of matrix 
metalloproteinase’s (MMPs), and decreases expression of matrix synthesis 
enzymes (lysyl oxidase (LOX) and prolyl 4-hydroxylase (P4H) leading to 
decreased deposition and increased degradation of elastin108,268,269,417. These 
form putative in-vitro targets that be studied to delineate the nature of the 
interaction between lymphocytes and VSMCs. 
 
Another possible way to investigate any direct connection between immune 
cells and aneurysm development/growth is to selectively knock B and T-cell 
function using pharmacotherapy (e.g. cyclosporine to inhibit T-cell function or 
selective monoclonal antibodies i.e. Rituximab against B-cells (anti CD20 
chimeric antibody) and Muromonab against T-cells (anti CD3 monoclonal 
antibody). This selective knock out would allow investigation on the putative 
roles of these immune cells in aortic wall tissue to investigate how this 
augments aneurysm expansion and behaviour on MR imaging.   
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There are numerous other novel agents that have been used in animal studies 
and may provide attractive biological markers of aortic wall instability. These 
include MMP’s and their inhibitors (TIMP’s), tropoelastin, oxidised LDL 
receptors, and other markers of platelet activity, apoptosis, inflammation and 
angiogenesis. Along with USPIO/SPIO other nanoparticles have been used to 
determine macrophage content. These include integrins (alpha nu beta 3 
(amb3)), matrix metalloproteinase (MMPs), micelles labeled with macrophage 
receptors or products (neutrophil gelatinase associated lipocalin (NGAL), 
peripheral cannabinoid receptors (CBR-2)251,468,522. Although many 
retrospective and small prospective studies demonstrate a link between 
functional imaging and clinical outcomes, there needs to be large prospective 
studies to evaluate this whilst also looking at the effects of anti-inflammatory 
therapies on aortic wall. The effectiveness of lifestyle modification on 
cholesterol and statins to reduce arterial wall inflammation has been studied 
with metabolic alterations in the aorta and carotid wall74,75,262. Similar studies 
have been conducted with MR to study aortic disease progression. Presently 
animal studies are en route to develop functional imaging to aid delivery of 
drugs. For instance targeted therapy geared towards angiogenesis inhibition or 
anti-inflammatory treatments targeted to vascular wall253,255,421,422.  
 
ESMA therefore allows non-invasive determination of aortic disruption site 
with ECM loss that precedes aortic wall dilatation. This is followed by in vivo 
assessment of aortic wall remodelling with subsequent increase in ESMA 
content at certain sites in aortic wall as it expands. The changes in the aortic 
wall elastin and tropoelastin content can be followed in a longitudinal manner 
and quantified with aneurysm growth. The MRI signal intensity following ESMA 
correlates with arterial wall elastin density (EvG staining) and tropoelastin level 
(specific antibody). The in vivo R1 values were in good agreement with the 
histomorphometric wall assessment of elastin and tropoelastin. ESMA also 
demonstrates regions of aortic wall immune cell content and sites where 
active inflammation is occurring (sites of no ESMA activity). This level of aortic 
wall biological assessment is currently not available in humans but would be 
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integral to provide additional predictive parameters as to which aneurysms will 
expand at which sites and are likely to progress to rupture.  
 
Recent data suggests numerous novel microRNA networks that are involved in 
tropoelastin synthesis and elastin formation428-431. It might be that modulating 
the microRNA networks involved could up-regulate ECM content in the aortic 
wall and change aortic phenotype. The ESMA MRI would form an ideal imaging 
modality to assess the response of the aortic aneurysm wall to this novel 
therapeutic modulation and study the aortic wall immune cell changes.  This 
aortic modeling response that stabilises the aortic wall endogenously in 
response to dilatation is critical in aortic wall stabilisation and this reinforces 
the importance of ESMA imaging.   
 
MRI allows marked higher resolution compared to other investigative 
modalities and therefore the aortic wall can be investigated. Although there is 
high relaxivity of the contrast agents, to provide soft tissue detail, the 
metabolic information remains limited compared to PET and SPECT imaging. 
One way to circumvent this is to combine the two modalities to a hybrid MRI-
PET system. MRI yields superb soft-tissue contrast, functional information, and 
potential biological data with use of bespoke tracers, allowing assessment of 
perfusion, diffusion, or metabolism. PET will enable visualization of molecular 
tracers with picomolar sensitivity, providing information about cell metabolism 
and targeted receptor status432,433. 
 
In the clinical setting the only predictor of aneurysm behaviour to decide 
management are symptoms and maximal aortic diameter. ESMA could 
potentially allow determination of the initial aortic disruption sites prior to 
dilatation in early aneurysms. It would allow assessment of aortic wall ECM 
content and the aortic remodelling processes that are on going to repair the 
aortic wall that is undergoing inflammatory cell degradation at certain focal 
aortic sites. ESMA MRI would therefore provide accurate risk assessment of 
 216 
the patients risk of developing an expanding aneurysm and if it is likely to 
dissect or rupture.  
 
Compared to the other MR imaging studies in aortic aneurysm models ESMA 
has the advantage of being able to image using a clinical 3T scanning system. 
This is the relaxation, rotational correlation and signal properties of ESMA are 
unchanged to traditionally used Gd-based agents. The small molecular weight 
of the ESMA makes adverse affects less likely when compared to more 
immunologically active nanoparticle imaging or using antibodies. The agent is 
rapidly cleared renally and there is minimal blood and background 
contamination. The next steps would be the clinical translation of this 
functional imaging modality to determine its utility in man. It would also be 
valuable to look at aortic phenotype therapeutic change in response to altering 














Chapter 6: Investigating the effect of altering microRNA 




Aneurysm development is characterised by infiltration of the arterial wall by 
inflammatory cells, typified by B and T lymphocytes, NK cells, macrophages 
and mast-cells90,146,152. These cells produce pro-inflammatory cytokines such as 
IL-1ß, 6, 12, TNFα and IFNγ44,91, leading to extracellular matrix (ECM) 
degradation through the up-regulation of matrix metalloproteases (MMP-2, -3, 
-12, -13)84,238,476, cathepsins C, S, K254,255 and down regulation of the tissue 
inhibitors of matrix metalloproteinase (TIMPS)43,434. The key regulator through 
which the immune cells have the effector actions are the VSMCs that perform 
the homeostatic role of ECM maintenance in the aortic wall.  Of the ECM 
components, elastin is a major component and elastolytic degradation with 
production of elastin peptides (EP) is a strong predictor of aneurysm expansion 
and rupture435,436. There are complex interactions at the transcriptional and 
translational levels that lead to elastogenesis. 
 
The production of elastin is finely regulated at a variety of levels, including the 
catalyses of pre-mRNA by RNA polymerase II to create mRNA followed by 
translation of the mRNA, which can be modulated by post-transcriptional 
regulators called microRNAs (miR). ELN is expressed before birth with the vast 
majority of elastin synthesis and deposition occurring before birth and within 
the first few years of life171-173. From a young age there is a reduction in the 
elastin synthesis with extremely low-level expression by middle age.  
Thereafter, there is a slow turnover of elastin in tissues, with small amounts 
being deposited in response to degradation in various tissues. Elastin is 
therefore a highly durable and stable structural protein with a biological half-
life of approximately 74-years in man173. In pathological states such as 
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degenerative aortic aneurysm elastin degradation is the final consequence of 
pro-inflammatory state. Elastin loss triggers an aortic remodelling response 
where there is attempted repair of the aortic wall with increased synthesis of 
tropoelastin and organisation in elastin fibers401,408. There is data to suggest 
that collagen synthesis is preferential to elastin providing adaptive stability, 
but both are upregulated402,438,439. Elastin provides the elastic recoil in the 
artery and progressive stiffening due to increased collagen in a larger diameter 
aorta leads to the increased risk of eventual dissection or rupture407,411,439.   
 
6.1.1 MiRs 
MiR’s are small (~20-25 nucleotides long), non-coding RNAs that post-
transcriptionally regulate gene expression by acting on mRNA441-445. They are 
important in cellular activities444,445, in diseases such as atherosclerosis445 and 
cancer446. MiRs are highly evolutionarily conserved nucleotides suggesting an 
important role in biological processes. They are generated in the nucleus by 
transcription of nascent pri-miRNA transcripts that are initially processed to 
~70 nucleotide pre-miRNAs by Drosha in the nucleus. Then processed by 
RNase-III to form precursor miRs440,447. These are transported into the 
cytoplasm by Exportin 5, where the miRs are processed by ribonuclease dicer 
into small 20-23 oligonucleotide duplexes, which are then incorporated into 
RNA-induced silencing complexes (RISC) to silence gene expression at the post 
translational level by targeting mRNAs. This is done by degrading mRNA 
leading to protein repression448,449. Dicer also processes long double stranded 
DNA to small interfering RNA (siRNA) duplexes. The miRs act in extensive 




Fig 6.0 The current paradigm of miRNA synthesis and post-translational suppression451 
 
Extracellular miRs can be found in the peripheral circulation in patients with 
cardiovascular disease452,453. MiRs are stable in serum as they exit bound to 
proteins, lipids, lipoprotein complexes i.e. exosomes or microvescicles. MiRs 
are not single oligonucleotide but sequences of numerous oligonucleotides 





6.1.2 MiR expression patterns in aortic aneurysm 
The miR expression profile in human aortic aneurysms is different from normal 
aortic wall tissue. There are differences in the expression profiles of 
endothelial (miR-20a, -21, -27, -92a, 126, -221 and -222), inflammatory (miR-
124a, -146a, -155, and -223) and fibrosis related miRs (miR29b)444. Vessel wall 
related and inflammatory cell derived miRs are upregulated in aortic aneurysm 
tissue. The miR signatures are correlated to increase in inflammatory cytokines 
expression and activity, including TNF, TGF and MCP1457-458. The circulating 
plasma concentrations of these miRs are reduced in aneurysm patients 
compared with tissues resident levels for the miRs457,459-461.  
 
MiRs such as miR-21 seem to control VSMC proliferation and apoptosis. These 
are important processes in the development and growth of aneurysms. The 
regulation of apoptosis might be through phosphatase production, tensin 
homology, regulation of a tumour suppressor gene PTEN and control of 
programmed cell death protein 4 (PDCD4)462. The phosphoinositide-3 kinases 
and Akt pathways are also important in these processes. PDCD4 expression is 
decreased by miR-21 and this might induce VSMC apoptosis through activation 
of its target molecules (activator protein 1)462.  MiR-21 has been shown to be 
an important regulator of VSMC apoptosis in a murine model of aortic 
aneurysm456,462-465.  
 
There is increasing evidence that certain miR networks might be important in 
augmenting vascular inflammation. For instance, miR-126 inhibits expression 
of vascular cell adhesion molecule-1 (VCAM-1) that mediates leukocyte 
adherence to endothelial cells466. A decrease in miR-126 would increase 
VCAM-1 expression and leukocyte adhesion and thereby promote leukocyte 
infiltration into the wall. Other miRs such as miR-223 regulate haematopoietic 
progenitor cells proliferation, granulocyte differentiation and activation467,468. 
IKKα is targeted by miR-223, during monocyte–macrophage differentiation, 
and decreased expression of this miRNA along with miR15/16 may prevent 
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macrophage hyperactivation and recruitment to tissues468-470.  MiR-146 is 
present in macrophages and can be induced in the cells by bacteria and 
proinflammatory cytokines in a nuclear factor  dependent manner471,472. It is 
therefore a NF transactivation target that negatively regulates IRAK1 and 
TRAF6, providing a negative feedback loop to control IL8 and RANTES thus 
regulating T-cell expression and secretion. Thus modulating innate immune 
responses through a variety of T-cell mediated effects471,472. MiRs involving 
miR-126, -223, -15, -16 and -146 may therefore be part of larger 
interconnected network responsible for inflammatory cell activity in the aortic 
wall. These along with other miRs might indirectly predict aortic wall 
inflammation.   
 
miR-29 family promotes cardiac fibrosis462 and other validated targets include 
elastin (ELN), collagen and fibrillin-1 (FBL-1)7,430,452,473-476. MMPs 2 and 9, 
associated with aortic aneurysms and may also be targets for miR29b475. Tissue 
levels of miR29b levels are elevated in patients with aortic aneurysms429, whilst 
inhibition of miR29b down-regulates murine aneurysm development429-431,465. 
MiR29b is important in early aneurysm development in ascending aorta of 
Marfan mice430. 
 
MiR-195 is part of another miR network thought to be involved in cardiac 
fibrosis and alters VSMC phenotype and function477. MiR-195 inhibits cell cycle 
progression and proliferation of cancer cells451,478-479. It forms part of the 
miR15 family of highly conserved miRs (namely miR15, miR15b, miR16, miR16-
2, miR195 and miR497). Of these the expression profile for miR195 and 
miR497 is altered in human aortic dissections481.  
 
6.1.3 Modulation of miRs  
MiR activity can be inhibited in vivo using synthetic complementary 
oligonucleotide sequences (antagomirs) 8-25 base pairs in length, against the 
seed sequences of the miR. These bind to the miR and last for the duration of 
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miR activity. Normally nucleic acids are rapidly degraded and thus chemical 
modifications are required to increase binding efficiency and cellular uptake. 
These include 2’-O-methyl-modified oligonucleotides (OMe) and locked nucleic 
acid (LNA)-modified oligonucleotides, where the 2-oxygen is connected to the 
4-position by a methylene linker leading to a tight bond that is locked into a 
C3-endo (RNA) conformation482-483. The balance between phosphodiester and 
phosphorthioate linkages is important leading to improved stability of the 
synthetic nucleotides484. In addition adding a cholesterol construct can 
improve the cellular uptake of the sequence441. LNA modification of 
oligonucleotides results in thermodynamically very stable duplex formation 
with complementary RNA. For example, delivery of the unconjugated LNA-
antagomir can silence miR-122 in mice and non-human primates 485,486. This 
technique is now under clinical investigation in phase I and II clinical trials in 
treating patients with hepatitis C486. 
 
Adding a cholesterol construct can improve the cellular uptake of the 
sequence441. The first mammalian knockdown of miR was reported using 
cholesterol conjugated antagomirs to inhibit liver specific miR, miR-122483. 
Knockdown miR expression has been reported in cardiac tissue after 
intravenous injection483. Various other miR sequences have been inhibited 
used specific antagomir target in studying cardiac hypertrophy  (antagomir to 
miR-133) and against fibroblasts (antagomir to miR-21)441,485. Other strategies 
to stabilise the antagomirs and effectively knockdown miR function include the 
use of miR erasers or sponges. This involves deploying vector constructs that 
can bind multiple miR binding sites where the miR of interest can bind to its 
intended target486.   
 
As well as silencing miRs, their actions can be amplified. A miR-mimic consists 
of a double-stranded oligonucleotide including the miR sequence and the 
complementary passenger strand. Improved chemical stabilization, 
conjugation and targeted delivery of the miR mimic are needed to have the 
desired biological effect487,489. MiR levels can also be augmented by delivering 
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miRs packaged in adeno-associated viruses489. Viral delivery of selected miRs 
can be enriched in specific tissues. Cytoplasmic RNA viruses of positive polarity 
can lead to mature miRs (virtrons) within the cytoplasm490-492. The additional 
advantage of using a viral vector is that the miR of interest can be continually 
expressed in the tissue of choice, to replace the downregulated miR. The 
increased number of adeno-associated viruses (AAV) make tissue specificity 
due to natural tropism, towards different organs likely. Recent work has used 
AAV delivery of miR26a to blunt tumour growth of liver cancer481. In this case 
targeted arrest of cell cycle by acting on cyclin D2 and E2 inhibited cancer 
growth.  
 
6.1.4 MiR therapeutics, pharmacokinetics and delivery  
The majority of the antagomirs are water-soluble and can be injected in water/ 
saline solutions into the intravascular compartment. Intraperitoneal injections 
of cholesterol-based antagomirs or LNA-based compounds have also been 
used to silence miRs494-496. Studies have demonstrated intravenous, 
intraperitoneal and subcutaneous delivery of cholesterol bound antagomirs to 
achieve high level inhibition of various miRs upto 14 days in different tissues 
497-498. There is differential delivery of antagomirs into various tissues. Tissues 
such as liver, kidney, plasma and heart demonstrate a much higher 
concentration of antagomir activity then for instance the aorta429. The limited 
penetration into certain tissues can, however, be overcome by increasing the 
dose and repeated dosing strategy498.  
 
AmiRs provide an attractive potential for therapeutics. They are specific for a 
miR, with a known sequence that is often completely conserved among 
species. This makes it attractive from a drug development point-of-view. 
Therapeutic mimic of miRs using synthetic RNA duplexes designed to mimic 
endogenous functions of the miR of interest can be used. These can be 
synthesized for stability and increased cellular uptake. This method would 
replace miRs lost in the disease process and there would be limited 
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modifications possible to the miR as the cell has to recognize it as such. Viral 
vector mediated delivery has therefore sought to continually express miRs in 
the target tissue of interest. Antagomir’s however remain the most developed 
and potent method at present to in vivo influence miR networks at present.  
 
Selective knockdown of miR21 with antagomirs has been shown to blunt 
cardiac myocyte hypertrophy by inhibiting and reversing interstitial fibrosis442. 
This effect was thought to be due to regulation of MAPK signaling in cardiac 
fibroblasts through miR21 targeted Spry1, a negative regulator of MAPK 
signaling440. However gene deletion of miR21 and anti-miR based inhibition 
failed to result in a phenotypic change and did not alter cardiac 
remodeling449,499.  
 
miR15 family including miR195 are thought to be involved in cell cycle 
regulation and cell survival. Global gene profiling studies and argonaute-2 
immunoprecipitation, has shown miR195 to regulate cell cycle genes including 
checkpoint kinase 1 (Chek 1). LNA modified knockdown of miRs lead to 
increased number of mitotic cardiomyocytes and derepression of Chek 
1496,497,500. miR15 family inhibition has been shown to reduce infarct size and 















1) To assess the effect of treatment with antagomirs to miR29b and  
  miR195 on the aortic phenotype and ECM content in the ApoE-/--ATII 
  infusion model of aneurysms 
 
2) Study the effect of miR29b and miR195 antagomir treatment on the 
  haemodynamics and cardiac phenotype in the ApoE-/--ATII infusion 
  model 
 
3) To determine the down stream effects of antagomir inhibition of 






















6.3.1 Laboratory animals and experimental protocol  
Homozygous ApoE-knockout male mice 10wks old (C57Bl/6J background, 
ApoE-/-) were obtained from Charles River (Edinburgh, UK). Housing, care and 
maintenance of animals was carried out in accordance with the regulations of 
the UK Home Office as previously described in section 4.3.1, page 147. 
 
The experimental protocol used in these experiments is illustrated in Fig 6.1. 
After acclimatisation for 1wk and prior to osmotic pump implantation, the 
animals (n=32) were imaged by MRI using 0.4mmol/kg of ESMA (elastin 
specific magnetic resonance agent)262,263 in order to obtain baseline aortic 
parameters using the 3T MTI. A separate 9.4T MRI was performed to 
determine the baseline cardiac parameters.  An osmotic pump (model 2004, 
Alzet, Durec Corp) containing angiotensin II (1µg/Kg/min, Sigma Aldrich) was 




3) Control antagomir sequence 
4) No injection control 
 
The antagomirs were administered intraperitoneally (i.p.) at a dose of 
80mg/kg/day on days 1, 2 and 3 day after osmotic pump implantation. MRI 
scans and haemodynamic assessment was carried out at weekly intervals until 
the animals were sacrificed at day 35 for histology, IHC, RT-PCR and 































6.3.2 Systemic silencing of miR in ApoE-/-ATII 
Cholesterol bound antagomiR constructs from Fidelity Biosystems were 
resuspended in sterile PBS at 37°C and stored at -20°C. The sequences of the 
antagomiR constructs were the following: Control AntagomiR: 5` 
A*A*GGCAAGCUGACCCUGAA*G*U*U* Chol*T-3’, AntagomiR-195: 
5`G*C*CAAUAUUUCUGUGCU*G*C*U* Chol*T-3’, AntagomiR29b: 
A*A*CACUGAUUUCAAAUGGUG*C*U*A*-Chol*T-3’.  
 
6.3.3 Anesthesia and euthanasia for tissue harvest 
Animals were anesthetised by induction with 5% isoflurane and maintained 
with 1% to 2% isoflurane during pump implantation and MRI.  Terminal 
exsanguination was performed by direct cardiac puncture and aspiration of 
blood. This was followed by continuous infusion with PBS into the left ventricle 
to wash out blood contamination, the outlet being the right ventricle. The 
complete arterial tree was dissected out and excised using an operating 
microscope (Leica S6D, Leica, UK). Lungs, thymus, heart, liver spleen and 
kidneys were also harvested. Tissues were either snap frozen in liquid nitrogen 
and then stored at -80°C pending further processing, or fixed in 10% formal 
saline for 24hrs before embedding in paraffin (See section 3.3.7.1, page 107) 
for immunohistochemical analysis.  
 
6.3.4 Non-invasive haemodynamic monitoring 
Tail cuff systolic, diastolic pressures were measured and the mean arterial 
pressure calculated using VPR non-invasive blood pressure monitoring system 
CODA-6 (Kent Scientific, Torrington, CT) at weekly intervals after 
acclimatisation of the animals. The protocol followed for the measurements 
was as previously described502. Briefly, 100 waveforms were analysed per 
animal per sitting. The heart rate and waveform amplitude was measured 
before cuff inflation. 10 initial readings were unrecorded. These were 
necessary to warm the mouse-tail and get mouse acclimatised to that session. 
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We carried out 5 days of training in order to accustom the animals to the 
procedure. The rapid appearance of a waveform to the tail-cuff procedure as 
judged by software for first 10 readings were excluded and likewise any 
waveforms deemed not to fall within the appropriate wave pattern. A single 
investigator from 1000-1800hrs weekly carried out and recorded the 
measurements. Each session included 2 sets of 10 measurements; therefore 
60-100 measurements were used for BP analysis in each mouse at each time 
point. For inclusion of each set of measurements for individual animals, we 
required the software to recognise at least 6 of the 10-trial run of 
measurements. 
 
6.3.5 Elastin specific magnetic resonance agent (ESMA) 
Vessel wall elastin content was assessed using the novel elastin specific 
contrast agent, ESMA (Lantheus Medical imaging, North Billerica, 
Massachusetts) as described previously in Chapter 5 and by the authors 
studying the porcine vascular tree263 and atherosclerotic plaques in ApoE-/- 
mice262. 
 
6.3.6 Magnetic resonance imaging 
6.3.6.1 In vivo MRI protocol at 3T 
The imaging was performed as described in section 5.3.2.1 on page 181.  
 
6.3.6.2 In vivo MRI protocol at 9.4T 
Cardiovascular MR images (n=4 per group) using a horizontal MR scanner 
(Varian Inc, Palo Alto, CA) with mice positioned in the prone position. The 
gradient coil had an inner diameter of 12 cm, a gradient strength of 1000 
mT/m, and a rise time of 120μs. A quadrature transmit/receive coil (RAPID 
Biomedical GmbH, Würzburg, Germany) with an internal diameter of 39 mm 
was used. Anesthesia was achieved as described above, and body temperature 
was maintained at 37°C with the use of a warm air fan (SA Instruments, Stony 
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Brook, NY). ECG gating was achieved via. 2 metallic needles placed 
subcutaneously in the anterior chest wall, and a pressure transducer was 
placed on the abdomen for respiratory gating (SA Instruments). The data was 
pressure transduced and gated with synchronous acquisition with ECG and to 
compensate for respiratory motion. Simultaneous ECG triggering and 
respiratory gating was carried out to minimise the motion artifacts. The typical 
heart rate was between 350-550bpm (cycle length 110-160ms) with a 
fluctuation of ±50bpm (12ms) per cardiac cycle. The respiratory rate was 
40±10 resp/minute (1500±500 ms) per respiratory cycle.  
 
Cine-FLASH was used to acquire the dynamic short axis images of the heart. 
The gradient echo technique was used for maintaining steady state. Spoiler 
gradients of 1ms duration and 100mT/m strength were used after each data 
acquisition readout to diphase transverse magnetisation before the application 
of the next radiofrequency (RF) excitation pulse. Cine-FLASH was performed 
with ECG and respiratory gating. Optimised imaging parameters were, TR=RR-
interval, TE=1ms, FOV 20x25mm, matrix size=128x128, slice thickness=1mm; 
flip angle=40º, 2 averages for the gating, 1 k-space line/frame, 10 frames per 
cardiac cycle to study the dynamic short axis view. The acquisition time was 
10±0.5mins.  The trigger was at peel QRS complex, with phase encoding to 
obtain the end systolic and diastolic frame. Ejection fraction (EF), stroke 
volume (SV), Cardiac output (CO) and LV mass were calculated.  
  
6.3.6.3 MR image analysis 
Analysis of vessel wall luminal diameter, wall thickness and aortic growth rate 
was performed using OsiriX (OsiriX Foundation, Geneva, Switzerland). Co-
registration was performed of the TOF images with the high-resolution DE-MRI 
images. The morphometric measurements were performed on high-resolution 
DE-MRI angiography images, which were taken after administration of ESMA. 
The signal intensity measurements, regions of interest (ROIs) were defined as 
areas of enhancement on high-resolution DE-MRI images that co-localised to 
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aortic aneurysms. The T1 values were calculated on a pixel-by-pixel basis using 
the Matlab software261. 
 
6.3.7 Histological analysis 
The washed normal thoracic and infra renal aortic segments and suprarenal 
aortic aneurysms were fixed in 10% formalin, and embedded in paraffin 
(described in section 3.3.7.1, page 107). Serial 5µm thick sections were stained 
with hematoxylin and eosin to detect cellular components. Elastin was stained 
using Verhoeff van Gieson stain (EvG) (as described in section 3.3.7.5, page 
109). Computer assisted contour tracing was used to determine the aortic 
elastin content. Leukocyte and tropoelastin content was estimated by IHC as 
described in sections 3.3.8, page 109 and 4.3.8, page 153. 
 
6.3.8 Genomics and proteomics 
6.3.8.1 MicroRNA target prediction 
The prediction of miR29b and miR195 putative targets was performed with the 
miRWALK algorithm (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk). 
The MiRNA targets on the 3' UTRs of all known genes in mouse were identified 
using 8 established miRNA prediction programs (RNA22, miRanda, miRDB, 
TargetScan, RNAhybrid, PITA, PICTAR and Diana-microT). 
 
6.2.8.2 MegaPlex reverse transcription 
To determine the level of miR in cells 100ng of RNA from the 25μl eluate were 
reverse transcribed using the Megaplex Primer Pools (Rodent Pool A v.2.0) 
from Life Technologies. The reaction was performed as per manufacturers 
guidelines. (0.8μl of Pooled Primers were combined with 0.2μl of 100mmol/L 
dNTPs with dTTP, 0.8μl of 10x Reverse-Transcription Buffer, 0.9μl of MgCl2 
(25mmol/L), 1.5 μl of Multiscribe Reverse- Transcriptase and 0.1 μl of RNAs in 
(20U/μl) to a final volume of 7.5 μl. The RT-PCR reaction was set as follows: 
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16°C for 2min, 42°C for 1min and 50°C for 1sec for 40 cycles and then 
incubation at 85°C for 5min using a Veriti thermocycler (Life Technologies). The 
RT reaction products were diluted to 1ng/µl corresponding RNA and stored at -
20°C. 
 
6.3.8.3 Taqman qPCR assay 
Taqman assays were used with Taqman probes designed by Roche Molecular 
Systems, Inc for Life Technologies, USA to determine the individual miR 
expression profiles. 2.25 ng of Megaplex reverse transcription product were 
combined with 0.25 μl of Taqman miRNA Assay (20X) (Life Technologies) and 
2.5μl of the Taqman Universal PCR Master Mix No AmpErase UNG (2X) to a 
final volume of 5μl. QPCR was performed on an Viia7 thermocycler at 95°C for 
10 min, followed by 40cycles of 95°C for 15sec and 60°C for 1min. U6 was used 
as a normalization control. 
 
6.3.8.4 Plasma RNA extraction, reverse transcription and 
preamplification 
miRNeasy kit (Qiagen, Valencia, CA) was used to extract the miRs. 3μl of the 
25μl RNA eluate was used as input for reverse transcription (RT) reactions 
500,501. miRs were reverse transcribed using Megaplex Primer Pools (Human 
Pools A v2.1, Life Technologies). The RT reaction products were amplified using 
Megaplex PreAmp primers (Primers A v2.1). The Taqman miR assays were 
utilised to determine the expression of the miRs, 0.5μl diluted pre-
amplification product were combined with 0.25μl Taqman miRNA Assay (20x) 
(Life Technologies) and 2.5μl Taqman Universal PCR Master Mix to AmpErase 
UNG (2x) up-to a final volume of 5μl. All samples were processed and run as 
duplicates, with the qPCR being performed on a Life Technologies 7900HT 
thermocycler at 95°C for 10min, followed by 40 cycles of 95°C for 15 sec and 
60°C for 1min. Relative quantification using the software SDS2.2 (Life 
Technologies) was performed and the exogenous miRNA (cel-miR-39) was used 
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as a spike-in normalization control as described previously500,501. All the RT and 
preamp products were stored at -20°C. 
 
6.3.9 In-vitro studies 
6.3.9.1 Cell extraction for co-culture  
Murine aortas were harvested from ApoE-/-ATII mice at day 35. The normal 
aortas and suprarenal aneurysms were processed separately as described 
previously in section 4.3.5, page 149. The final aortic wall tissue obtained was 
filtered through a 100μm cell strainer (Falcon BD), incubated with 100μl of 
Annexin V beads (Miltenyi Biotec, UK) for 15mins at room temperature for 
removal of dead cells. The cell suspension was applied to a MACS MS column 
(Miltenyi Biotec, UK) and the effluent collected as a live cell fraction. Live cells 
were pelleted, re-suspended in 80μl of PBS supplemented with 1% BSA and 
2mM EDTA and incubated with 10μl of biotinylated anti-CD3ε for 15mins at 
4°C. Cells were washed, pelleted and re-suspended in 20μl of anti-biotin 
microbeads and incubated for 15mins at 4°C. The cell suspension was applied 
to the MACS MS column and unbound cells washed away with buffer. Bound 
CD3+ cells were collected from the column by applying the plunger supplied 
with the column. The remaining unbound cells were pelleted, re-suspended in 
90μl of buffer and incubated with 10μl of CD19+ microbeads for 15mins at 4°C. 
CD19+ cells were collected as described above. Cells were counted using a 
haemocytometer and viability determined by trypan blue exclusion.  
 
6.3.9.2 In vitro co-culture system 
Mouse vascular smooth muscle cells (mVSMCs, Cell Biologics, USA) grown in 
DMEM containing 1g/l D-glucose, 10% FCS, 1% antibiotics and 1% L-glutamine. 
Passage 4-5 mVSMCs were plated at 2x104 cells in 12well plates and incubated 
for 24hrs at 37°C, in 5% CO2. T-cells (5.5±1.4 x105) and B-cells (3.9±4.8 x105) 
were cultured in 0.4μm cell culture inserts (placed above the mVSMCs in the 
12 well plates) with RPMI medium supplemented with 10%FCS, 
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1%penicllin/streptomycin and 1%L-glutamine. Lymphocytes were co-cultured 
with the mVSMCs as pure CD3+T-cells, CD19+B-cells, or a combination of T and 
B-cells in a 1:1 ratio. A mVSMC well, to which RPMI only was present in the 
insert acted as a control in each experiment. At day 3, DMEM medium was 
replaced and additional RPMI medium added to the lymphocytes. Cells were 
lifted off with 1% trypsinisation for analysis at day 5. Normal aortic wall 
derived and aneurysm derived lymphocytes were incubated with mVSMC’s 
with and without 0.2μg/ml Antagomir-miR29b (AmiR29b) in the culture 
medium through out the duration of the experiment. 
 
6.9.3.3 RNA extraction from mVSMCs 
At day 5, total mRNA was extracted from mVSMCs using the RNAeasy MicroKit 
(Qiagen, Valencia, CA). Briefly, 700μl of QIAzol lysis reagent was added to cell 
culture wells containing 1ml culture medium and the lysate vortexed for 1min 
to homogenize the cells. 140μl of chloroform was added to the homogenate, 
centrifuged for 15mins at 12,000g and 4°C and the upper aqueous phase 
transferred to a fresh RNAse free collection tube. 525μl of 100% ethanol was 
added and transferred to RNeasy MinElute spin column before centrifugation 
at 8000g for 15sec at room temperature. The eluate was discarded and the 
above procedure repeated after each addition of 700μl of buffer RWT, 500μl of 
RPE and 500μl of 80% ethanol. The column was placed in a 2ml collection tube 
and centrifuged at full speed for 5mins. 14μl of RNase-free water was added to 
the centre of the spin column and centrifuged at 16,000g for 1min at room 
temperature to elute the RNA which was stored at -20°C till the RT-PCR.   
 
6.9.3.4 RT-PCR for cell cultures 
Each sample was diluted 1:60 with nuclease free water. A further 10-fold 
dilution series was carried out to produce 1:10, 1:100: 1:1000 dilutions of each 
sample. A nuclease free water negative control was also used. All samples 
were further diluted 1:5 with nuclease free water to produce enough cDNA for 
analysis of 10 genes. Top standard was made using 1μl from each sample into a 
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single well and diluting using nuclease free water to the final volume of 60μl. 
cDNA was transferred to a 96-well plate (5μl/well) for each gene to be 
analyzed. 1030μl of Taqman Fast Advanced Mastermix (Invitrogen) and 700μl 
of nuclease free water was added to 100μl of assay gene/housekeeping gene 
(Invitrogen). An automated robotic system (Beckman Coulter) was used to 
transfer 50μl of mastermix to each well of to the cDNA samples. Samples from 
the 96-well plates were then scaled up to a 384-well plate for analysis of 4 
replicates of each sample. The plate was run on the RT-PCR system (7900HT 
Fast Real Time PCR system Applied Biosystems) and data acquired using SDS 
(Invitrogen, UK) The data was analysed using DataAssist software v3.01. The 
cT values of each sample were normalized to the housekeeping genes and then 
expressed as fold changes relative to the control samples of each experiment 
using DataAssist™ software v3.1 (Invitrogen, UK). The average fold change was 
calculated and logged to allow an interpretation of gene regulation.    
 
6.3.9.5 Cytokine Bead Array (CBA) 
Day 3 and 5, conditioned DMEM media was collected from mVSMCs co-
cultures centrifuged at 300g for 5mins and the supernatant collected, snap 
frozen in liquid nitrogen and stored at -80C. Conditioned media from both 
days were pooled to increase the final concentration of the cytokines for each 
incubated co-culture condition. A 10K Amicon Ultra-2 centrifugal filter devices 
(Millipore, UK) used to concentrate the 2ml sample to 100l. Samples were 
pipetted into the centrifugal filter device and spun for 25mins at 4000g. To 
recover the concentrated solute, the filter device was inverted and centrifuged 
again for 2mins at 1000g to transfer the concentrated sample to the collection 
tube.  
 
The BD CBA Mouse Th1/Th2/Th17 Cytokine kit (BD Biosciences), in which the 
cytokine capture beads of known size and fluorescence were conjugated to 
specific cytokine antibodies, was used to measure the concentrations of IL-2, 
IL-4, lL-6, IFN-, IL-17A, TNF- and IL-10 protein in the conditioned media 
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concentrates. The standard stock solution, 5000pg/ml was reconstituted with 
assay diluent and a double dilution series carried out to produce standards of 
20-2500pg/ml and a blank control of 0pg/ml. Beads were briefly vortexed and 
10l of each capture bead suspension added to a single tube. 50l of mixed 
capture beads were added to all assay tubes followed by 50l of Mouse 
Th1/Th2/Th17 PE Detection reagent and incubated for 2hrs at 21 C. Wash 
buffer (1ml) was added, samples centrifuged at 200g for 5mins and the 
supernatant discarded. A further 300l of wash buffer was added to resuspend 
each bead pellet. The fluorescence signals from each bead were acquired on a 
two-laser BD flow cytometer and analysed using FCAP Array software v3.0.1 
(BD, UK).  
 
6.3.10 Statistical analysis 
Data was analysed using SPSSv21 (IBM Inc, US). Graphpad Prism 5 has been 
used for selective graphical analysis. Data is presented as mean and standard 
error of the mean (SEM) or standard deviations (SD) when specified. Paired 
student’s t-test was used when comparing parametric data. For multiple 
variables a two-way ANOVA with post-hoc Bonferroni was used. An alpha value 
of 0.05 was considered significant. Correlations were analysed using Pearson’s 
correlation coefficient. Inter-observer variability was assessed using Cohen’s 
kappa coefficient. All cell culture data was normalised to control co-culture 












6.4.1 In vivo effects of AmiR29b and AmiR195 treatment on 
aortic dilatation and rupture  
Aneurysm development was inhibited by treatment with miR29b compared 
with control antagomir (P<0.01 2-way ANOVA) or controls with ATII infusion 
(P<0.01, 2-way ANOVA), while the effect of AmiR195 was not statistically 
significant (Fig 6.2). The Kaplan Meier survival analysis for the AmiR groups 
demonstrates the survival advantage of AmiR29b over AmiR195 and the 
controls (Fig 6.2). The survival advantage following AmiR29b treatment 
represents an absolute risk reduction of 37.5%, with HR 1.75, P<0.01 compared 
with the controls. 
 
The control groups started to developed aneurysms by day 5 post AngII 
infusion, whereas aneurysm development in the AmiR29b group was delayed 
until day a mean of day 15. There was a significantly lower aortic diameter in 
AmiR29b group (n=8) compared to the control antagomir and control groups 








Fig 6.2 The Kaplan Meier survival analysis and cumulative frequency table for the 
AmiR29b and AmiR195 group and the control groups 
There is a significant lowering of the mortality with the miR29b treatment 















6.4.2 In vivo assessment of the aortic diameter and aortic wall 
elastin content and continuity 
Aortic morphology was assessed by magnetic resonance TOF-angiography (Fig 
6.3A, day 15) and used to determine the maximal aortic diameter on 























Fig 6.3 In vivo assessments of the aortic aneurysm diameter, volume and elastin content 
The black lines represent the imaging plane of subsequent performed axial MRI sequence slices. The two axial slices taken 20μm apart. The false 
colour fused maps of axial slices and the angiogram allowed determination of the vessel wall ESMA content throughout the aneurysm (red arrows). 
The upper panel shows measurement of the aortic diameter on the fusion angiogram with the aortic wall thickness. The outer and inner aortic wall 
can be delineated due to the presence of ESMA. This varied according to the axial slice analysed throughout the aneurysm. The lower panel 
represents aortic outline further down and demonstrates heterogeneity within the aortic wall as to the presence of ESMA. An overall value for the 
complete aneurysm was obtained through analysis of all the axial sections through the suprarenal aorta. The aortic aneurysm volume was also 





AmiR29b significantly inhibited aneurysm development (reduction in the 
maximal aortic diameter) compared with the controls and AmiR195 (P<0.001 
each, Fig 6.4). At end point analysis AmiR195 was also at a lower aortic 
diameter compared to the control groups, P<0.001. 
 
 
Fig 6.4 Temporal change in suprarenal aortic aneurysm maximal diameters 
following treatment with AmiR29b, AmiR195, control AmiR or vehicle control 
N=8/group for the time points, error bars represent S.E.M. *P<0.001 at end-point 
analysis between AmiR29b, AmiR195 and control groups, two-way ANOVA, post hoc 
Bonferroni correction.   
 
The overall aortic volume measured over the complete suprarenal aortic 
segments was also significantly lower in the AmiR29b compared with control 
groups at end-point analysis at final time point (P<0.001, 2-way ANOVA, post 








































Fig 6.5 The aortic volume from the MRI of the suprarenal aneurysm 
N=8/group for the time points, error bars represent S.E.M. At end-point analysis there 
is significant reduction in aortic volume in miR29b group vs. control groups, P<0.001, 
two-way ANOVA, post hoc Bonferroni test.  
 
When the growth velocity is calculated as proportional fold change in the 
maximal aortic diameters there is a clear difference in the AmiR29b group with 
a much lower proportional aortic diameter, which is 2 to 4-fold lower 




Fig 6.6 Fold changes in the maximal transverse aortic diameter in the suprarenal aortic 
aneurysm 
N=8/group for the time points, error bars represent S.E.M, P<0.01 for AmiR29b group 
compared to the AmiR195 and control group. (Two-way ANOVA, post hoc Bonferroni 
correction). 
 
Aortic wall thickness measured, as ESMA content was greatest in the 
AmiR195 group followed by the AmiR29b group compared with the 
controls from day 0 till day 10, (P<0.001 at specific time point analysis for 
AmiR195 vs. controls). After day 15 the level of ESMA uptake in the 
AmiR195 group was not statistically significantly different from the other 
groups (Fig 6.7). There were no differences in the AmiR29b at any time-




Fig 6.7 Total aortic wall thickness (ESMA content) of supra-renal aortic aneurysm 
following treatment with AmiR29b and AmiR195 
 N=8/group for the time points, error bars represent S.E.M. At specific time point 
analysis there was a significant difference between AmiR195 and the control groups 
from days 0-10 (P<0.001, paired T-test); thereafter there were no significant 
differences between the groups on statistical analysis.  
 
The aortic aneurysms from the AmiR29b group had decreased maximal 
aortic diameters, decreased aortic volume and lowest fold change in the 
aortic dimensions, and on detailed morphometric analysis, the aortic 
architecture was markedly altered (Fig 6.8). On overall aneurysm wall 
ESMA quantification there was no difference in the AmiR29b group 
compared to the controls but axial slices consistently demonstrated 
increase in intensity of ESMA in the axial slices which correspondingly 
matched increased R1 relaxivity values on T1 mapping. This also 
correlated to histological increase in the elastin and tropoelastin staining 









































Fig 6.8 In vivo assessments of aortic potential disruption sites with aortic dilatation and ex 
vivo histomorphometric assessment of elastin and tropoelastin content 
A) Three dimensional magnetic resonance angiogram volume rendered reconstruction (A1) of 
the murine aorta from the control group taken at day 35. Close up anterior view of the 
aneurysm (A2). The red line represents an example of axial slice taken for analysis through the 
middle of the aneurysm. This demonstrated the aortic wall delineated using ESMA (A3) and the 
absence of ESMA at the 6 o’clock and 9 o’clock positions in the aorta (A4): Axial fusion image 
of the contrast angiogram demonstrating the absence of ESMA in the same position suggesting 
an aortic break with likely decreased elastin/ tropoelastin content. Measurement of T1 
relaxation times (A5) of the aortic wall to determine the quantification of the ESMA uptake. 
(A6) The histology on EvG stained aortic section from the aneurysm at the same site as the 
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scan image demonstrating reduced elastic lamellar units at sites of decreased elastin content 
in the aortic wall (red arrow) (A7) Decreased aortic wall tropoelastin content (red arrow) at the 
same site on immunohistochemical assessment using tropoelastin specific antibody. It is likely 
that the aneurysm will expand/ rupture at a site such as this due to marked loss of elastin/ 
tropoelastin. (B) Three dimensional magnetic resonance angiogram volume rendered 
reconstruction (B1) of the murine aorta from the AmiR29b taken at day 35. Close up anterior 
view of the aneurysm (A2). The red line represents an example of axial slice taken for analysis 
through the middle of the aneurysm. This demonstrated the aortic wall delineated using ESMA 
(A3) and the abundance of ESMA throughout the aortic wall. (A4) Axial fusion image of the 
contrast angiogram demonstrating the high ESMA uptake suggesting an aortic wall has high 
elastin/ tropoelastin content. Measurement of T1 relaxation times (B5) of the aortic wall to 
determine the quantification of the ESMA uptake. Compared to control group the higher T1 
times were observed (B6) The histology on EvG stained aortic section from the aneurysm at 
the same site as the scan image demonstrating reduced elastic lamellar units at certain sites 
(red arrow). However the majority of the wall has high homogeneous elastin staining (B7) 
Markedly increased aortic wall tropoelastin content (red arrow) at the same site on 
immunohistochemical assessment using tropoelastin specific antibody (n=6). It is likely that the 
aneurysm is actively remodelling with up regulation of tropoelastin in response to elastin 
breakdown.  
 
As the aortic aneurysms develop and enlarge there was disruption of the 
internal and external elastic laminae in the tunica media that could be 
observed in all aneurysms. The location of the aortic disruption was seen on 
the ESMA-MRI and ex vivo on histological sectioning (Fig 6.8, 6.9). Complete 
aortic wall disruptions were only seen in the control groups (6/8 animals in 
each group) compared with 0/8 (i.e. total elastin continuity per axial aortic 
section) seen in the wall of animals in the AmiR9b group  (Fig 6.8, 6.9).  
Intraluminal thrombus was seen the aorta in aneurysms at day 35 in the 
control groups (5/8 in control antagomir and 3/8 control), but this was absent 






Fig 6.9 Temporal changes in vessel wall elastin content   
Increased aortic wall elastin signal (B1) (ESMA uptake) was seen at day 5 throughout the vessel wall (A1-2 vs. B1-2) from the endothelium to the adventitia and this 
was demonstrated on T1 mapping studies (A3 vs. B3). At days 15 and 30 ESMA uptake was maintained in the face of increased aortic diameters (B4-9) compared 
with lower and less homogenous uptake in the control wall (A4-9).  
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6.4.3 Ex vivo assessment of aortic wall composition  
The aortic wall architecture and composition was assessed histologically (Fig 
6.10, 6.11). The vessel wall elastin content (EvG staining) and tropoelastin 
content (tropoelastin specific monoclonal antibody) was greater in the 
AmiR29b group compared with the control groups (P<0.01)  (Fig 6.10, 6.11). 
When the elastin and tropoelastin content are correlated to the maximal aortic 
diameters there is a positive aortic remodelling response that is seen and is 
more pronounced in the AmiR29b groups.  
 
When the immune cell content is analysed on IHC the AmiR29b treatment was 
associated with a lower content of T lymphocytes, NK cells and macrophages in 
the aortic media, P<0.01 (Fig 6.12). 
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Fig 6.10 Correlation between the maximum aortic diameters and the histological percentage staining area for elastin and tropoelastin as percentage of overall 
slide area  
There is a proportional relationship between the maximal aortic diameter and the percentage of aortic wall elastin content that normally increases with time (black 
circles). This is a positive aortic remodelling response seen to an expanding aortic lumen (black circles; R20.81, P<0.001). When the AmiR29b is plotted on this graph 
(black squares), the vessel wall elastin content (EvG) can be seen to be higher at all aortic diameters. Hence the proportional relationship is now skewed positively 
with EvG upregulation. Similarly there is normally a positive correlation between tropoelastin content (black circles and the aortic diameter, R20.79, P<0.001). This 
correlation is skewed and lost within the AmiR29b group (black squares) that has a higher tropoelastin aortic wall content. (N=16, persons correlation coefficient, 





Fig 6.11 Histological assessment of the aortic wall elastin and tropoelastin content 
The histological vessel wall elastin content for the control aorta versus AmiR29b, demonstrates significantly higher elastin content in the AmiR29b group, P<0.01 
(paired two-tailed, T-test). The histological vessel wall tropoelastin content for the control aorta versus AmiR29b demonstrates significantly higher tropoelastin 





 Fig 6.12 Histological assessment for aneurysm wall immune cell content 
AmiR29b aortic aneurysms (A2-C2) had a reduced number of T-, B-cells and macrophages compared to the control antagomir group (A1-C1). These 
apprear as brown (DAB+) staining cells for the immune cell specific cell markers.  
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On semi-quantitative analysis the number of T-cells (D1, P<0.01), NK cells (D2, P<0.01) and macrophages (D3, P<0.01) infiltrating the tunica 
media/adventitia was higher in the control ApoE-/-ATII. Cell counts given as percentage area of total aneurysm wall stained for specific leukocyte markers 
(meanSEM, students T-test). 
D1 D2 D3 
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6.4.4 AmiR29b and AmiR195 effects on blood pressure 
The baseline mean systolic pressure was similar in all the groups (control 
102.1mmHg, control antagomir 94mmHg and AmiR29b 100mmHg, P>0.05) Fig 
6.13. Similarly the diastolic baseline blood pressure was the similar across the 
groups (control 66.7mmHg, control antagomir 71.9mmHg, AmiR29b 69mmHg, 
P>0.05) Fig 6.14. The mean arterial pressure was similar across the groups 
(control 78.3mmHg, control antagomir 74.4mmHg, AmiR29b 84.2mmHg) Fig 
6.15. There was a statistically significant divergence in systolic blood pressure 
in all the groups compared to the baseline from day 5 onwards to mean 
systolic pressure of 145mmHg (P<0.01) Fig 6.13. Elevated systolic pressures 
were maintained upto day 35 (Fig 6.13). There was a statistically significant 
difference in the diastolic pressures between the control/ control antagomir 
groups and the AmiR29b group (P<0.01) (Fig 6.14). There was no difference in 
the MAP across the groups (P>0.05). The MAP increased in the control and 
control antagomir from baseline by day 5 (control 92.8mmHg, control 
antagomir 88.2mmHg). Due to a drop in diastolic pressures in the AmiR29b 
group the MAP was lower in the AmiR29b group on day 5 compared with the 
control and control antagomir group (P<0.01), thereafter there were no 











Fig 6.13 Non-invasive systolic blood pressure measurements taken at weekly intervals for all ApoE-/-ATII groups 
There was an increase in the systolic pressures across all the groups compared with baseline (mean SBP of 10127 mmHg to mean SBP 14518 mmHg, P<0.01), 


















Fig 6.14 The non-invasive haemodynamic assessment of the diastolic blood pressure 
The diastolic blood pressure was reduced in the AmiR29b group from day 5 to the end of the study at specific time point analysis, P<0.01. This could be due to 

















Fig 6.15 The non-invasive mean arterial pressure was not significantly altered continuously across the time course of the study 
There were transient decreases in the MAP in AmiR29b group at day 5 and 15 but these were not maintained. There were no significant differences in between the 















6.4.5 Cardiac MRI left ventricular cardiac remodelling and 
haemodynamics 
The left ventricular end-systolic and diastolic volumes were lower in the 
AmiR29b treated group compared with control anatagomir (P<0.01) and 
control (P<0.01) over a period of 4weeks (Fig 6.16). However, the left 
ventricular muscle mass and the derived cardiac haemodynamic parameters 
























Fig 6.16 ECG gated cardiac magnetic resonance angiogram of the left ventricle in short axis 
view (SAX) using the 9.4Tesla MRI scanner  
A) Images above displayed demonstrating LVES dimension in first panel and LVED dimension in 
the second panel. Cardiac parameters calculated from the data obtained in these sequences. 


































Fig 6.17 Cardiac indices  
At specific time point analysis of the indices there are differences in the aortic and ventricular 
dimension that could be due to an alteration in the aortic vessel wall due to aortic remodelling 
and mVSMC responses. A) The LVES starts from a similar baseline value however there is a 
divergence of the LVES beyond day 7 with a decrease of LVES in the AmiR29b cohort compared 
to the control groups with the effects maximal at day 35 (P<0.01). B) The LVED starts from a 
similar baseline across the groups with a non-significant decrease in dimensions at around day 
14. At day 35 the LVED is decreased in the AmiR29b vs. control groups (P<0.01). C) The LV 
muscle mass trended to be slightly lower in the AmiR29b group till day 28, however this was 
not statistically significant. (Two-way ANOVA P>0.05, post hoc Bonferroni test) 
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Fig6.18 The cardiac parameters calculated from echocardiograms 
 
The calculated cardiac indices that represent alteration in cardiac physiology 
did not show any significant differences across the various treatment groups. 
The percentage left ventricular ejection fraction (LVEF) remained similar across 
the animals at 60% throughout the course of the study.  The left ventricular 
stroke volume and cardiac output what transient variations within the groups 
but there were no statistically significant discernable differenced between the 







































6.4.6 Inhibition of miR-29 and 195 in vivo in the ApoE-/-ATII  
 
There was marked inhibition of the miR29b activity in the liver and with a 
decreased efficiency of inhibition in the aorta (Fig 6.19A). Accordingly, an 
upregulation of elastin expression and other ECM genes was detected in the 
liver of AmiR29b injected mice (Fig 6.19B). The genes for collagen were up-
regulated  (Fig 6.19C). 
 
 
Fig 6.19 The regulation of the ECM microenvironment by miR29b in liver 
A) Expression levels of the miR-29 family in the liver following AmiR29b administration. MiR 
expression was normalized to U6. P<0.05 compared to control antagomir B) Elastin 
expression in the liver following antagomiR treatment. C) Correlation between the efficiency 
of miR29b knockdown and the derepression of ECM genes as quantified by QTPCR. Gene 
expression was normalized to b-actin 
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Fig 6.20 The gene expression profiling in aorta following AmiR195 administration 
Correlation between the efficiency of miR-195 knockdown in the aorta (n=4) and the 
derepression of a panel of 30 ECM genes on Day10 after AngII infusion. Expression levels 
were normalised to b-actin.  
 
Following AmiR195 administration there are mild downregulated affects on 
elastin, fibrillin and collagen genes, whereas upregulation of certain MMPs, 
notably 2, 9 and 12.  
 
4.6.7 Inhibition of miR29b in vivo mVSMCs co-culture system 
AmiR29b addition to the mVSMC media during co-culture with normal aortic 
wall specific CD3+ T lymphocytes resulted in up regulation of TFG expression 
in the mVSMCs (Fig 6.21, P<0.01). The CD3+ aortic aneurysm derived 
lymphocytes demonstrated an up regulation of TGF expression and LOX (Fig 
6.21, P<0.01 and P<0.05). There were no significant differences in gene 
expression of Cttk, FBN, and MMP2 in this group. These effects were specific 
 262 
to the co-culture set-up with isolated CD3+ cells. The genetic changes were 
not seen in the CD19+ or the CD3+/CD19+ groups (Fig 6.21).  
 
 
Fig 6.21 RT- PCR data showing average log fold change differences in gene expression of 
CttK, FBN, LOX, MMP-2 and TGF 
A) Average log fold change differences in expression of CttK, FBN, LOX, MMP-2 and TGF- in 
AmiR29b treated mVSMCs co-cultured with T lymphocytes (CD3+) derived from aortic 
aneurysm from ApoE-/-ATII. There is significant up regulation of TGF gene along with LOX in 
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the mVSMCs (**P<0.01, *P<0.05). B) Average log fold change differences in expression of 
CttK, FBN, LOX, MMP2 and TGF in AmiR29b treated mVSMCs co-cultured with B 
lymphocytes (CD19+) derived from the supra renal aortic aneurysm from ApoE-/-ATII infused 
group. There is no statistical change in cellular gene expression pattern.  
 
 
C) Average log fold change differences in expression of CttK, FBN, LOX, MMP2 and TGF in 
AmiR29b treated mVSMCs co-cultured with B and T lymphocytes (CD3+ and CD19+) derived 
from the suprarenal aortic aneurysm from ApoE-/-ATII infused group. There is no statistical 
change in cellular gene expression pattern. D) Average log fold change differences in 
expression of CttK, FBN, LOX, MMP2 and TGF in AmiR29b treated mVSMCs co-cultured with 
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T lymphocytes (CD3+) derived from the normal aorta from the ApoE-/-ATII infused group. 
There is up-regulation of the TGF genes to a greater degree in the normal aortic wall 
derived lymphocyte incubated mVSMCs in the AmiR29b group compared to controls 





E) Average log fold change differences in expression of CttK, FBN, LOX, MMP2 and TGF in 
AmiR29b treated mVSMCs co-cultured with B lymphocytes (CD19+) derived from normal 
aortic wall from ApoE-/-ATII infused group. There is no statistical change in cellular gene 
expression pattern. F) Average log fold change differences in expression of CttK, FBN, LOX, 
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MMP2 and TGF in AmiR29b treated mVSMCs co-cultured with T and B lymphocytes (CD3+ 
and CD19+) derived from normal aortic wall from ApoE-/-ATII infused group. There is no 

























6.5 Discussion  
6.5.1 MiR29b 
MiR29b is a critical regulator of elastin turnover in aortic wall by modulating 
several genes and pathways responsible for ECM composition, dynamics and 
inflammatory interactions. In murine aortic aneurysms inhibition of miR29b 
lead not only to decrease in the in the incidence of aortic aneurysms, their 
speed of progression, maximal eventual aortic diameter and therefore 
rupture risk. The extensive aortic remodelling response seen on MRI using 
ESMA, demonstrated aortic wall composition was significantly altered with 
the antagomir. The increase in wall thickness and up regulation in elastin 
being laid down within the tunica media was responsible for high wall signal 
in the AmiR29b group compared to the controls. This correlates with 
histological preservation of the elastic lamellae in the tunica media. 
Moreover the tropoelastin synthesis in the aortic wall was significantly 
elevated on immunohistochemistry staining with tropoelastin specific 
antibody. This represents up regulation of the elastin synthesis pathway 
possibly with increased up regulation of lysyl oxidase and TGF production. 
Concomitantly the aortic wall histomorphometric analysis reveals a decrease 
in inflammatory cell infiltration in AmiR29b inhibited wall is decreased 
compared to controls. The number of T lymphocytes (CD3+), natural killer 
cells (NCAM1) and macrophages (Mac2) were down regulated in the 
antagomir group. 
 
Lysyl oxidase is responsible for catalysing an oxidative de-amination of lysine 
and hydroxylysine residues to peptidyl a-aminoadipic-semialdehydes in aortic 
wall. These highly reactive semialdehydes can spontaneously condense to 
form intra- and intermolecular covalent bonds that assure ECM stability 502. 
Additionally lysyl oxidase has been demonstrated to suppress secretion of 
MCP-1 in cultured VSMCs 503,504. In murine models of aneurysms enhanced 
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lysyl oxidase activity has demonstrated decreased macrophage infiltration 
and aneurysm progression 502. Furthermore inactivation of the lysyl oxidase 
gene LOX leads to aortic aneurysms, cardiovascular dysfunction and perinatal 
death in mice 172. Hence the up regulation of LOX expression in miR29b 
inhibited group in our aneurysm co-culture system demonstrates a protective 
phenotype in VSMCs. Similarly in the normal aortic co-cultured lymphocytes 
with VSMCs there is a marked up regulation of TGF gene expression. TGF 
has been shown to increases LOX expression activity in the VSMCs 115,505. 
TGF concomitantly increases collagen synthesis in VSMCs and known to 
enhance peptidoglycan and fibronectin production in rat aortic models 494.  
 
TGF activity protects against inflammatory aortic aneurysm progression and 
complications in the ApoE-/-ATII infusion model 113. Treatment with TGF1, a 
known regulator of miR29b expression and a profibrotic stimulant, has been 
reported to significantly decrease miR29b expression in human aortic 
adventitial fibroblasts but not in human aortic smooth muscle cell lines 432,507. 
Function of TGF in aortic aneurysm formation remains controversial. 
Hyperactive signaling of TGF is associated with Marfans syndrome and has 
been shown to stimulate multiple signaling molecules including Smad2/3, 
RhoA and MAP kinases in FBN1 mutant mice 508. However, other studies 
suggest TGF- has a protective role in aortic aneurysms. Neutralization of 
TGF prevents the resistance of normocholesterolemic C57BL/6 mice to 
angiotensin-II induced aneurysm formation 113. Increased TGF by 
endovascular gene delivery in rats has been associated with diameter 
stabilization, decreased inflammatory infiltration, reduced MMP-2 and MMP-









miR29b has been shown to down regulate TGF in aneurysms. AmiR29b can 
be protective by regulating VSMC targeted TGF expression. We demonstrate 
augmentation of TGF gene expression following miR29b inhibition 
supporting its protective role in aortic aneurysm development by altering 
VSMC phenotype to elastosythetic type. In the aneurysm group the addition 
of a miR29b inhibitor reversed the pattern of gene expression across all genes 
investigated, with the exception of Cttk, which was upregulated compared to 
the control. In vivo administration of the AmiR29b decreased expression of 
miR29b and increased expression of its target genes: LOX. AmiR29b can 
increase synthesis of ECM synthesis genes to leading to positive aortic 
remodelling response, stabilize aneurysm lesions and prevent aortic 
dilatation and rupture.  
 
MiR29 in human thoracic aortic aneurysmal disease is up regulated 417, 
whereas in a small group of abdominal aortic aneurysm patients there is a 
decrease in miR29b expression 504,505. Other authors have found no difference 
in the expression of miR29b in thoracic aneurysms 509, however they describe 
a drop in miR29a levels compared with controls. The likely explanation of 
such variations in the results is highly anatomically specific differences 
between sites in the aortovascular tree. Hence we specifically and accurately 
removed the suprarenal aortic aneurysm section and divided any normal 




There were no aneurysms with thrombus in our samples from the miR29b 
groups or substantial atherosclerotic plaques as the aneurysms were away 
from the major aortovascular branch points at which traditionally plaques are 
described in this model 262. Inhibition of miR29a alters ELN expression in 
different human cells 510 and our work using ESMA in vivo, 
histomorphometric assessment of aortic tissue, genomic and proteomic 
alteration of targets and in-vitro co-culture studies support this supposition.  
 
The cardiac manifestations of AmiR29b with reduction in LVES and LVED 
dimensions might be the result of regulation of cardiomyocyte fibrosis with 
augmentation caused by ATII induced BP changes 511. Cardiac fibroblasts 
communicate in a paracrine manner with the myocytes allowing modulation 
of ECM and cell-cell interactions 512. MiR29b suppresses the expression level 
of collagens and ECM proteins and is normally down regulated in myocardial 
infraction and cardiac disease models of LV hypertrophy, contributing to scar 
formation and cardiac fibrosis 442,474,499. Treatment with AmiR29b could, 
therefore, result in increased production of collagens in the myocardium to 




In this study we report decreased miR195 in vivo, but no effects on aortic 
phenotype in the ApoE-/-ATII model of aneurysms. MiR195 is a member of the 
miR15 family and as such ubiquitously expressed miR with and highly 
conserved seed region. This implies overlap in the miR targets between 
different members of the family 512. miR195 plays a critical role in the cell 
cycle with active post-transcription changes to proliferation and apoptosis 
previously reported. miR195 can regulate WEE1, CDK6, Sirt1 and Bcl2 
expression 502-505. Within the cardiovascular system miR195 is upregulated in 
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the heart after transverse aortic constriction or expression of activated 
calcineurin. miR195 overactive and expression leads to cardiomyocyte 
hypertrophy and heart failure in transgenic animals 474. Embryonic forced 
expression of miR195 lead to ventricular hypoplasia and ventricular septal 
defects 517,518. This was due to cell cycle arrest in the development of βmyosin 
heavy chain 517,518. Chek1 as a direct regulator of mitosis was identified to be 
under the control of miR195 517,518. miR195 have been shown to effect ECM 
deposition 519. There was a decrease in damage to renal mesangial cells with 
decreased apoptosis in early diabetic renal injury in mice when miR195 was 
inhibited 520. Inverse association between miR195 expression and INFβ 
induced hepatic fibrosis has been reported 479. Prior to our study the role of 
miR195 within the vasculature was not known.  We have demonstrated that 
AmiR29b is far more effective than AmiR195 in reducing aortic diameter, 
volume and mortality from aortic aneurysms. There are increases in the 
vessel wall elastin content earlier on with AmiR195 but by day 15, these 
changes are reversed. Consistent with the in vivo data, the in vitro data 
suggests that AmiR19b has a more robust effect on ECM deposition by VSMCs 
than AmiR195. These apparent differences for AmiR29b might be due to its 
protective effects on the aortic wall in addition to the effects on elastin 
homeostasis, namely the effects on TGFβ and other ECM proteins such as 
collagen. 
 
Future work needs to focus on the mechanism of miR29b-mediated effects 
on VSMCs through expression changes in LOX and TGFβ activity. Analysis of 
the other ECM components and how these might be affected by AmiR29b to 




Chapter 7: The effect of immune cells on vascular 
smooth muscle cell phenotype 
 
7.1 Introduction 
The functional imaging data from the 18F-FDG and ESMA in vivo studies has 
shown that lymphocytes infiltrate the aneurysm wall in large numbers and 
that these may act locally to affect the capacity of vascular smooth muscle 
cells (VSMCs) to regulate the turnover of ECM proteins such as elastin that is 
vital for aortic wall integrity.  
 
i)  Lymphocyte infiltration - The presence of T- and B-cells in the 
aneurysm wall suggests they can directly alter VSMC viability, proliferation 
and synthetic ability 138,428,521. The immune composition of the aortic wall is 
dynamic and changing. The predominant immune cell types within the aorta 
are CD3+ T-cells and CD20+ B-cells with fewer CD68+ macrophages520,521. 
 
When T-cell function is assessed using intracellular staining and flow 
cytometry, 15.7% of T-cells are shown able to progress to the proliferative 
phase of the cell cycle. T-cells also differentiate down the CD4+Th1 phenotype 
characterized by the production of TNF-α and IFN-γ, variable amounts of IL-5 
and IL-6 and no production of the Th2-type cytokines IL-4 or IL-10. In human 
studies, T-cells produce IFN-γ, in pro-inflammatory states, with these effects 
predominating over IL-4, reflecting a Th1 cytokine response 110,138. 
Quantitative RT-PCR has shown increased IFN-γ transcript levels in the aorta 
compared with IL-2 and IL-4110,138. However advanced human aneurysms 
have also been shown to be associated with Th2 expression with IL-4 and IL-
10 levels increasing522. As these cytokines inhibit the macrophage expression 
of MMP9, they may have a role in protecting the aorta from degradation. 
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There is currently no evidence that Th17 or T-regulatory cells (T-regs) are 
present in the aortic wall and if present what their role would be (potentially 
for dampening the pro-inflammatory response and leading to a more 
protective remodelling phenotype). Our work has suggested the presence of 
activated T-cells, memory T-cells and T-reg cells in the aneurysm compared to 
an absence of these cells in the normal aortic walI. It is intriguing to 
investigate which T-cell phenotype(s) predominate and a possible role for 
these cells in the expansion of the aortic wall. 
B-cells infiltrating the wall of aortic aneurysms and express immunoglobulin 
heavy chains123. The ratio of tissue resident CD19+ B-cells compared to 
peripherally circulating CD19+ B-cells was greater in human AAA patients96. 
On phenotyping the surface expression of light chain, kappa+ and lambda+ 
with k/ ratio was maintained in patients AAA and peripheral circulation96. 
The isotype of surface Ig expressed by infiltrating B cells is different from 
circulating B cells with fewer B cells expressing IgD+IgM+ phenotype; if not 
the secretory phenotype there might be other populations present in tissue. 
 
The antigenic triggers that stimulate these cells to enter the aortic wall, and 
remain there, are unknown. We have demonstrated that memory B-cells, 
synthetically active B-cells (producing IgM/IgD and a specialised subset of B-
regs are present in the aneurysm wall). These cells are absent in the normal 
aortic wall. The B-regs are known to interact and modulate T-cell activity and 
expression368,523, but the biological role of these B-cells in the aortic wall 
remains unclear. 
 
ii) VSMC activity – These cells are the key biological determinants of aortic 
wall function and its metabolic activity. When compared with normal aortic 
wall, aneurysm derived VSMCs produce a higher level of MMP2 and MM9524-
526. This may contribute to ECM degeneration and aortic wall weakness. It is 
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not known why this occurs527. The effect of immune cells on VSMC activity 
and has not yet been elucidated.  
 
VSMCs are responsible for aortic wall ECM maintenance, with a continuous 
low-level production of tropoelastin (that is cross-linked by lysyl oxidase to 
form elastin) and separate pathways to form collagen400,408,440. During in-vitro 
studies with decellularised porcine aortas seeded with macrophages and 
lymphocytes, the induced pro-inflammatory changes are reversed by seeding 
the decellularised porcine xenografts with healthy VSMCs, thus preventing 
aneurysm development108. VSMCs repair aortic wall damage through 
increased proliferation, migration and gene expression for ECM proteins, 
partly through elastosynthetic enzyme systems515,516. During the late stages 
of aneurysm development there is increased apoptosis of VSMCs with loss of 
the repair mechanisms to maintain ECM in the aortic wall528. There is an 
increased expression of p53 and p21 in the aortic aneurysm wall and this 
correlates to decreased levels of VSMCs and ECM content529,530. VSMCs have 
a key regulatory role in maintain aortic wall ECM homeostasis. 
 
TGF seems to be a key regulatory of VSMC behaviour. Increased TGF 
signaling is associated with aortic aneurysms in Marfans syndrome as already 
discussed in Chapter 1. It is worth noting again that TGF-β antagonists such as 
the angiotensin II type 1 receptor blocker, losartan prevents aortic root 
dilatation in fibrillin-1 mutant mice508,509. TGF1 is able to inhibit VSMC 
proliferation and induce apoptosis by arresting the cells in G1 phase of the 
cell cycle532. Increased TGF expression is associated with increased VSMC 
density at regions of aortic dilatation with an increased VSMC TUNEL staining, 
decreased Ki67+ staining and decreased cell proliferation508. There are some 
studies that however suggest TGF expression can confer a protective 
phenotype against inflammatory aortic aneurysm disease113. Neutralization of 
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TGF prevents the resistance of normocholesterolemic C57BL/6 mice to ATII 
induced aneurysms113. Anti-TNF antibody enhanced monocyte activity and 
MMP12 activity and levels leading to aneurysm progression46,84,113,234. There 
was no affect on aneurysm progression by IL4, IL6, TNF, IFN inhibition but 
genetic deletion of T-and B-cells results in partial protection to development 
of aneurysms113. The lymphocyte interaction with VSMCs and TGF signaling 




The aims of this part of the study were to determine the effect of 
lymphocytes isolated from normal and aneurysmal human and murine wall 
on VSMC activity.  
 
1) Isolate CD3+ T-cells and CD19+ B-cells from human and murine aortic 
aneurysm tissue and normal aortic wall 
 
2) Develop an in vitro co-culture system with VSMCs and tissue-derived 
lymphocytes to study the affect of lymphocyte populations on 
human and murine VSMC proliferation, viability and synthetic 
capacity 
 
3) Determine the alteration of the immune cell phenotype when 








A schematic diagram of the experimental layout below to summarise the 
techniques used to study the interaction between lymphocytes and VSMCs. 
 
Fig 7.0 Experimental layouts for studying the interaction between tissue-derived 
lymphocytes on VSMC genotype and phenotype 
The CD3+ T lymphocytes and CD19+ B lymphocytes isolated from normal and aneurysmal 
murine and human aortic wall were co-cultured with VSMCs for 5days. Thereafter the VSMCs 
were analysed for proliferative capacity, viability and synthetic activity. VSMCs were also 
assessed for their extracellular matrix remodeling capacity using RTPCR and ELISA. VSMC 












































7.3.1 Human aortic samples 
Aortic aneurysm samples were collected from patients undergoing elective 
surgical repair (n=5). Three were thoracic aortic aneurysms and two 
abdominal aortic aneurysms. Normal aged and sex matched control aortic 
biopsy specimens were collected from patients undergoing other cardiac 
operations such as coronary artery bypass surgery where the ascending the 
aorta was exposed and clamped allowing tissue biopsy to be taken (n=9). The 
tissue collection was under the ethics protocol as described previously in 
section 3.3.1, page 101.  
 
7.3.2 Murine ApoE-/--ATII infusion model of aortic aneurysms 
This was carried out as described in section 4.3.1 on page 147. 
 
7.3.3 Lymphocyte extraction 
7.3.3.1 Human aortic wall processing 
Aortic biopsies were transferred in cold 0.9% saline and processed within 1hr 
of harvesting. The aortic wall was thoroughly washed in cold PBS to remove 
all blood contamination. The EC layer was scrapped off with a scalpel and the 
aorta finely sectioned manually. Approximately 4g of tissue was incubated in 
15mls of PBS containing 0.5%BSA and 1mM EDTA with 1 mg/ml collagenase 
D, 100 units/ml DNAase I and 500 units/ml hyaluronidase IV-S at 37C for 
30mins. Samples were filtered through a 100μm cell strainer, washed x2 at 
450g in PBS and pelleted. The final resuspension in PBS was incubated with 
100μl of Annexin V microbeads (dead cell removal) for 15mins at room 
temperature (Miltenyi Biotec, Bergisch Gladbach, Germany). Annexin V 
microbeads bound phosphatidylserine on the outer-membrane of dead cells. 
The cell/bead suspension was applied to a MACS MS column (Miltenyi Biotec) 
placed in the magnetic field of a magnetic bead separator (Miltenyi Biotec), 
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and the effluent collected as a live cell fraction. Live cells were pelleted, re-
suspended in 80μl of wash buffer (PBS supplemented with 1% BSA and 2mM 
EDTA) and incubated with CD3ε Biotin (10μl per 107 total cells) (Miltenyi 
Biotec) for 15mins at 4°C. Cells were washed with wash buffer, pelleted and 
re-suspended in anti-biotin microbeads (20μl per 107 total cells) (Miltenyi 
Biotec) and incubated for 15mins at 4°C. The cell suspension was applied to a 
MACS MS column and unbound cells washed away with wash buffer. CD3+ 
cells were collected from the column using a plunger. The remaining unbound 
cells were pelleted, re-suspended in 90μl of buffer and incubated with CD19+ 
microbeads (10μl per 107 total cells) (Miltenyi Biotec) for 15mins at 4°C. 
CD19+ cells were collected as above. Cells were counted using a 
haemocytometer and viability determined using trypan blue. The purity of 
CD3+ and CD19+ lymphocyte populations was determined by CD3+ and CD19+ 
staining using flow cytometry. 
 
7.3.3.2 Murine aortic harvest 
This was done as outlined in section 4.3.4 on page 149. Prior to processing 
the aortic wall was washed additionally with PBS and excess connective tissue 
and periaortic fat was meticulously dissected away using an operating 
microscope (Leica Microsystems ltd, UK). The endothelial cell layer was 
scraped off after the aorta was opened longitudinally and the aorta digested 
as previously described in section 4.3.5 on page 149. Thereafter the extracted 
cells in suspension were treated in the same manner as human cells. 20μl anti 
human CD3+, CD19+ beads were used (Miltenyi Biotec, Bergisch Gladbach, 
Germany). The purity of CD3+ and CD19+ lymphocytes was determined by 





7.3.4 Flow cytometry 
Cells were centrifuged at 300g for 10mins and re-suspended in FACS buffer 
(PBS, 1%BSA, 2mM EDTA) and incubated in FcR block (Miltenyi Biotec) for 
15mins at 4C. Staining was performed with the following primary antibodies: 
Table 7.0 Primary flow cytometric antibodies for immune cell typing 





Fluorophores Concentration Code 
Leukocyte CD45 PE 0.25 µg/ml 553081 
T-cell CD3 PE-Cy7 0.1 µg/ml 552774 
B-cell CD19 APC 0.25 µg/ml 550992 
Monocyte CD16 APC-647  5 µg/ml 558636 
Human 
Leukocyte CD45 APC-H7 3µg/ml 560178 
T-cell CD3 FITC 15µg/ml 555339 
B-cell CD19 PeCy7 6µg/ml 557835 
Monocyte CD16 PE  5 µg/ml 555407 
 
Flow cytometric sample processing and analysis was carried out using the 
Canto II as described previously in sections 3.3.4, 3.3.6, pages 103 and 106. 
 
7.3.5 In-vitro co-culture studies 
Human mature aortic VSMCs (obtained and maintained after removal and 
cultured from patients donated aortae) were plated at passage 5 and human 
umbilical arterial VSMCs plated at passage 11 (Cell Biologics, Chicago IL, USA), 
and grown in DMEM (1g/l D-glucose, containing 10% FCS, 1% streptomycin, 
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1% penicillin and 5% L-glutamine). Murine VSMCs were used at passage 5  
(Cell Biologics, Chicago IL, USA) and grown in DMEM (1g/l D-glucose, 
containing 10% FCS, 1% streptomycin, penicillin and L-glutamine). All VSMCs 
were plated at 2x104 in 12 well adherent plates (Greiner Bio-one, UK) and 
incubated for 24hrs at 37C, 5% CO2 prior to the co-culture. Lymphocytes 
were cultured in 0.4m cell culture inserts (Greiner Bio-one, UK) with RPMI 
medium (supplemented with 10% FCS, 1% streptomycin, 1% penicillin and 5% 
L-glutamine). Lymphocyte populations were co-cultured with VSMCs as CD3+ 
T-cells, CD19+ B-cells or a combination of CD3+CD19+ T and B-cells. Control 
VSMCs wells were grown without lymphocyte co-culture (Standard errors 
were obtained from n=6 experiments). The cells were incubated for 5days. All 
experiments were terminated on day 5 to carryout the various analyses. The 
plating densities are given in Table 7.1.  
Table 7.1 VSMC plating density 
Murine 
Cell Marker Tissue Number 
T-cells CD3+ Normal aorta 5.3x105 6.2x104 
B-cells CD19+ Normal aorta 2.4x105 2.3x104 
T-cells CD3+ Aneurysm 5.5x105 1.4x105 
B-cells CD19+ Aneurysm 3.9x105 4.8x104 
T and B-cells CD3+CD19+ Aneurysm 1.6x105 3.6x105 
Human 
T-cells CD3+ Normal aorta 1.14x1062.9x105 
B-cells CD19+ Normal aorta 5.5861.9x105 
T-cells CD3+ Aneurysm 1.17x1065.4x105 
B-cells CD19+ Aneurysm 1.34x1065.9x105 
T and B-cells CD3+CD19+ Aneurysm 1.9x106 3.6x105 
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7.3.6 Assessing cellular proliferation and viability 
7.3.6.1 5-Ethynyl-2-deoxyuridine (EdU) and propidium iodide 
assay 
The VSMCs were plated on collagen coated 24-well coverslips (Sigma-Aldrich, 
Poole, UK). 5000 cells were co-cultured per well with the lymphocyte 
densities mentioned above. The VSMCs were incubated with 10μm EdU 
(Click-iT EdU Imaging Kit, Invitrogen, UK) 48hrs later. 5 days after the initial 
plating the cells were fixed in 4% paraformaldehyde (appendix 3, page 347) 
for 15mins. The cells were subsequently washed with PBS (3% BSA) and 
permeabilised in PBS (0.1% Triton X-100) for 20mins. Cells were washed again 
in PBS (3% BSA) and incubated in 100μl/well Click-iT reaction cocktail (1x 
click-it reaction buffer, CuSO4, Alexa Fluor azide, reaction buffer additive) for 
30mins at room temperature. Final wash with PBS (3%BSA) was performed 
and coverslips were mounted to glass slides using vectashield-mounting 
medium with DAPI (Vector Labs CA) containing 50μg/ml propidium iodide (BD 
Biosciences). Light microscope (Leitz, Leica, UK) was used with a microscope-
mounted camera (Coolpix, Nikon, UK) along EXi Blue (QImaging), to capture 
light microscope and fluorescent images. Analysis of captured images was 
performed using Pro Plus software (Media Cybernetrics, USA) and Image J as 
described previously 532,533. Proliferating cells were calculated as number of 
EdU stained cells/DAPI stained cells expressed as a percentage. 
 
7.3.7 Gene analysis 
7.3.7.1 RNA extraction 
RNA was extracted using the RNAeasy MicroKit (Qiagen, Valencia, CA). Cell 
culture media was removed on day 5 and 700l of QIAzol lysis reagent added. 
Lysate was vortexed for 1min to homogenize the cells and 140l of 
chloroform was added to the homogenate, with centrifugation for 12,000g at 
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4C for 15mins. Upper aqueous phase was transferred to a new collection 
tube and 525l of 100% ethanol was added and transferred to an RNeasy 
MinElute spin column before centrifugation at 800g at room temperature for 
15mins. The flow through was removed and discarded. The above steps were 
repeated after adding 700l of buffer RWT, 500l of RPE and 500l of 80% 
ethanol independently. The column was placed in a new 2ml collection tube 
and centrifuged at full speed for 5mins. 14l of RNase-free water was added 
to the center of the spin column and centrifuged at full speed for 1min to 
elute the RNA. RNA concentration was measured using a Nanodrop and the 
samples stored at -20C.  
 
7.3.7.2 cDNA synthesis 
RNA was synthesized to cDNA using a high capacity RNA-to-CDNA kit (Applied 
Biosystems, Foster City, CA). All the RNA samples were normalised to the 
lowest concentration; murine VSMC normalised to 13.3ng/ml, human VSMC 
normalised to 15.8ng/ml. 2X reverse transcriptase buffer and 20x enzyme mix 
was added to each sample and the volume made up to 20l using nuclease-
free water. The plate was centrifuged and incubated at 37C for 60mins. The 
reaction was stopped by heating to 95 C for 5mins and cooling to 4C.  
7.3.7.3 RT-PCR 
Each sample was diluted 1:60 with nuclease free water. A further 10 fold 
dilution series was carried out to produce 1:10, 1:100: 1:1000 dilutions of 
each sample. A nuclease free water negative control was also used. All 
samples were further diluted 1:5 with nuclease free water to produce enough 
cDNA for analysis of 10 genes. cDNA was transferred to a 96 well plate 
(5l/well) for each gene to be analyzed. 1030l of Taqman Fast Advanced 
Mastermix (Invitrogen) and 700l of nuclease free water was added to 100l 
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of assay gene/housekeeping gene (Invitrogen). An automated robotic system 
(Beckman Coulter) was used to transfer 50l/well of mastermix to the cDNA 
samples. Samples from the 96-well-plates were then scaled up to a 384 well 
plate to make 4 replicates of each sample. The plate was run on the RT-PCR 
system (7900HT Fast Real Time PCR system Applied Biosystems) and data 
acquired using SDS (Invitrogen, UK) The data was analysed using DataAssist 
software v3.01. The cT values of each sample were normalized to the 
housekeeping genes and then expressed as fold changes relative to the 
control samples of each experiment using DataAssist™ software v3.1 
(Invitrogen, UK). The average fold change was calculated and logged to allow 
an interpretation of gene regulation.    
 
7.3.8 Assessment of VSMC synthetic ability 
7.3.8.1 Immunofluroscence microscopy 
5000 VSMCs/well were plated onto collagen coated 24-well coverslips and co-
cultured with lymphocytes as previously described in section 7.3.6. Cells were 
fixed in 4% paraformaldehyde for 10mins, washed x1 in PBS and 
permeabilised in PBS (0.1% Triton X-100) for 3mins. The cells were placed for 
45mins in protein block (Dako, Cambridgeshire, UK). The cells were incubated 
with the primary antibodies (Table 7.2) at room temperature for 1hr, 
followed by 2 washes in PBS for 5min and incubation in secondary antibodies 








Table 7.2 Primary immunofluorescence antibodies 
Primary 
Antibody 






Tropoelastin  Rabbit 1l/ml Ab21600 Abcam, MA 
Anti-α-actin  -smooth 
muscle actin 
Mouse 1l/ml C6198 Sigma, UK 
 
Table 7.3 Secondary immunofluorescence antibodies 
Secondary 
Antibody 














The cells were washed in PBS x1 and coverslips mounted onto glass slides 
with vectashield mounting medium with DAPI (Vector Labs, CA). Slides were 
imaged on a Leica Leitz DMRB fluorescent microscope. Sequential images 
were taken of the complete cover slip with atleast 5 quadrants covered per 




Elastin levels were measured using an elastin (ELN) ELISA Kit (USCN Life 
Science Inc, China). VSMCs were cultured at a density of 2x104 and co-
cultured with lymphocytes as described previously in section 7.3.5, page 279. 
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At day 5 the cells were lysed with RIPA lysis buffer (ThermoFisher Scientific) 
containing protease inhibitor 100ul-200l. The standard stock solution of 
120ng/ml was diluted to 30ng/ml with standard diluent and a double dilution 
series performed to produce standards ranging from 0.47 to 30ng/ml along 
with a blank standard at 0g/ml all at 100l. Standards, blank and samples 
were added to the ELISA plate in duplicate and incubated at 37C for 2hrs. 
The solution was removed, and the plate washed 5x with PBS of Detection 
Reagent A (100l) was added and the plate incubated at 37C for 1hr. The 
solution was removed, wells washed x3 with PBS and 100l of Detection 
Reagent B added and incubated at 37C for 30mins. Wells were washed x5 in 
PBS and 90l of substrate solution added and incubated for 25mins at room 
temperature. The reaction was stopped on addition of 50l of Stop Solution. 
The optical density of the solution in each well was measured on microplate 
reader (SpectraMax, Molecular Devices, USA) at 450nm.  
 
7.3.9 Cytokine bead array (CBA) for cell signaling 
This was carried out as previously described in section 6.3.9.5, page 235.  
 
7.3.10 Statistical analysis 
All results were normalised to the control group, which had no lymphocyte 
co-cultures. A Kolmogorov-Simonov test was used to test for normality. Data 
was analysed using SPSSv21 (IBM Inc, US). Graphpad Prism 5 has been used 
for selective graphical analysis. Data is presented as mean and standard error 
of the mean (SEM) or standard deviations (SD) when specified. Paired 
student’s t-test was used when comparing parametric data. Non-parametric 
data was analysed using a Mann Whitney U test. For multiple variables a two-
way ANOVA with post-hoc Bonferroni or Newman-Keuls correction was used. 
An alpha value of 0.05 was considered significant. 
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7.4 Results 
7.4.1 Human  
7.4.1.1 Aortic aneurysm formation 
Three thoracic aortic aneurysms and two abdominal aortic aneurysms from 
patients undergoing elective surgical repair were obtained (n=5). Normal 
aged and sex matched control aortic biopsy specimens were collected from 
patients undergoing other cardiac operations (Table 7.4). There were no 
differences in the demographics between the thoracic and abdominal aortic 
aneurysm patients, with patients presenting with degenerate aortic 
aneruysms. 
 






7.4.1.2 Verification and quantification of lymphocyte 
phenotypes(s) isolated from normal and aneurysmal wall 
98.5% of live cells eluted from the T-cell column were CD3+ (Fig 7.1) and 98% 
of live cells eluted from the B-cell column were CD19+ (Fig 7.2). All the cells 
isolated from the normal human aortic wall were CD45+ (leukocytes), but 






Age 66 68 ns 
Sex 4M:1F 7M:2F ns 
Hypertension 5 7 ns 
Smoking 4 7 ns 
Hyperlipidemia 5 9 ns 
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Fig 7.1 Flow cytometric analysis of T-cells isolated from normal human aortic wall by 
anti-CD3 linked magnetic beads 
A) The cells population gated on forward and side scatter properties, clear population to gate 
on seen B) Doublet exclusion performed C) Gating on CD3+ T lymphocytes that are extracted 
as a clean discrete population. D) The sample was stained and was negative for B-cell marker 
CD19+ E) The cells in this population all stained positive for CD45+ hence belonged to 
leukocyte fraction. F) The cells stained negative for CD16- demonstrating absence of 
monocytic lineage. (98.5% of CD3+ cells were live with 12x103 ±8.5 x103 cells/mg tissue, N=4, 




Fig 7.2 Flow cytometric analysis of B-cells isolated from normal human aortic wall by 
anti-CD19 linked magnetic beads 
A) The cells population gated on forward and side scatter properties, clear population to gate 
on seen B) Doublet exclusion performed C) Gating on CD19+ B lymphocytes that were 
extracted as a clean discrete population. D) The sample was stained and was negative for T-
cell marker CD3-. E) The cells in this population all stained positive for CD45+ hence belonged 
to leukocyte fraction. F) The cells stained negative for CD16- demonstrating absence of 
monocytic lineage. (97% of CD19+ cells were alive with 16x103±5.8 x103 cells/mg tissue, N=4, 
20 biopsy sites analysed). 
 
 
Flow cytometric analysis was carried out for CD3+CD19+ population and 98.5% 
of CD3+ and 96% of CD19+ cells were alive with 12-20x103cells/mg tissue. The 
cells were CD45+, CD16- (Fig 7.3). Annexin V bead separation of cells was 
performed and samples were run on the flow cytometer with and without 
Annexin V beads. This demonstrated a clear distinct difference in the 





Fig 7.3 Flow cytometric analysis of B and T lymphocytes isolated from human aortic 
aneurysm wall by antibody-coated magnetic bead separation  
A) The cells population gated on forward and side scatter properties, clear population to gate 
on seen B) Doublet exclusion performed C) Gating on CD19+ B lymphocytes that are extracted 
as a clean discrete population. D) The sample was then gated for CD3+ T lymphocytes. E) The 
cells in this population all stained positive for CD45+ hence belonged to leukocyte fraction. F) 
The cells stained negative for CD16- demonstrating absence of monocytic lineage. (98.5% of 





Fig 7.4 Representative flow cytometric analysis of anti-annexin V magnetic bead 
separated B and T lymphocytes 
A) Pre and B) Post anti Annexin V bead extraction complete cell population on forward and 
side scatter properties. C) Doublet gating exclusion strategy D) clear CD19+ B lymphocyte E) 
CD3+ T lymphocyte populations extracted for human aortic aneurysm biopsy site.  
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7.4.1.3 Co-culture of VSMCs and lymphocyte 
VSMC lymphocyte culture was set up as described with the pating densities 
and cell numbers. The final ratio of incubation for VSMC: T-cells was 1:50; 
VSMC: B-cells 1:10 and VSMC:T-B-cell 1:60. Lymphocyte viability was >96% in 
all experiments. The VSMCs were morphologically typical on light microscopy. 
There were no phenotypical differences between the groups on visual 
inspection at day 5 or when compared to the controls.   
 
7.4.1.4 Proliferation/Viability 
7.4.1.4.1 Assessment of VSMC proliferation  
Fluorescent images show EdU staining of human vSMCs co-cultured with 
CD3+, CD19+ or CD3+/CD19+ lymphocytes isolated from aneurysm tissue (Fig 
7.5).   
 
Fig 7.5 Proliferation of human VSMCs co-cultured with lymphocytes isolated from aortic 
aneurysm tissue 
A) VSMCs co-cultured with CD3+ T-cells B) VSMCs co-cultured with CD19+ B-cells C) VSMCs co-
cultured with T- and B-cells D) VSMCs alone. Images are representative of 3 independent 
experiments n=5, 20 isolates. Scale bar 10μm. 
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VSMC proliferation was higher when cells were co-cultured with lymphocytes 
from aneurysm aorta than normal aortic lymphocytes. All aneurysm 
lymphocyte subtype populations increased VSMC proliferation compared to 
the normal group (Fig 7.6). The results were not statistically significant 
despite showing a higher trend. The cell proliferation counts are normalized 
to control samples of VSMC wells. 
 
 
Fig 7.6 Percentage of proliferating human VSMCs co-cultured with lymphocytes isolated 
from aneurysm and normal aortic wall 
Percentage of proliferating human VSMCs co-cultured with CD3+, CD19+ or CD3+/CD19+ 
lymphocytes. 3 independent experiments (n=5, 20 isolates) 
 
7.4.1.4.2 Cell death - propidium iodide (PI) staining 
Staining with PI (Fig 7.7) revealed that co-culture with lymphocytes regardless 
of sub-type resulted up to 30% death of human VSMCs. This applied to co-
cultures with lymphocytes isolated from both aneurysm and normal tissue. 
There were no differences between the groups in the percentage of dead 














































Fig 7.7 Representative micrographs of PI staining to show cell death of human VSMCs 
after co-culture with aortic wall derived lymphocytes  
A) VSMCs co-cultured with CD3+ T-cells B) VSMCs co-cultured with CD19+ B-cells C) VSMCs co-
cultured with T and B-cells D) VSMCs alone. Images are representative of two independent 
experiments n=5, 20 isolates.  Scale bar 10m.  
 
Fig 7.8 Percentage of dead human VSMCs following co-culture with lymphocytes 
isolated from aneurysm and normal aortic wall. 










































l)% Cell death 
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7.4.1.5 Synthetic ability 
7.4.1.5.1 Assessment of tropoelastin staining in VSMCs co-
cultured with CD3+, CD19+ or CD3+/CD19+ lymphocytes  
There was no apparent difference in VSMC tropoelastin staining (intensity or 
numbers of cells) between cells co-cultured with the different lymphocyte 
sub-populations in either the normal or aneurysmal wall (Fig 7.9) groups. 
 
 
Fig 7.9 Representative immunostaining for tropoelastin at 5 days in human VSMCs co-
cultured with aortic aneurysm lymphocyte populations 
A) VSMCs co-cultured with CD3+ T-cells B) VSMCs co-cultured with CD19+ B-cells C) VSMCs co-
cultured with T and B-cells D) VSMCs alone. Images are representative of 3 independent 
experiments with 6 co-culture experiments, n=5, 24 isoaltes. Scale bar 10μm. 
 
For each experiement a negative control isotype to the primary antipbody 
was used. (Fig 7.10). 
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 Fig 7.10 IgG anti-rabbit negative control. A) DAPI B) FITC C) Merge. Scale bar 10μm 
 
 All cells expressed alpha-actin, verifying their smooth muscle phenotype (Fig 
7.11). 
 
    
Fig 7.11 Tropoelastin and αSMA expression in human vSMCs co-culture with aortic 
aneurysm lymphocytes at 5 days 
Images are representative of three independent experiments where 6 co-culture 
experiments were set-up n=5, 30 isolates. 
 
There was an a greater number of number of tropoelastin expressing VSMCs 
co-cultured across all lymphocyte populations from aneurysmal aorta 
compared with normal aortic wall, P<0.01, Mann-Whitney U test (Fig 7.12). 
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Addition of the CD19+cells to CD3+ cells leads to reduction in the percentage 
of tropoelastin expressing cells (P<0.01). 
 
Fig 7.12 Percentage of tropoelastin expressing human VSMCs co-cultured with lymphocytes 
isolated from aneurysm and normal tissue 
All results normalized to the control group with VSMCs without co-culture set-up. A) Normal 
aorta vs. aortic aneurysm tropoelastin expression B) Percentage of tropoelastin expressing 
vSMCs co-cultured with CD3+, CD19+ or CD3+ and CD19+ lymphocytes.*P<0.01 (n=5, 24 
isolates).  
 
There is upregulation of tropoelastin expression across all lymphocyte 
population co-cultures from the aneurysm wall when compared to the 
normal aortic wall P<0.01, (two way ANOVA, with post hoc Bonferroni 









7.4.1.5.2 Elastin ELISA 
Identical standards and standard curve were applied. Total mean elastin 
content of human VSMCs co-cultured with aneurysm CD3+ lymphocytes was 
1.49±0.20ng/ml, CD19+ lymphocytes 1.51±0.15ng/ml and with CD3+/CD19+ 
lymphocytes, 1.45±0.26ng/ml. There were no static (Fig 7.13; n=5, two-way 
ANOVA, Bonferroni post hoc test, P>0.05). 
 
 
Fig 7.13 Total elastin content of human VSMCs co-cultured with lymphocytes isolated from 
aortic aneurysms 
There were no differences in the elastin content across the different groups P>0.05 n=5 







































7.4.2.1 Aortic aneurysm formation 
ApoE-/- mice were fitted with an osmotic mini pump containing AT II as 
described before (n=24). In this cohort of the model, aneurysms developed in 
75% of the animals by day 28. The normal aorta and aneurysms were 
harvested at this time point. 10% of animals were lost due to aortic aneurysm 
rupture or aortic dissection. 
 
7.4.2.2 Verification of murine lymphocyte phenotypes 
95% of live cells eluted from the T-cell column were CD3+. 96.8% of live cells 
eluted from the B-cell column were CD19+. All the cells isolated from the 
columns stained for CD45+ leukocytes, but CD56-CD16- demonstrating 
absence of natural killer, monocyte/macrophage lineage (Fig 7.14). The 
remaining cell suspension was run to test the efficacy of the magnetic bead 
separation. This was to ensure that minimal cell loss occurred due to the 






Fig 7.14 Normal aortic wall extracted lymphocytes post magnetic bead separation for B 
and T-cells 
A) The cells population gated on forward and side scatter properties, clear population to gate 
on seen B) Doublet exclusion performed C) Gating on CD3+ T lymphocytes that are extracted 
as a discrete population. D) The sample was subsequently gated for CD19+ B-cells that are 
seen as a discrete extracted population. E) The cells in this population all stained positive for 
CD45+ hence belonged to leukocyte fraction. F) The cells stained negative for CD16- 
demonstrating absence of monocytic lineage. G) The cells stained negative for CD56- 
demonstrating absence of NK cells. (95% of CD3+ cells and 97% of B-cells were live, N=6, 12 





Fig 7.15 Flow cytometry of the cell suspension remaining following CD3+ and CD19+ cell 
extraction A) The cells that passed through the selection column are seen to be negative for 
T-cells CD3- and B) B lymphocytes (CD19-). This implies near 100% efficiency of cellular 
extraction from the samples for the CD3+ and CD19+ cells. 
 
7.4.2.3 Co-culture of VSMCs and lymphocyte 
CD3+ T-cells were incubated with VSMC in a ratio of 1:50. CD19+ B-cells were 
incubated with VSMC in a ratio of 1:10 or as T and B-cell combined incubation 
at 1:60. Lymphocyte viability was >96% in all experiments. The cells were 
imaged using light microscopy on the first and last day of the co-culture 
experiment to look at the differences in the VSMC phenotype. Typical VSMC 
shape and morphology was seen across the groups at day 5 with no visual 
differences. Mouse VSMCs were cultured alone as a control sample.  
 
7.4.2.4 Proliferation/Viability 
7.4.2.4.1 Assessment of proliferation  
An EdU assay (Click-iT EdU Imaging Kit, Invitrogen, UK) was used to determine 
the proliferative capacity of the VSMCs. The intensity of fluorescent signal 
determined the proliferation rate (Fig 7.16). Only bright, highly proliferating 
cells were counted as dividing cells.  
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Fig 7.16 Proliferation of mouse VSMCs using the EdU assay 
A) EdU incorporated cells (1μm, 72hrs) were fixed and detected with click reaction using 
AlexaFluor488. B) DNA was counterstained with DAPI. (C) Images were merged using ImageJ, 
to demonstrate nucleated cells expressing the EdU. Scale bar 10μm. 
 
The EdU positive cells were counted as a proportion of the total cell number 
and finally normalized to the control well that only contained the VSMCs, 
thus the cellular proliferation is normalized to background VSMC proliferation 
rate. 
 
VSMC proliferation was greater when cells were co-cultured with 
lymphocytes from aneurysm aorta than normal aortic lymphocytes (Fig 7.17). 
The most pronounced effect was in the CD3+CD19+ group lymphocytes from 















Fig 7.17 Percentage of proliferating mouse VSMCs co-cultured with lymphocytes isolated 
from aneurysmal and normal aorta 
The percentage of proliferating cells was calculated as number of EdU stained cells/DAPI 
stained cells x100 and normalized to the control VSMC wells. Results are from 3 independent 

















7.4.2.4.2 PI staining 
There were no differences between the normal aortic or aneurysm derived 
lymphocyte population in term of the PI staining of VSMCs (Fig 7.18) to 
demonstrate a panel examples of PI staining when lymphocyte co-cultures 






Fig 7.18 Micrographs of propidium iodide (PI) stained murine VSMCs following co-culture 
with 1) normal aortic or 2) aneurysmal wall lymphocyte isolates to assess cell viability 





CD3+	 CD19+	 Both		 Control		
Aneurysm	MVSMC		





CD3+	 CD19+	 Both		 Control		
Normal	MVSMC		
A	 B	 C	 D	
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immediately. A) VSMCs co-cultured with CD3+ T-cells B) VSMCs co-cultured with CD19+ B-cells 
C) VSMCs co-cultured with T and B-cells D) VSMCs alone. Images are representative of two 
independent experiments (isolates from n=6 wall samples from each condition) Bar=10m.  
 
There was a greater VSMC loss when co-cultured with CD3+ and CD3+/CD19+ 
lymphocytes derived from aortic aneurysms compared to VSMCs co-cultured 
with normal aortic lymphocytes (Fig 7.19). VSMCs co-cultured with CD19+ B-
cells had decreased cell death (results were not statistically significant P>0.05, 
Mann-Whitney U test). 
 
Fig 7.19 Cell viability of murine VSMCs following co-culture with lymphocytes isolated 
from aneurysm and normal aortic wall as determined by PI staining 
The percentage of dead was calculated as number of PI stained cells/DAPI stained cells x100. 
Results were normalised to the control group. Data are from 2 independent experiments 








7.4.2.5 Synthetic ability 
7.4.2.5.1 Tropoelastin Staining 
There were no differences in the tropoelastin expression on fluorescent 
imaging of the VSMCs cross the different lymphocyte incubation conditions. 
Fig 7.20 demonstrates a representative staining pattern for cellular staining. 





























Fig 7.20 Tropoelastin and αSMA expression in mouse VSMCs co-cultured with 1) aortic 










 A) VSMCs co-cultured with CD3+ T-cells B) VSMCs co-cultured with CD19+ B-cells C) VSMCs 
co-cultured with T and B-cells D) VSMCs alone. Images are representative of three 
independent experiments n=9, 36 isolates. Scale bar 10μm.  
 
A negative control IgG anti-rabbit antibody secondary was used for each 
experiment alongside staining for tropoelastin and SMA staining (Fig 7.21).  
 
 
Fig 7.21 IgG anti-rabbit negative control for tropoelastin staining 
A) DAPI B) FITC C) Merge. Scale bar 10m 
 
There were increased numbers of tropoelastin expressing VSMCs co-cultured 
with CD19+ B-cells from aneurysm wall compared with normal aorta (Fig 7.31; 
Mann-Whitney U test P<0.001). There was also an increase in the number of 
tropoelastin VSMCs co-cultured with CD3+/CD19+ cells from aneurysm wall 
compared with normal aorta (Fig 7.22; Mann-Whitney U test P<0.01). There 
was no statistically significant difference in the tropoelastin expression of 
VSMCs co-cultured with CD3+ lymphocytes from normal and aneurysm aortic 
wall (Fig 7.22; Mann-Whitney-U P>0.05). Lymphocyte populations from 
normal aortic wall behaved differently from aneurysm wall, where they cause 
a more profound increase in the tropoelastin expression from VSMCs. 
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Fig 7.22 Percentage of tropoelastin expressing mouse VSMCs co-cultured with lymphocytes 
isolated from aneurysm and normal tissue at day 5 
The percentage of tropoelastin expressing cells is expressed as a percentage of the total 
number of SMA+ VMCs. All results normalized to the control group with VSMCs grown 
alone. (n=9, 27 co-culture experiments P<0.01 **P<0.001, Mann- Whitney U test).  
 
7.4.2.5.2 Elastin ELISA 
A typical standard curve plot can be seen in Fig 7.23.  
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Fig 7.23 Standard curve for elastin ELISA 
Total mean elastin content of mouse VSMCs co-cultured with combined 
lymphocyte populations was greater in the aneurysm group than untreated 
controls, but this did not reach statistical significance (Table 7.5, Fig 7.24; 
two-way ANOVA, Bonferroni post hoc test, P<0.08).  
 
Table 7.5 Elastin ELISA results for mouse VSMCs 
Tissue Lymphocyte 
subset  added 
Elastin content 
(ng/ml ±SEM) 
VSMCs alone none 1.56±0.11 
Normal aorta 
 











Fig 7.24 Total elastin content in murine VSMCs co-cultured with normal aortic and aortic 
aneurysm derived lymphocytes 
There was an increase in elastin content in the aneurysm group in all the co-cultured vSMCs 
with lymphocytes. This however, did not reach statistical significance P<0.08 (2-way ANOVA) 
n=6, 24 cell isolates.  
 
7.4.2.6 Gene expression 
Real-time PCR was used as described previously (section 6.3.9.4, page 235) to 
quantify mRNA levels and determine the effect that lymphocyte co-culture 
has on VSMC gene expression. Genes investigated include those regulating 
extracellular matrix turnover - cathepsin S (Ctts), cathepsin K (Cttk), elastin 
(ELN), fibrillin (FBN), lysyl oxidase (LOX), matrix metalloproteinase-2 (MMP-2), 
matrix metalloproteinase-9 (MMP-9) and transforming growth factor-β (TGF-
β). All results were normalized to the housekeeping genes, peptidylprolyl 
isomerase B (PPIB, Cyclophilin B) and 50S ribosomal subunit protein (RPLP0).  
 
The slope of the standard curve indicates PCR efficiency and should be 




































value of the standard curve gives an indication of the quality of the results. A 
value of 0.9 and higher indicates good precision. Analysis of these parameters 
shows the assays for; Ctts, ELN and MMP-9 had poor PCR efficiency and low 
precision and therefore were eliminated from further analysis (appendix 4, 
page 349). The remaining genes had good PCR efficiency and precision 
(appendix 4, page 349). A summary of the slope value and efficiency is 
presented in table 7.6 
 
Table 7.6 RT-PCR efficiency (slope values) and precision (R20 values from the standard 
curves of all assay genes. Ctts, ELN and MMP9 were excluded from further analysis. 
Gene Slope Value  Efficiency  R2 
Cttk -3.42 96.1% 0.99 
Ctts -0.89 1229.2% 0.68 
ELN -1.81 256.9% 0.20 
FBN -3.57 90.6% 0.99 
LOX -3.47 94.2% 0.99 
MMP-2 -3.18 106.3% 0.99 
MMP-9 -2.589 143.4% 0.83 
TGF-B -3.11 109.7% 0.97 
PPIB -3.91 80.2% 0.99 
RPLP0 -2.848 124.5% 0.98 
 
The standard surves for all the genes are given in Appendix 4, page 349. The 
cT value (threshold cycle) represents the intersection between the 
amplification curve and the threshold line. It is a measure of the 
concentration of gene target in the sample (Fig 7.25). The linear portion of 
the curve is the exponential phase of PCR, where the amount of product 
doubles after each cycle (Fig 7.25).  
  Fig 7.25 RT-PCR amplification plots of assay genes that meet the slope efficiency and precision criteria 
The cT value is the intersection between the amplification curve and the threshold reaction. The amount of PCR product doubles after each cycle.  
(A) Cttk K (B) FBN (C) LOX (D) MMP-2 (E) TGF-β.  
A B C 
D E 
Analysis of the different lymphocyte populations derived from the normal 
aorta demonstrated significant down-regulation of TGF expression in VSMCs 
co-cultured with CD3+ cells compared with CD19+ cells (Fig 7.26; two way 
ANOVA, Bonferroni post hoc test P<0.01). There was also significant down-
regulation of TGF expression in the VSMCs co-cultured with CD3+ cells 
compared to CD3+/CD19+ cells (Fig 7.26; two way ANOVA, Bonferroni post 
hoc test P<0.01). There were no significant differences in gene expression of 




Fig 7.26 Gene expression profiling of VSMCs co-cultured with normal aortic wall-derived 
lymphocytes 
Average log-fold differences in gene expression of CttK, FBN, LOX, MMP-2 and TGF- in 
mouse VSMCS co-cultured with CD3+, CD19+ and CD3+/CD19+ lymphocytes from normal aorta 
using real time PCR (RT-PCR) n=9 wall biopsies measured in triplicate (27 co-culture 
conditions, 81 wells), *P<0.01, two way ANOVA, post hoc Bonferroni correction P<0.001.  
 
Analysis of the aneurysm derived lymphocyte populations showed there was 
down-regulation of LOX and TGF expression in the VSMCs co-cultured with 



































post hoc test P<0.01).  There was also significant down-regulation of TGF 
and LOX expression in the VSMCs co-cultured with CD3+ cells compared to 
CD3+/CD19+ cells (Fig 7.27; two way ANOVA, Bonferroni post hoc test P<0.01). 
 
 
Fig 7.27 Gene expression profiling of VSMCs co-cultured with aneurysmal wall-derived 
lymphocyte 
Average log-fold change differences in expression of CttK, FBN, LOX, MMP-2 and TGF- in 
mouse VSMCS co-cultured with CD3+, CD19+ and CD3+/CD19+ lymphocytes from aneurysms. 
Three independent experiments n=9 *P<0.01, two way ANOVA, post hoc Bonferroni 
correction P<0.001.   
 
7.4.2.7 Cytokine Bead Array 
The BD Cytometric Bead Array (CBA) was used to determine the 
concentrations of IL-2, IL-4, IL-6, IFN-γ, TNF-α, IL-17A and IL-10 in the 
conditioned media of mVSMCs co-cultured with lymphocyte populations. All 
results have been normalized to control samples. This would allow Th 
phenotyping of the CD3+CD4+ cells. Amongst the cytokines there was 
upregulation of IL-10, TNF-α, and Il-6. There was significant up-regulation of 
IL-10 (Fig 7.28; two way ANOVA; P<0.001). There was down-regulation of IL-
17a, IFN-γ, IL-4 and IL-2 (Fig 7.28-7.29). IL-10 and IL-6 were the most highly 



































lymphocytes normal aortic tissue. Conditioned media of VSMCs co-cultured 
with lymphocytes from aneurysm aortic tissue had down-regulation of IL-10, 
Il-17a, TNF-α, Il-6 and IL-2 compared to the control. IFN-γ is slightly 
upregulated compared to the control (Fig 7.28-7.29).  
 
 
Fig 7.28 Cytokine bead array for mVSMC conditioned with normal or aneurysm derived B 
and T lymphocytes 
6 independent experiments, 12 co-culture set-ups, n=22. Results are normalised to the 












Fig 7.29 Cytokine expression profiles of VSMCs and lymphocyte co-cultures 
A) IL-10 (B) IL-17a (C) TNF-α (D) IFN-γ (E) IL-6 (F) IL-4 (G) IL-2. Data is from six independent 







































































































































































































































Table 7.7 Cytokine bead array data summary  
 
 
Cytokine Co-culture condition Lymphocytes derived 
from normal Aorta 



































































We studied the in-vitro effects of specific aortic wall derived lymphocytes on 
VSMCs to determine the effects of proliferation, synthetic ability, gene 
expression and cytokine production.  
 
7.5.1 VSMC Proliferation and death 
There was marked increase in proliferation in murine and human VSMCs in 
the lymphocyte group compared with controls. Specifically CD3+ and 
CD3+/CD19+ cells from the aneurysm wall increased the proliferation rate 
most. It could be that the increased proliferation is to compensate for 
increased cell death as PI staining tended to be also higher in this group 
compared to the normal aortic wall derived lymphocyte group. Previous work 
has shown that Ki67 expression and apoptotic markers are higher at the site 
of aortic aneurysms534. It has also been suggested CD3+CD4+ T-cells enhance 
VSMC stability by causing VSMC proliferation when there is cell-cell 
contact535. The mechanism responsible for this effect is unknown but it is 
unaffected by blocking V-Cam, I-CAM or CD40535. The role of p53 in VSMC 
proliferation and regulating the cell cycle checkpoints is thought to play a 
critical role in aortic remodelling534. Overall VSMC density is reduced in upto 
74% in aortic aneurysms compared to normal aortic wall536. Upto a third of 
the cells that are SMA positive are apoptotic536. It has been postulated that 
lymphocytes might causes VSMC death in the aortic wall by mediation 
through death proteins such as Fas ligand and perforin36. Binding of Fas to its 
ligand would lead to the activation of a series of proteases and caspases the 
initiate cell death. Double TUNEL staining of human SMA expressing cells 
has shown that there is increased DNA fragmentation and apoptosis that is 
correlated with cytotoxic T lymphocytes that are thought to produce Fas and 
perforin 36. CD4+ are also able to produce TNF related apoptosis inducing 
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ligand (TRAIL) that can bind and trigger transmembrane proteins with 
activation of death signaling induced pathways. Anti-TRAIL antibodies to 
immunodeficient murine human aorta’s prevents VSMC apoptosis537.  
In contrast to our murine model data the human VSMCs demonstrated less 
cell death in the lymphocyte groups derived from normal and aneurysm 
tissue compared to control VSMCs. This suggests that CD3+ lymphocytes that 
are derived from the aortic wall and not blood confer a protective phenotype 
that promotes cell proliferation and decreased apoptosis. This would be in 
keeping with our earlier subtyping phenotype data that suggests that the 
aortic wall resident CD3+ lymphocytes tend to be the T-regulatory and 
memory phenotype cells that are acting as an anti-inflammatory modulator 
to VSMCs. This is further supported as discussed below when we assess the 
synthetic capacity of the VSMCs. This is increased in the lymphocyte group 
compared to controls.  
 
7.5.2 VSMC synthesis of ECM 
VSMCs are the key mediator of elastogenesis. This is a complex post-
translational extracellular process that begins with tropoelastin formation, 
anchoring into the microfibrillar scaffold. Cross-linking steps with LOX and 
production of an insoluble elastin fibre that is linked to desmosine and 
isodesmosine58,538,539.  Our data shows increase in tropoelastin synthesis in 
the murine CD19+ and CD3+/CD19+ group and in all the human aneurysm 
derived lymphocyte groups compared to controls. There is upto a 50% 
increase in tropoelastin expression in CD3+/CD19+ cell incubated VSMCs. 
Earlier preliminary work in human aneurysm segments showed a five fold 
increase in tropoelastin with increased presence of macrophages along with 
tropoelastin mRNA538. We did not investigate macrophages as a source of the 
tropoelastin in aneurysms we instead have strong evidence to suggest the 
importance of lymphocytes in modulating VSMC behaviour into producing 
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more elastin. It is likely that the presence of macrophages in tissue is a causal 
association as inflammatory processes are ongoing in the aortic wall. Indeed 
when we perform histology in the aortic aneurysm wall there is increased 
Mac2 staining in the regions of the tunica media with specific tropoelastin 
antibody staining. It might be that there is aortic degradation at these sites 
associated with elastin breakdown and there is a corresponding increase in 
tropoelastin synthesis that is mediated through the lymphocytic up-
regulation of VSMC activity. Human lymphocytes are able to express elastin-
laminin receptor, which when activated by elastin peptides triggers the 
release and synthesis of elastases540,541. This ability to modulate tropoelastin 
synthesis in aortic aneurysms is important part of the aortic remodelling 
response. Tropoelastin synthesis has been demonstrated in aortic aneurysms 
using an adenoviral vector transfected into aortic VSMCs that were perfused 
into rat aneurysm542. The adenoviral transcripts were able to reverse 
aneurysmal change and there was increased elastic fibre formation in the 
aortic wall542. Tropoelastin is a key component that is responsible for 
providing aortic wall its strength and prevent further aortic dilatation and 
aortic rupture. The ELISA studies showed very little increase in the elastin 
expression in VSMCs co-cultured with aneurysm-derived lymphocytes across 
human and murine derived cells. Although the results did not reach statistical 
significance in the studies the trend was to see higher elastin levels. It might 
be that termination of the experiment was far too early at day 5 to allow 
enough mature elastin to be laid down in the co-culture plate. Under normal 
physiological conditions in adults elastin deposition is a slow processes 
occurring over many weeks and months. The reason for terminating the 
experiment at day 5 is that we wanted to investigate the true effects of all 
vessel wall derived lymphocytes on VSMCs. Lymphocytes are known to alter 
their phenotype after 5 days in culture96,101,110,543. It is also known that other 
structural proteins are needed (fibrillin1/2, laminin and emilin) in the 
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formation of mature structured elastin fibres58,175,176,184. The cross-linking of 
tropoelastin requires fibulin and LOX activity. It might be that although there 
is increase tropoelastin levels the necessary post translational proteins are 
not present and functional to allow the elastin fibre formation. In vitro co-
cultures have their limitations and growing VSMCs in plastic wells might not 
facilitate the required microenvironment with necessary signaling molecules 
for elastin fibre organisation and ECM formation. 3D collagen gels/ matrices 
might be more appropriate for future studies into ELN generation by the 
VSMCs544,545. 
 
7.5.3 VSMC gene expression profile 
When we studied gene expression we characterised the elastogenic 
processes looking at expression for elastin (ELN), fibrillin (FBN), lysyl oxidase 
(LOX) and TGF. For elastolytic processes we characterised MMP2, MMP9, 
cathepsin S (Ctts) and cathepsin K (Cttk). The assays for Ctts, ELN and MMP9 
were not analysed due to late amplification with poor RT-PCR quality. The 
main difference was an up regulation of fibrillin and down regulation of all 
the other remaining genes when comparing the lymphocyte groups 
compared to VSMCs alone. When analysed by lymphocyte subgroups there 
were significant differences in the TGF levels that were down regulated by T 
lymphocytes derived from normal and aneurysm aortic wall vs. B-cell and 
B/T-cell groups. This suggests an isolated T-cell effect that is neutralised by 
the B-cells. Increased TGF signaling is associated in Marfans syndrome and is 
shown to increase signaling with Smad2/3, RohA and MAP kinases in FBN1 
mutant models546. Neutralisation of the TGF prevents the resistance of 
normocholesterolemic C57Bl/6 mice to ATII induced aneurysm formation113. 
TGF over-expression by endovascular gene delivery in rat models has been 
associated with diameter stabilisation, decreased inflammation, decreased 
MMP2/MMP9 expression and reduced ECM degradation114.  There was 
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down-regulation of LOX in the aneurysm derived T-cell group compared to 
the B and B-T cell cohorts. It is likely that the down regulation of the LOX 
genes in the CD3+ group would mean decreased elastin fibre formation. There 
is emerging evidence that CD4+ T-cells are involved in ECM remodelling 
through modulation of LOX expression547. It is known that T lymphocytes 
orchestrate fibrotic response through an array of cytokines548,549. TGF has 
shown to increase LOX mRNA but also LOX activity in VSMCs538. Also TNF, 
IL have been implicated in LOX induction550,551. Several studies have 
suggested that pro-inflammatory cytokines such as TNF, IL1 and TGF1 are 
involved in modulation and expression of MMP’s that inturn affect the ECM 
via. LOX activity552,554.  
 
7.5.4 Cell cytokine profile 
The cytokine bead array data showed a significant up regulation of IL10 and 
IL6 in the conditioned media of VSMCs co-cultured with lymphocytes from 
normal aortic tissue and down regulation of IL10 and IL6 in the aneurysm 
group. In normal aortic tissue the high concentrations of IL10 and IL6 implies 
a Th17 phenotype. IL10 is an anti-inflammatory cytokine and inhibits the 
production of INF522,554,555. IL10 is produced by T-regulatory cells and leads to 
expression of transcription factor FOXP3+ that reduces the activity of other 
inflammatory cells556. It is likely that the Tregs are dampening the 
inflammatory response. This could explain low expression of pro-
inflammatory cytokines IL2, IL4, IL17a and IFN.  When aortic tissue explants 
are analysed there is uniform increase in pro-inflammatory cytokines (IL6 and 
IL10)556. Comparison between tissue extracts of aneurysm wall and in-vitro co 
culture aren’t directly comparable as the cell concentrations, inflammatory 
cell content and therefore the cytokine profile are different. The other 
important difference in the co-culture set-up was that the cells were not 
stimulated with PMA or known inflammatory stimulants. The results are 
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therefore likely to represent endogenous milieu from the tissue resident 
lymphocytes. Another study where CD3+ cells were isolated alone or in 
combination with anti-CD28 (MOPC)521. The activation of CD3+ cells with anti-
CD3 lead to TNF and INF expression with little IL5, IL6 521. Whereas 
activation of T and B-cells with mitogens such as PMA and Ca2+ionophore 
leads to increased IL5, IL6, TNF and a switch to Th1 phenotype. It is likely 
that the cytokines from CD3+ lymphocytes from the normal aortic wall are 
more biologically active with production of IL6 and IL10 compared to the 
aneurysm derived T-cells.  
 
The data shows lymphocytes isolated from aneurysm tissue increase VSMC 
proliferation and tropoelastin synthesis. There is a trend to increased elastin 
formation. The effects are maximal in the CD3+ subset with the cytokine 
profile suggesting a T regulatory phenotype that produces anti-inflammatory 
cytokines leading to positive aortic remodelling. Lymphocytes may have a 
protective role in aneurysm formation by increasing VSMC proliferation and 
tropoelastin synthesis, ECM degradation is reduced, which decreases the 
chances of aortic dilatation and rupture. Gene expression of TGF is down 
regulated in this group that might additionally offer protective response to 











Chapter 8: General Discussion and future work 
 
8.1 General discussion 
Imaging that can better predict the progression of aneurysms and 
development of complications would be of great clinical benefit. Additionally 
if we understand the chronic inflammatory processes that underlie the 
pathophysiology of aneurysm development we could target specific drugs to 
augment aneurysm growth. The development of novel radiotracers and MR 
agents allows functional imaging of aortic aneurysms to yield potential 
physiological, biochemical and cellular correlates to events occurring in the 
aortic wall as aneurysms progresses.  
 
The main immune signal in the aneurysm wall is from the B and T 
lymphocytes and their interaction with VSMCs. This inturn dictates aortic 
remodelling behaviour through alteration of the ECM content. It is possible 
that as yet unknown antigenic trigger activates the B-cells to be attracted to 
aortic wall and produce immunoglobulins. Through MHC class II peptide 
antigen presentation CD4+ T-helper cells are recruited to the region. These 
would in turn activate CD8+ cytotoxic T-cells that are responsible for cytokine 
release and further interaction with B-cells to produce plasma cells 108,427. The 
role of T and B regulatory cells in the pathogenesis of aneurysm is not before 
reported. We have demonstrated that there are two distinct population 
subtypes that reside in the aortic wall. This was discovered in the context of 
functional imaging using 18F-FDG PET-CT in human and murine aortic wall. 
This was the CD3+CD4+CD25+ activated cell population that is likely 
responsible for the pro-inflammatory cell activity in the aortic wall and the 
corresponding Treg cell population that expresses CD4+CD25+CD127- 
(humans) and CD4+CD25+FOXP3+ (murine). It is likely that these cells are 
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responsible for dampening down the inflammatory response and encourage 
positive aortic remodelling behaviour. The B-cell subtypes that predominated 
in the metabolically active aortic wall on functional imaging were also the 
activated B-cell phenotype that expressed CD19+CD25+IgD/IgM. This also 
typifies memory B-cells in the aortic wall as well as cells that expressed 
CD27+.  The CD38+ B-cells were present that would interact with T-cells and 
modulate the immune response in the aortic wall. As well as Bregs that form 
an elusive ever changing population expressing CD24hiCD27+ that arise from 
memory B-cells can produce IL-10 and TGFß leading to inhibitory effects on 
CD4+ T-cells. These B-cell subtypes can go on and express CD24+CD38+IgMhigh 
phenotype and alter widespread cytokines responses.  
It is the increased metabolic activity of these cells that is being picked up by 
the functional imaging tracer, as confirmed in the murine studies. However 
the sites at which these cells are active is focal yet heterogeneous and varies 
significantly with time. Hence although it informs us of the biological activity 
at that time in the aortic wall, it is not predictive of aortic wall expansion at 
the site, or eventual rupture. There was no correlation between 18F-FDG 
uptake and aortic wall expansion or rupture in the murine studies. These 
findings have also been reported in small scale human studies281,281,282. The 
interaction between the identified B and T lymphocytes and their influence 
on VSMCs was not understood. It is known that pro-inflammatory cytokines, 
mechanical stress and oxidative state activates the c-Jun N terminal kinase 
(JNK) pathway169,398,400 in VSMCs that increases activation of activating 
protein (AP-1), increases expression of matrix metalloproteinase’s (MMPs), 
and decreases expression of matrix synthesis enzymes (lysyl oxidase (LOX) 
and prolyl 4-hydroxylase (P4H) leading to decreased deposition and increased 
degradation of elastin108,251.  
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We therefore sought to determine how the aortic wall resident B and T-cells 
would interact from aneurysmal and normal aortic tissue with in-vitro co-
culture of VSMCs. We further linked the cell signaling (looking at cytokine 
expression profiles) and gene expression data to VSMC activity, proliferation, 
viability and cell synthetic capacity (this being a marker of aortic remodelling 
ability). The aortic aneurysm derived cells that were CD3+CD4+Th2 phenotype 
influenced VSMC death. It is unclear through which mechanism that was 
induced. Previous work has implicated Fas, perforin and p53 activity as being 
responsible36. The interaction between aneurysm tissue derived lymphocytes 
and VSMCs confirmed the biological behaviour that was seen from the 
functional imaging data on flow cytometry and IHC. The lymphocytes are 
responsible for up-regulation of VSMC mediated increased ECM generation 
and hence a protective phenotype. 
In-vitro studies performed focused on tropoelastin synthesis, and the 
enzymes and transcription factors involved in regulation of elastin 
modulation, namely LOX and TFGß.  The VSMCs isolated from aneurysms had 
increased expression of tropoelastin under the influence of B-T lymphocytes. 
This was independent of antagomir mediated modulation of immune cell and 
VSMC function. The antagomir mediated miR29b inhibition was responsible 
for upregulation of LOX gene expression. It has to be remembered that there 
are other ECM components and enzyme systems apart from the elastogenic 
and elastolytic pathways. For instance, a disintegrin and metalloprotease 
domain containing proteins  (ADAMs) produced by VSMCs ADAMs 10, 12, 15 
and 17 are present in the aortic wall in the absence of immune cell 
infiltration558,559. These have a role in proteolysis, cell adhesion, migration, 
cell extracellular matrix activation and angiogenesis558. TIMPs 1 and 3 
counteract ADAMs activity and are found in aortic aneurysms428,559. 
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Turning the attention back to novel tracers that might be better able to 
inform us of aortic aneurysm biology, there are numerous other novel agents 
that have been used in animal studies and may provide attractive biological 
markers of aortic wall instability. These include MMP’s and their inhibitors 
(TIMP’s), tropoelastin, oxidised LDL receptors, and other markers of platelet 
activity, apoptosis, inflammation and angiogenesis. Along with USPIO/SPIO 
other nanoparticles have been used to determine macrophage content. 
These include integrins (alpha nu beta 3 (amb3)), matrix metalloproteinase 
(MMPs), micelles labeled with macrophage receptors or products NGAL, and 
CBR-274,75,251. Although many retrospective and small prospective studies 
demonstrate a link between functional imaging and clinical outcomes, there 
needs to be large prospective studies to evaluate this whilst also looking at 
the effects of anti-inflammatory therapies on aortic wall. The effectiveness of 
lifestyle modification on cholesterol and statins to reduce arterial wall 
inflammation has been studied with 18F-FDG uptake in the aorta and carotid 
wall74,75,252,253. Similar studies have been conducted with MR to study aortic 
disease progression. Presently animal studies are en route to develop 
functional imaging to aid delivery of drugs. For instance targeted therapy 
geared towards angiogenesis inhibition or anti-inflammatory treatments 
targeted to vascular wall241,249,305,560,561.  
Various imaging endpoints can be used to provide surrogate markers of 
disease development and progression. For instance the intima-medial 
thickness in the carotid artery is accepted as a phenotypic marker that 
signifies cardiovascular disease131,293,309,560,561. Similarly, it might be possible 
to use functional imaging end-points as surrogate markers of disease activity 
and progression. The biomolecular imaging phenotypes would complement 
current imaging to enhance the process of drug development and discovery. 
If we can measure and quantify the biological correlates in the aortic wall 
then we could identify patients that are likely to progress rapidly with the 
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disease process and therefore require earlier intervention. The imaging would 
allow us to report on cellular events that reflect the mechanism of disease 
progression and therefore facilitate evaluation of drugs with novel 
mechanisms, using these tracers in rapid clinical trials. The imaging 
phenotype can show us if the drug is having the desired effect that is 
proposed based on its mechanism of action. If the drug fails to cause a 
mechanistic change on functional imaging then it could be abandoned earlier. 
This is especially important in aortic aneurysms, as this is a slowly progressive 
indolent disease in the earlier stages. Aneurysms expand episodically over 
many years and it would take decades to see clinical changes in patients with 
this condition. Additionally 18F-FDG PET-CT provides an assessment of the 
metabolic pathways as it interacts with glucose uptake. For instance in cancer 
imaging inhibitors for rapamycin (mTOR) – an important step in nutrient 
response and phosphoinositide-3 kinase (PI3) – a regulator of serine-
threonine kinase Akt that is in turn a key mediator of growth factor and 
insulin signalling131,309,560,563. Changes in 18F-FDG uptake in neoplasia correlate 
with tumour mass in patients. Therefore 18F-FDG PET-CT might be able to 
inform us on aortic wall metabolism in aneurysms.  
Functional imaging techniques might be used clinically to gain information on 
aortic wall metabolism, blood flow, regional biochemical and cellular 
composition. As opposed to anatomical imaging (simple radiography, USS, CT, 
MRI), functional imaging aims to reveal physiological activities within the 
tissue with the use of tracers and probes. These are radiolabelled or 
gadolinium attached molecules that locate to specific sites within the body. 
To provide clinical utility many of the functional imaging systems are coupled 
for hybrid imaging that combines two or more modalities to inform us about 
the anatomical and physiological and/or biochemical composition of the 
tissues. The biological correlates to the uptake of the specific tracers such as 
18F-FDG are not known. 
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Preliminary pilot retrospective human data postulate that 
monocyte/macrophage infiltration into the aortic wall is responsible for the 
18F-FDG uptake seen in human aneurysms 131,309,558. However, there has been 
no direct attempt to determine the biological correlates(s) of 18F-FDG uptake. 
Examining the meaning of the uptake of currently available ‘non-specific’ 
tracers and development of novel tracers that are specific for biological 
processes (on-going in the aortic wall) could lead to a greater understanding 
of the mechanisms that underlie aneurysm development, expansion and the 
development of complications.  
From our in vitro work we have demonstrated the importance of lymphocyte 
and VSMC interactions in maintenance of the aortic wall ECM content. The 
lymphocytes have a key role in proliferation of VSMCs and preventing cell 
death. There is at the same time increased VSMC death in the lymphocyte 
groups. It might be that there are two distinct cellular effects at play. We 
could use anti-Fas ligand and an anti-Perforin antibody to determine the 
expression within the VSMCs of these proteins. Flow cytometric assessment 
of the lymphocyte population post VSMC culture could determine the 
direction in which the lymphocyte population is skewed as a result of the cell-
cell interaction with VSMCs. We could also determine the presence of p53, 
p21, protein kinase C-delta  (PKCδ) as key mediators of VSMC apoptosis550. 
PKCδ expression has been previously been shown to be higher in aneurysms 
compared to normal aorta. PKCδ deficient mice have decreased aneurysm 
expansion on CaCl2 administration556. PKCδ deficient VSMCs have impaired 
monocyte chemoattractant protein-1 (MCP-1) production556. CD3+ T-cells 
affects via. PCKδ mediated VSMC apoptosis could be analysed using western 
blotting or immunoprecipitation technique.  
For the effects on ECM as well as assessing tropoelastin synthesis, we need to 
be able to assess desmosine and isodesmosine levels. These would be 
eventually important in determining the elastin content in the aortic wall. 
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Small levels of desmosine <200pg would be evident with radioimmunoassays 
and this would provide sensitive method of detection with low number of 
VSMCs and their interactions with lymphocytes. As the ELISA to detect elastin 
levels and the ELN gene on RT-PCR were unable to detect any significant 
differences in the VSMC co-culture experiments, the native cells could be 
stimulated with ascorbic acid to allow synthesis of ECM564. Alternative 
strategy would be to use [3H] elastin-coated plates and soluble tritium 
measured to quantify the effect lymphocytes.  
The CBA profiling revealed an increased signal from the TGFβ to be important 
and under the effect of AmiR29b to augment aortic wall homeostasis. These 
needs to be confirmed with anti-TGF antibody mediated inhibition of the 
signaling pathway and assess the response on VSMC phenotype. 
For the complex flow cytometric phenotypic analysis we utilized the 
multilaser Canto cytometer. If we wanted to not only analyse the cell 
phenotype in a very niche population of cells but also assess 
intracytomplasmic proteins such as perforin, fas, micro cytokine levels, 
microRNAs and intranuclear proteins all simultaneously we could deploy 
CyTOF® (DVS imaging). This would allow single cell high-speed analysis in a 
conventional manner to flow cytometry to determine cell type followed by a 
multi-probe analysis with over 100 metal halide probes with a minimal sign of 
overlap (as using mass spectroscopy) thus allowing simultaneous 
phenotyping and functionally profiling of the cells. 
 
8.2 Limitations of the study 
Aneurysm patients We had a combination of thoracic and abdominal aortic 
patients in whom the analyses were carried out. Although the cellular 
compositions were the same in relation to the functional imaging tracers 
assessed, the aneurysms that develop in thoracic and abdominal aorta might 
represent slightly different disease processes with subtle differences in 
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pathophysiology. Also although the majority of the aneurysm patients had 
age related degenerated aneurysms, we did have patients with connective 
tissue disease and chronic aortic dissection leading to aneurysms. Due to 
limitation in the number of patients coming to open surgery all patients were 
included in the study. 
 
The aneurysm model The ApoE-/-ATII model of aneurysms provides an 
excellent model to study the pathophysiology and natural history of the 
disease. It is however still a model that might not completely recapitulate the 
ongoing biological processes in the aortic wall as in humans. The small 
volume of aortic and other tissue has impact on the number of analyses that 
can be performed and experiments have to be replicated at cost. 
 
18F-FDG PET-CT The radiation dose, time taken to perform the scan, its 
invasive nature and cost all preclude this imaging modality in its current state 
from clinical utility for vascular imaging. The poor spatial resolution, 
difficulties in having appropriate ROIs for vessel wall imaging, no time-of-
flight imaging and high-definition fusion would be the limits. However as 
discussed in detail in chapter 3, we sought out to and resolve some of these 
problems in aortovascular metabolic imaging. This included standardization 
of the imaging protocol, reducing noise with image parameter alteration, 
SUVmax assessment for the ROIs targeted on aortic wall, fused IV contrast CT 
imagining and the 3D image fusion, reconstruction and overlay. 
 
MR T1 mapping The scan time for a mouse takes two hrs. The data 
processing is considerably longer. The generation of T1 maps being longer 
still. Bespoke in-house software was used for the analysis. Fused images from 
commercially available software were exported and slice-by-slice manual 
segmented analysis of performed of the aortic wall regions to obtain the T1 
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values. The process requires a considerable learning curve and time to 
develop expertise in all elements of the data analysis, fusion, measurements 
and calculations to be performed. The clinical utility of ESMA MRI for use in 
patients with aortic aneurysm would need to be addressed with refinement 
of the image processing. 
 
Comparative analysis of MRI and histology We correlated the aortic axial 
slices on MRI to the histology of the aorta at the termination of the 
experiment. It was anticipated that the MR image of the aorta could be 
divided into quadrants and compared to the histology of the aorta. However 
even when using fixed anatomical landmarks such as the diaphragm, renal 
arteries, it was difficult to perform robust analysis to match the imaging data 
to the histological sections. In vivo MR images were compared to ex vivo 
histological data on pixel-by-pixel fusion basis, with multiple high numbers of 
sections taken through the aneurysm wall to get to the sections that would 
correlate it to MR axial slices. We also performed mean T1 relaxation / R1 
time correlations to ECM area analysis for tropoelastin and elastin to 
circumvent this and additionally analyse large amounts of data points from 
multiple sections throughout the aneurysm in many aneurysms and animals.  
 
Histological analysis We used histology to confirm the position of the 
immune cells within the aortic wall and semi-quantified the immune cell 
content and infiltration in the aorta. However it is known that histological 
assessment can vary between batches of slides. To minimize this effect, we 
analysed multiple regions from within the same slide or the complete slide 
with multiple slides taken through the section of the aneurysm at all levels so 
the complete aortic profile can be accurately determined. Also batches of 
slides were analysed at the same time and adequate stain made for the 
whole study.  
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8.3 Conclusions 
This study has: 
i)   Defined the role of 18F-FDG imaging in human aortic aneurysms and 
  determined the biological correlates for the imaging tracer in the  
  aortic wall 
ii) Determined the utility of 18F-FDG imaging in the ApoE-/-ATII model of 
  aortic aneurysms and defined its pattern during the natural history 
  of aneurysm development. We have also determined the biological 
  correlates to 18F-FDG in the murine ApoE-/-ATII model 
iii)  Determined the utility of ESMA MRI in defining the aortic wall  
  extracellular matrix content. We have described the biological  
  correlates to ESMA uptake in the aortic wall and determined the  
  natural history of aneurysm development with ESMA uptake 
iv) Determined the role of microRNA network involving miR29b and  
  miR195 in vivo on ApoE-/-ATII model of aneurysms. We have also  
  determined the mechanisms involved in in vitro alteration of VSMC 
  phenotype due to change in AmiR29b activity 
v) Demonstrated a change in the aortic and cardiac phenotype in  
  response to alteration of gene and proteomic signaling due to  
  antagomir mediated inhibition of miR29b  
vi) Determined the in vitro interaction and effects of aortic wall resident 
  T and B-cell subsets involving regulatory cells in modulating the  
  aortic VSMC activity, dampening inflammatory response and  












A study of emerging functional imaging techniques in aortic aneurysms. 
 
Background 
Aortic aneurysm diameter is an important predictor of risk of rupture1.  Size 
is, however, not the only determinant of rupture. Some aneurysms may 
rupture when small2, while large aneurysms can grow to a considerable size 
without rupture. Aortic aneurysm expansion is associated with inflammatory 
cell infiltration and enzymatic degradation of the vessel wall3,4. Increased 
inflammatory infiltrate, absence of smooth muscle cells and high levels and 
activity inflammatory cytokines such as metalloproteinases (MMPs) have also 
been found at the site of aneurysm rupture3,4.  
 
The PET tracer, 18F-FDG, is used to detect areas of high metabolic activity such 
as tumours and inflammation. It also accumulates in atherosclerotic plaque, 
where active macrophage uptake is associated with plaque instability4,5. 
Studies in small numbers of patients show that there is focal uptake of 18F-
FDG in the aortic aneurysm wall of patients with large, rapidly expanding or 
symptomatic aneurysms and suggest that this may be associated with the 
likelihood of rupture6,7. At St Thomas’ we reviewed PET-CT fusion scans in 30 
patients with abdominal aortic aneurysms (AAA) (median diameter 48mm, 
range 33-74mm) and graded localized 18F-FDG uptake in the wall. Uptake 
varied from none (39% of patients), minimal (32%), moderate (14%) and high 
(14%). The pattern of uptake varied, from patchy to generalised. One patient 
with high 18F-FDG uptake presented to another hospital with a ruptured 
aneurysm 6weeks later and died. FDG uptake in AAA wall might reflect 
inflammation, macrophage or other cellular infiltration, active atherosclerotic 
plaque or increased vascularity (neovascularisation). Understanding the 
meaning of uptake would further our knowledge of aneurysm disease 
progression and possibly reveal novel targets for therapies to reduce 









1. Uptake of the PET tracer (18F-FDG) will correspond to aortic wall 
inflammation, macrophage infiltration indicating active atherosclerotic 
plaque. 
2. Aortic wall with high 18F-FDG uptake will be more likely to expand 
and/or rupture.  
 
Study design 
This will be a prospective study. We will evaluate aortic aneurysms with a 
PET-CT scan. Patients with a positive scan will have biopsy of aortic wall taken 
at time of surgery for their aneurysm repair.  The patient will be anesthetised. 
There will be one to three biopsies approximately 5mm each from the aortic 
wall. This tissue is of no use for the operation and normally gets either 
completely excised or left to cover the aortic graft. The biopsies will not affect 
the operation or operative recovery. 
 
Inclusion criteria 
Adult patients with aortic aneurysm that need an open operation and who 
have a positive aortic PET scan. 
 
Exclusion criteria 




Patients will be provided with an information sheet and consent form about 
the study prior to having the PET-CT and aortic biopsies. The information 
sheet will clearly explain the purpose and nature of the research. Patients will 
be given one week to decide about participation in the trial. The information 
sheet will clearly state that if the patients do not want to participate they 
would still receive the best available treatment. A contact number for a 
clinical research fellow would also be available with the information sheet in 
case the patients are not clear about some point and would like to ask 
someone about it. Once agreed the patient will sign the consent form which 




Trial will start only after approval by the ethics and local research and 
development committee. Recruitment in the study will not disadvantage any 
patient groups. The recruited patients will be monitored in a usual manner by 
the consultant who is supported by a team of junior doctors, nursing staff and 
allied health professionals 24 hrs a day. In case of any specific information 
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required about this study a contact number for a clinical research fellow will 
be available to the patients and the clinical staff. The patients will not need 
any special follow-up for this study. 
All patients will be informed of the research outcome through a written letter 
at the end of the study. 
 
Power Calculation 
Considering our categorical data we have used a Nomogram to calculate the 
sample size. Based on previous studies6,7 we expect 40% of aortic aneurysms 
to have PET uptake. At out unit we undertake 200 aortic aneurysm repairs 
per year. Of these 5% are open repairs. Based on these values we will need 15 
patients in this study. To account for subject withdrawal and follow up loss 
we will target 30 patients.  
 
Statistical analysis 
As the comparison for the primary end point is made with an intention to 
treat, a Kaplan Meier analysis will be used. For continuous variables a 
Student's t test or Mann Whitney U test will be used. Categorical variables 
will be compared using Fisher's exact test. 
 
Conflict of Interest 
There are no conflicts of interest from any of the researchers. The patients 
recruited will be given the same treatment as any other patient with similar 
disease. 
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PATIENT INFORMATION SHEET   
(Patients with aortic aneurysms) REC REF: 10/H0711/56  
Study Title: 
A study of emerging functional imaging techniques in aortic aneurysms. 
 
Invitation: 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it 
will involve.  Please take time to read the following information carefully and 
talk to others about the study if you wish.  
 Part 1 tells you the purpose of this study and what will happen to you if you 
take part.   
 Part 2 gives you more detailed information about the conduct of the study.  
Please ask if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part in our 
study. 
 
What is the purpose of the study? 
You are coming to St Thomas Hospital to attend the out-patients clinic to 
monitor your aortic aneurysm. You have been under follow-up to monitor the 
size of the aneurysm as this determines when surgery will take place to repair 
it. Usually aneurysms only burst when they reach a certain size. This is a very 
serious complication of aneurysms with a high risk of death. There are some 
small aneurysms that burst while some patients develop large aneurysms 
that do not burst. It is still not known why aneurysms behave in this manner.  
 
We intend to study this by looking at the activity of cells in the aneurysm wall 
by performing a PET-CT scan two weeks before your operation. This scan 
shows up active cells and is currently used in other clinical areas to detect 
cases of infection or cancer. The PET-CT involves injection of a radioactive 
marker (18F-FDG) that can be taken up by aneurysms. If this marker shows up 
on the scan, then we propose to take a small sample of the aneurysm wall at 
time of your operation. We will analyze this tissue to determine what tracer 
uptake in aneurysm wall means, and find out what cells and biochemical 




What is PET scanning? 
A PET scan is a special kind of scan that detects the radioactive sugar 
molecule and then the computers create a picture of where this is in the 
body. An injection of the radioactive sugar is given before the scan. The scan 
involves radiation. Extra radiation can increase the chances of developing 
cancer however the risk from the extra scan in this study is small (1 in 500) 
compared with the natural lifetime risk of getting cancer (1 in 4). 
 
Why have I been chosen? 
You have been chosen because you have an aortic aneurysm that needs an 
open operation to repair it at St Thomas Hospital. 
 
Do I have to take part? 
No.  It is up to you to decide whether or not to take part or if you want to 
participate in some part of the study and not the whole of it. If you do, you 
will be given this information sheet to keep and be asked to sign a consent 
form. You are still free to withdraw at any time and without giving a reason.  
A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
Will this affect my treatment? 
No, you will receive the same treatment by the same team of doctors and 
nurses if you were not taking part in the study.  
 
What will happen to me if I take part? 
We would like to take the following material when you attend the clinic. You 
will be invited for a PET-CT scan. You will have to fast prior for at least six hrs 
prior to the scan. Following the scan, you will be secluded for surgery as 
usual, and aortic tissue biopsy will be taken at time of operation. This does 
not influence the duration or the nature of the surgery in any way. The aortic 
tissue taken is small (approximately 5 millimeters i.e. pea sized) and does not 
influence the outcome of the repair. 
What are genetic tests and will any be done? 
No. We do not plan to perform any genetic tests. 
 
What are the side effects of any treatment received when taking part? 
The PET-CT scan will require you to be in the hospital for about two hrs longer 
than normal. It will mean having an additional dose of radiation that carries 
an added risk of about 1 in 500 compared to normal lifetime risk of cancer 
that is 1 in 4. For the complete scan the level of radiation dose given in the 
study corresponds to about 13-18 years of natural background radiation.  
Some people may find not eating six hrs before the scan unpleasant and the 
injection into you arm prior to the scan. This causes minor discomfort (as 
when having a blood test).  
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What if I am pregnant? 
All women of childbearing age will have a mandatory pregnancy scan prior to 
the scans. Pregnant women can NOT be involved in this study. 
 
What are the possible benefits of taking part? 
There are no direct benefits to you, but we hope that the results will 
contribute to work that will eventually lead to new treatments for aortic 
aneurysms. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed. If you have a concern 
about any aspect of this study, you should ask to speak with the researchers 
who will do their best to answer your questions (02071880214).  If you 
remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure. Details can be obtained from the hospital 
(02071887188). 
 
Is there someone I can talk to independently about the research trials in 
general? 
You can talk to any of the staff in the cardiovascular unit if you have any 




Will my taking part in the study be kept confidential?  
Yes.  If you consent to taking part in the study, relevant parts of your medical 
records will be seen by your surgeon and the doctor who is carrying out the 
research study. All information including the results of the scan and all other 
investigations and tests will be kept entirely confidential. No individual 
patients will be identifiable when the results of the study are published in the 
medical literature. Your General Practitioner will, however, be informed of 
your participation in accordance with our usual practice. All the information 
about your participation in this study will be kept confidential.   
 
What will happen to the results of the study? 
In approximately 3 years the results will be analysed and published in an 
appropriate medical journal and presented at relevant scientific meetings. 
The results will be available to you at this stage and a copy of the results will 
be sent to you if you wish. If the scans indicate a need for additional 
treatment or further scans your surgeon or the clinical research doctor 




Clinical Research Doctor-   Mr Rizwan Attia 
       Academic Department of 
Surgery 
       1st Floor, North Wing, 
       St Thomas’ Hospital, 
       London SE1 7EH 
       Tel: 0207188021 
Mob: 07525857015 





What will happen if I don’t want to carry on with the study? 
If you withdraw from the study it will not affect your treatment.  
 
What if there is a problem? 
In the unlikely event that you become unwell after any procedure then you 
should contact your family doctor. Alternatively you can contact the 
researchers for advice on the number given above. 
 
Harm: 
In the event that something does go wrong and you are harmed during the 
research study there is indemnity provided by King’s College London. This 
covers both non-negligent and negligent harm. 
 
Will my taking part in this study be kept confidential? 
Any information collected about you in the course of the study will be kept 
strictly confidential at all times. Any personal details will be kept in the 
Academic Department of Surgery at St Thomas’ Hospital. Anonymised data 
will be stored on King’s College London computers in the department, which 
are password protected to allow access only to authorised researchers. The 
department is locked and only authorised researchers have access. The 
Research Doctor involved will be responsible for the data collected. 
 
Tissue samples will be labelled with a code and no identifying details. The 
data collected (including tissue specimens) will be stored. When the data is 
no longer needed it will be disposed of securely and confidentially. 
 
Authorised researchers directly involved in the study will have access to the 
data. Authorised representatives from King’s College London and the 
Research and Development department may need access to the data in order 
to confirm that the study is being carried out appropriately. 
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What will happen to any samples I give? 
Tissue specimens will be stored anonymously in the locked Academic 
Department of Surgery at St Thomas’ Hospital. They will only be accessible to 
the authorised researchers. They will be stored until they are used in this or 
further research studies looking at aneurysm behaviour. Tissues are used 
until they are depleted as further tests may be helpful over time. If not 
depleted, they will eventually be disposed of securely. 
 
What will happen to the results of the research study? 
The results of the study will be written up as a thesis for a post graduate 
degree and may be published in scientific journals or presented at scientific 
meetings. The individual participants involved will remain anonymous at all 
times.  
 
Who is organising and funding the research?   
The research is sponsored and funded by King’s College London (KCL). The 
doctors and scientists carrying out the research are employed by KCL and 
Guy’s and St Thomas’ Hospitals to conduct research. 
 
Who has reviewed the study? 
This study has been reviewed and received favourable outcome from the 
research Ethics Committee at Charing Cross Hospital as part of South West 
Research Network.  
 
You will be given a copy of the information sheet and a signed consent form 
to keep. 


























Title of Project:  A study of emerging functional imaging techniques in aortic 
aneurysms. 
 
Name of Researcher: Mr Rizwan Attia 
 
                                                     Please tick box 
 
1. I confirm that I have read and understand the information sheet 
dated 21/07/2010          
      (Version 2.6),for the above study. I have had the opportunity to consider 
the  
      Information, ask questions and have had these answered satisfactorily.  
 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time,     




3.   I understand that relevant sections of any of my medical notes and data 
collected during   
      the study, may be looked at by responsible individuals from regulatory 
authorities or from  
 the NHS Trust, where it is relevant to my taking part in this research.   
 I give permission for these individuals to have access to my records.  
 
 
4. I agree to allow my samples to be stored in subsequent future 
research projects related to aortic aneurysms 
                     
                                                                                                                                             












_________________________               ________________                   
________________ 
Name of Person taking consent Date  Signature 




_________________________ ________________                    
_______________ 
Researcher   Date  Signature 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be 























Table 1  Criteria for PET data reconstruction 











Output Image Image 




Z Filter axis Standard  Standard  
Subsets 20 20 
Iterations 1 1 
Diameter 70.00 70.00 
Centre L 0.0 0.0 
Centre P 0.0 0.0 
Post filter  Hanning 6.0 Hanning 
6.0 
Cutoff_freq 10.9 10.9 
Axial_cutoff 6.5 6.5 



















Decay Yes Yes 
Deadtime Yes Yes 
Scatter Yes No 
Geometric  --- Yes 
Attentuation Type Measured None 
Transmissio
n scan  
Most recent 




















D Tracer Nuclide 
1 4-7 5min 11 0 No 3|D F18 FDG 
 
Table 3  Acquisition technique for CT scan 
Patient setup 
 
Head first  
Supine 
Arms up (Arms down if patient is unable to raise  
Wedge under knees) 
Scan 
Margins 
Landmark: Sternal notch 
ROI for PET scan: Aortic Arch to femoral head  
(2cm above aortic arch to femoral head or nearest bed 
step below femoral head) 
 
ROI for CT contrast 
Abdomen aneurysm: renal artery to femoral head 
Chest aneurysm: Aortic Arch to Diaphragm 









































3.27 50.00 0.00 0.00 512 Std Full  
w400/wl 
40 
STD 5mm 5.0 
1.375:1 























































40grams paraformaldehyde  
1-litre distilled water with sodium hydroxide heated to 65°C at pH7.35 
 
Working elastin solution 
5% alcoholic hematoxylin 20 ml 
10% ferric chloride  8 ml 
Weigert’s iodine solution 8 ml 
 
Weigert’s iodine solution: 
Potassium iodide  2 g 
Iodine     1 g 
Distilled water   100 ml 
4 ml of distilled water to dissolve potassium iodide and add iodine; once 
iodine is dissolved, then the solution is diluted by adding 96 ml of distilled 
water.  
 
5% alcoholic hematoxylin 
Hematoxylin   5 g 
100% alcohol   100 ml 
Mixed to dissolve with the aid of gentle heat and then filtered. 
 
10% aqueous ferric chloride 
 Ferric chloride   10 g 
 Distilled water    100 ml 
 
2% aqueous ferric chloride 
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10% ferric chloride  10 ml 
Distilled water    50 ml 
  
5% aqueous sodium thiosulfate - Van Gieson’s counterstain 
1% aqueous acid fuchsin 5 ml 
Saturated aqueous picric acid 100 ml 
 
TRIS buffer 
Sodium chloride   80g 
Tris (Tris hydroxymethylamine)  6.06g 
1M hydrochloric acid    44ml  
 
1M Hydrochloric acid (HCL) 
(85ml HCL/1000ml distilled water) dissolved in 10liters of distilled water and 
stored at 4oC for up to a month).  
 
Ammonia water (37 mmol/L) 
Concentrated Ammonia hydroxide (15 mol/L)  2.5 mL 













Cell composition for each patient’s aortic aneurysm wall with varying SUVmax. Cell counts from 
flow cytometry data obtained as events per mg of wet tissue analysed. These counts are used as e 
a percentage of the total CD45 positive fraction to obtain correlations between leukocyte content 















































































































































































































































































































































































































































































































































































































RT-PCR standard curves and slope efficiencies 
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